The Synthesis of Pyrrolobenzothiadiazepines and Related Compounds, and a Study Into the Reaction of Cyclopropenones with 2-Vinyl-1-Azetines and other Cyclic Imines. by Newman, Christopher D
U n iv er s i ty o f  H u d d e r s f i e l d  R e p o s i t ory
N e w m a n,  Ch ris top h e r  D
The  Syn t h e si s  of Pyr rolob e nzo t hia diaze pine s  a n d  Rela t e d  Co m po u n d s,  a n d  a  
S t u dy In to  t h e  Re ac tion  of Cyclop rop e no n e s  wit h  2-Vinyl-1-Azetine s  a n d  o t h e r  
Cyclic Imine s.
Ori g i n a l  Cita t i o n
N e w m a n,  Ch ris top h e r  D (202 1) The  Syn t h e sis  of Pyr rolob e nzo thi a diaz e pin es  
a n d  Rela t e d  Co m po u n d s,  a n d  a  S t u dy In to  t h e  Re a c tion  of Cyclop rop e no n es  
wi th  2-Vinyl-1-Azetine s  a n d  o t h e r  Cyclic Imin es .  Doc to r al t h e sis ,  U nive r si ty of 
H u d d e r sfield.  
This  ve r sion  is available  a t  h t t p:// ep rin t s .h u d. ac.uk/id/ ep rin t/355 4 2/
The  U nive r si ty Re posi to ry is a  digi t al  collec tion  of t h e  r e s e a r c h  ou t p u t  of t h e
U nive r si ty, available  on  Op e n  Access .  Copyrig h t  a n d  Mo r al  Righ t s  for  t h e  
it e m s
on  t hi s  si t e  a r e  r e t ain e d  by t h e  individu al a u t ho r  a n d/o r  o t h e r  copyrigh t  
ow n e r s .
U s e r s  m ay  a cc e s s  full it e m s  fr e e  of c h a r g e;  copie s  of full t ex t  it e m s  g e n e r ally
c a n  b e  r e p ro d uc e d,  dis pl aye d  o r  p e rfo r m e d  a n d  given  to  t hi rd  p a r ti e s  in a ny
for m a t  o r  m e diu m  for  p e r son al  r e s e a r c h  o r  s t u dy, e d u c a tion al  o r  no t-for-p rofi t
p u r pos es  wi tho u t  p rio r  p e r mission  o r  c h a r g e ,  p rovide d:
• The  a u t ho r s,  ti tl e  a n d  full bibliog r a p hic  d e t ails  is c r e di t e d  in a ny copy;
• A hyp e rlink  a n d/o r  URL is includ e d  for  t h e  o riginal m e t a d a t a  p a g e;  a n d
• The  con t e n t  is no t  c h a n g e d  in a ny w ay.
For  m o r e  info r m a tion,  including  ou r  policy a n d  s u b mission  p roc e d u r e ,  ple a s e
con t ac t  t h e  Re posi to ry Tea m  a t :  E. m ailbox@h u d.ac.uk.
h t t p://ep rin t s .h u d. ac.uk/
  
The Synthesis of 
Pyrrolobenzothiadiazepines and 
Related Compounds, and a Study 
Into the Reaction of Cyclopropenones 
with 2-Vinyl-1-Azetines and other 
Cyclic Imines. 
Christopher D. Newman MChem. 
 
 
This thesis is submitted to the University of Huddersfield in partial 
fulfilment to the requirements for the degree of Doctor of Philosophy.  





Professionally, I would first and foremostly like to offer my complete gratitude to Dr 
Karl Hemming. Thank you for giving me the opportunity to work with you and sharpen 
my skills as a researcher, I have learned so much, and my desire to stay in the 
synthetic organic field has only grown.  You have been constantly level-headed, giving 
sage advice and calm reassurance throughout my PhD. 
Secondly, I would like to thank the wonderful people in the Hemming group and 
beyond. Gabriel, Heidi, the Moran Group, the Laws Group, and the Scott Group, thank 
you for making the lab such a welcoming and friendly place to work. Finally, I would 
like to single out and extend my thanks to Rhianne, you were an amazing placement 
student, and made my final year in the lab a genuine pleasure and you have made a 
wonderful friend to this day.  
Outside of the Hemming group, I would also like to extend my thanks to the technical 
staff for all their support with technical services and friendly chats.  
Personally, I want to thank my closest friends, Harry, John, Martin, and Scott. Your 
support has always kept my spirits high - sometimes literally. Our get-togethers were 
and are the highlight of my calendar. You lads have been my best friends for years, 
and I would not have it any other way.  
I also want to thank Scarlett, for all your support during my PhD and through the final 
years of my degree. Thank you for putting up with my grumpy writing moods and my 
nihilistic episodes. It means the world to me.  
Finally, I would like to thank my family, Mum, Nan, Jack, and Gramps, you have 
supported me in everything I have done since my first day of school- and before that. 
I could not wish for a better group of people to have helped me become who I am 
today and to have my back at every step. (I will appreciate not being asked “how’s the 




The focus of this thesis is split between two projects, the first of which describes the 
synthesis of novel analogues of pyrrolobenzodiazepines (PBDs). The established 
biological activity of the PBDs make such analogues worthy targets. Sulfone 
analogues (I and II) of the natural products fuligocandin B (III) and fuligocandin A (IV) 
were the first target molecules, as fuligocandin B has shown promising activity against 
leukaemia cells. 
The initial approach to these pyrrolobenzothiadiazepine (PBTD) analogues was based 
on using the Eschenmoser episulfide contraction as a key step in the synthesis. Whilst 
this approach proved unsuccessful, analogue II was eventually synthesised via an 
intermediate diazoketone based method. This route, summarised below, also led to 
work beginning on the synthesis fuligocandin homologues (V, for example) in a similar 
manner.  
The synthesis of analogue I was attempted using several methods, however these 
proved ineffective due to low recoveries and unoptimized reaction conditions. 
The circumdatin series of natural products was also a target for the development of 
routes to PBTD analogues. Attempts to synthesise the sulfonyl analogue of 
circumdatin H (VI) via a range of N-arylations on a PBTD backbone were 
III 
 
unsuccessful, before finding success by utilising a copper-catalysed N-arylation to the 
quinazolino moiety. 
As an extension to the synthesis of analogue VI, two new homologues (VII, X = S and 
X = (CH2)2) of the PBD the natural product circumdatin H (VII, X = CH2) were 
successfully synthesised through an N-arylation and subsequent aza-Wittig imine 
formation. 
With an effective route to novel PBTDs and PBD homologues, a selection of 
compounds was selected and tested in vitro against human colon carcinoma cells. 
Most of the results from these tests were inconsequential, however one compound 
tested showed impressive selectivity towards the cancer cells and has prompted 
further research for the future. 
The second focus of this thesis explores the reaction between symmetrical 
diarylcyclopropenones and 4-vinyl-1-azetines, and a subsequent aza-Cope 
rearrangement. It was observed that when the reaction was carried out at room 
temperature, the intermediate cycloadduct VIII was isolated along with aza-Cope 
rearrangement product, the azabicyclo[4.2.1]nonene IX. It was also observed that 
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when carried out at a higher temperature, only azabicyclo[4.2.1]nonene IX was 
observed. This reaction was carried out using a number of azetines and 
cyclopropenones, resulting in the isolation of twenty azabicyclo[4.2.1]nonenes, and 
five intermediate cycloadducts.  
Five azabicyclo[4.2.1]nonenes were subjected to biological testing against human 
ovarian carcinoma cells and it was found that two of these compounds showed 
promising effects on both cisplatin sensitive and resistant carcinoma cells. 
Expanding upon this, cyclopropenones were reacted with the polycyclic imine X, and 
it was observed that a dimerised compound (XII) was produced, as opposed to the 
expected cycloadduct (XIa). This was further explored with other cyclopropenones to 
similar effect. A mechanism is proposed involving the formation of a captodative 
radical (XIb) at the bridgehead. 
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radicals detailed in section 2.5 of this thesis contributed to the contents of this paper. 
The paper itself is referenced in section 2.5 of the results and discussion section as 
reference 157.  
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Chapter 1 – Literature Review 
This chapter will introduce the pyrrolobenzodiazepines and 
pyrrolobenzothiadiazepines (section 1.1), the homotropane alkaloids (section 1.2), 
and cyclopropenones and azetines (section 1.3). These sections introduce a range of 
topics including natural product subsets, published synthetic approaches, and 
chemical and biological applications. The aim of this section is to provide a 
comprehensive insight into the molecules and targeted reactions that comprise the 
discussion of this thesis.  
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1.1 An Introduction into the Pyrrolobenzodiazepines 
 Anthramycin-Like Pyrrolobenzodiazepines 
In the late 1960s, the first pyrrolobenzodiazepine (PBD) 
was discovered1-2. Anthramycin (1) was initially isolated 
from Streptomyces refuineus by Leimgruber et al1. In the 
decades since its discovery, many more PBDs have 
been reported, from both natural sources and the 
product of synthetic studies. The main commonality between all PBDs whether 
synthetic or natural, is the tricyclic ring structure (figure 1.1.1.1), which consists of an 
aryl ring (A), a 1,4-diazepin-5-one ring (B), and a pyrrolidine ring (C). The main 
variations between molecules, therefore, occur in points of substitution across the 
three ring systems. Figure 1.1.1.1 shows a selection of naturally occurring PBDs. 
The interest in PBDs arises from their natural antibacterial and selective cytotoxic 
properties toward certain tumour cells. The reason behind these biological properties 
arises from the S configuration of carbon 11a, resulting in a mild “twist” in the molecular 
structure, resulting in a three-dimensional molecule capable of fitting in the minor 
groove of DNA and forming an aminal bond between C11 of the PBD and N2 of the 
guanine base3-4 (scheme 1.1.1.1). 
 
 




The morphology of the moiety around N10 and C11 is dependent on the method of 
isolation, or work-up. This can be seen over several PBDs: anthramycin (1) is most 
often cited in the carbinolamine methyl ether form, DC-81 is seen as the imine, and 
sibriomycin is seen as the carbinolamine. Rarely obtained, the carbinolamine PBD 
form was first observed by Leimgruber et al, who then proceeded to show the 
interconvertible nature of all three PBD forms1. Scheme 1.1.1.2 shows this cycle of 
interconversions. It has been noticed however, that through synthetic, semisynthetic, 
and natural isolation, PBDs have been observed as mixtures of two, three, or single 
functional forms, giving the implication that these forms are biologically equivalent3. 
Thurston et al developed C2-aryl substituted PBDs, utilizing a Suzuki coupling to 
introduce the aryl component. The three novel compounds produced by the group 
(figure 1.1.1.2), showed promising results against various cancer cell lines, with 
compound 3c being chosen to enter in vivo testing5. 
Scheme 1.1.1.1: Interaction between the PBD structure and the guanine DNA base. 
Scheme 1.1.1.2: PBD interconversion cycle. 
13 
 
 Figure 1.1.1.2: Some C2-aryl substituted PBDs. 
Compound 3c, now known as DRH-417, proved to be potentially therapeutic, showing 
affinity towards renal cell carcinoma6, resulting in the development of other C2-aryl 
PBDs that show more potent cytotoxic properties. This study revealed that fused 
aromatic systems, quinolinyl, for example, drastically increase cytotoxicity, along with 
other factors such as the stereochemistry between the C2 substituent and C1 and C37.  
Following the boom of synthetic/semisynthetic PBDs, a subcategory of PBDs was 
established, the PBD hybrid, or conjugate molecules. The focus for these molecules 
was to increase one or more properties found in PBD “monomers”, such as DNA 
binding affinity, selectivity, and in vitro cytotoxicity. These molecules feature a PBD 
unit (typically DC-81) linked at C8 to a variety of moieties. Research suggests that 
planar ring compounds possess therapeutic activity by way of intercalating with DNA 
bases8. Kamal and co-workers took advantage of this and synthesised a range of PBD 
molecules linked to planar structures such as anthraquinones (4), naphthalimides (5), 
and acridones (6) (figure 1.1.1.3). 
Figure 1.1.1.3: A selection of PBD/planar molecule hybrids. 
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It was found that the addition of the planar moiety significantly improves the DNA 
binding affinity in comparison to a non-hybrid PBD. In addition to the increased binding 
affinity of these hybrids, Kamal and co-workers also showed that some hybrids show 
impressive cytotoxic behaviour when tested in vitro against various cancer cell 
lines9,10,11. While very promising as standalone data, the biological implications 
proposed by Kamal and co-workers have all been carried out in vitro, and there is an 
obvious lack of in vivo studies. IN6CPBD (7 – figure 1.1.1.4) is an exception.  
Derived from DC-81 by Wang et al12, compound 7, was found to support the theory of 
increased binding affinity due to intercalation. Compound 7 proved to not only be more 
cytotoxic than the parent compound DC-81 in cell line testing13, but in vivo, 7, was 
more effective than DC-81, showing fewer negative side effects, such as reduced 
muscle damage and liver function impairment, and preferential apoptosis to cancerous 
cells, as opposed to normal fibroblasts14.  
Arguably the most significant milestone in the development of PBDs as antitumor 
agents, was the discovery of the potential of PBD “dimers”. The initial theory of the 
dimers was to create molecules that kept the DNA interactions of PBD “monomers”, 
but could also span whole sections of DNA chains, binding to two different guanine 
bases. The first of these dimers were synthesised by Farmer, Rudnicki, and Suggs15, 
while showing the synthesis of such molecules were possible, the cytotoxicity and 
cross-linking potential were limited. Building upon the work of Farmer et al, Thurston 
and co-workers developed DSB-120 (8 – figure 1.1.1.5). 
DSB-120 was synthesised with the intent of having two PBD units tethered at the C8 
position with a flexible linking moiety, in theory, increasing the number of base pairs 
Figure 1.1.1.4: Structure of intercalating agent IN6CPBD (7). 
Figure 1.1.1.5: Structure of PBD dimer DSB-120 (8). 
15 
 
that can be spanned, and as such, increasing DNA selectivity. Such intents proved 
successful, with DSB-120 having the ability to span up to six base pairs, and 
preferentially pairing with 5’-PuGATCPy, or 5’-PyGATCPu sequences. DSB-120 also 
showed incredibly promising cytotoxicity towards a variety of in vitro cell lines, 
including human ovarian and cervical carcinoma, and leukaemic cells16. 
Despite such promising in vitro results, DSB-120 showed a poor therapeutic index, 
and a low stability in vivo. The poor antitumour activity of DSB-120 was postulated to 
be due to low tumour selectivity and drug uptake, caused by a combination of high 
protein binding, and in vivo drug metabolism17. The “second generation dimers” were 
designed around tomomycin, as the C2 unsaturation flattens the pyrrolo ring, flattening 
the overall molecule, achieving a better fit in the minor groove of DNA18. Thus, SJG-
136 (9 in figure 1.1.1.6) was developed. SJG-136 was found to be far more cytotoxic 
than DSB-120, corresponding to the better fit in the minor groove.  
The interstrand crosslinks are considered the main driving force in the cytotoxicity 
towards cancerous cells. It was suggested that SJG-136 had a distinct mechanism of 
action compared to other DNA binding agents, as the interstrand links made were non-
distorting, which differs from more conventional drugs such as platinum drugs and 
nitrogen mustards. Based on a series of impressive in vitro testing, SJG-136 went on 
to rigorous in vivo testing, providing several significant findings, including very 
promising results against ten human xenografts19, activity against cisplatin resistant 
cancers in mice, and in vitro doses that were tolerated by rats, dogs, and mice20a-c. As 
such, SJG-136 went onto stage 1 and 2 clinical trials, concluding that SJG-136 was a 
safe, and active drug for patients with advanced leukaemia. Further work on these 
kinds of dimers have been since developed, some appearing more cytotoxic than SJG-
13621. 
Figure 1.1.1.6: Structure of PBD dimer SJG-136 (9). 
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 The Fuligocandin Series 
Conversely to anthramycin and its derivative compounds, there are PBDs that are not 
as well established, yet could still prove to be biologically significant. One such series 
of PBDs are the fuligocandins, a series of three PBDs (figure 1.1.2.1) first extracted 
from myxomycete Fuligo candida, by Nakatani et al in 200422. It was found by 
Hasegawa et al, that fuligocandin B (FCB) 11, in combination with TRAIL (tumour 
necrosis factor related apoptosis inducing ligand) in doses of 2.5 µg/ mL FCB, and 500 
ng/ mL (TRAIL) showed 69% of cells tested positive for cell death, making a huge 
difference from FCB and TRAIL individually (13.4, and 6.8% respectively)23. 
In more recent years, Arai et al. elucidated the mechanism of action of 5’-iodo-
fuligocandin B (13)24. Arai showed valosin-containing protein (VCP) was a target of 
the substituted fuligocandin B, and as such, further work focussed on replacing the 
indole moiety with a variety of aromatic substituents including furans, thiophenes, and 
pyridines (figure 1.1.2.2). 
Figure 1.1.2.2 A selection of substituted analogues of fuligocandin B. 
Figure 1.1.2.1: Fuligocandins A – C. 
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From their findings, Arai et al found, when tested against human gastric 
adenocarcinoma (AGS), that compound 17 boasted an almost 50% difference in cell 
viability compared to TRAIL alone, and an almost 16% increase in activity compared 
to the natural fuligocandin B, suggesting heterocyclic derivatives of fuligocandin B hold 
potential in overcoming TRAIL resistance25. With biological interest established shortly 
after their discovery, a reliable synthetic pathway to the fuligocandins seemed 
necessary. Arai and co-workers were the first to report a total synthesis of 
fuligocandins A and B, their synthetic pathway relying on a Meyer-Schuster 
rearrangement as the key step26, as detailed in scheme 1.1.2.1. 
Following the coupling of N-Boc anthranilic acid and L-proline methyl ester, the methyl 
ester was hydrolysed, and the subsequent acid was subjected to an intramolecular 
cyclisation, affording the Boc-protected PBD 21. Following this, propargylic alcohol 22 
is formed, and under acidic conditions, the Meyer-Schuster rearrangement takes 
Scheme 1.1.2.1: The synthetic pathway to fuligocandin A reported by Arai. 
 




place, affording exclusively the Z isomer of Fuligocandin A. The selectivity of this 
rearrangement can be explained by the mechanism above in scheme 1.1.2.2. 
Originally carried out at 0 °C, it was observed that the enantiomeric excess (ee) of 10 
had dropped by 60% after the Meyer-Schuster rearrangement. This was due to a 
propargylic cation forming upon dehydration of 22, followed by tautomerization 
between the imine/enamine forms, thus resulting in a racemized 25, and subsequent 
products. The subsequent transformation of fuligocandin A to fuligocandin B was 
carried out via aldol condensation using a protected indole aldehyde (scheme 1.1.2.3). 
With an overall yield of 34% over 5 steps, or 21% over 7 steps to afford fuligocandin 
B, the route demonstrated by Arai et al is a relatively facile synthesis, however it is not 
without shortcomings. Chiefly, the 72-hour reaction time for the intramolecular 
cyclization, and the loss off ee during the Meyer-Schuster rearrangement. 
Following the route proposed by Arai et al, in 2011 Bergman et al proposed a synthesis 
based on PBD 2827 utilizing the Eschenmoser episulfide contraction as a key step. 
Scheme 1.1.2.4 shows the full route.  
Scheme 1.1.2.3: Transforming fuligocandin A to Fuligocandin B via the aldol condensation. 
 




As PBD dione 28 is readily synthesised by reacting isatoic anhydride and L-proline, 
that was a logical starting point for Bergman. PBD 28 was thionated at C11 using P2S5-
pyridine complex, used as other thionating agents were unselective, dithionating the 
precursor PBD. The thioamide was converted to intermediate sulfide 30. Sulfide 30 
undergoes the Eschenmoser episulfide contraction, extruding the sulfide, and forming 
the vinylogous amide moiety seen in 10 exclusively in the Z configuration, once again, 
induced by intramolecular hydrogen bonding during the reaction. Scheme 1.1.2.5 
shows the mechanism of action. 
It is interesting to note, whilst the opportunity to utilize the aldol conversion to transform 
fuligocandin A to fuligocandin B exists in this route, Bergman and co-workers do not 
do this, instead, employing indole species 31, and forming fuligocandin B directly from 
thioamide 29 as shown in scheme 1.1.2.6. 
In the path utilised by Bergman et al, fuligocandin A is synthesised over 5 steps with 
an overall yield of 79%, and fuligocandin B is synthesised over 6 steps with a yield of 
36%. While the yield and the number of steps to synthesise fuligocandin A are much 
improved when compared to the route used by Arai et al, in the Bergman pathway, the 
chirality of C11a is lost during the episulfide contraction step. It is assumed that the 
racemisation is caused by tautomerization after deprotonation occurs, as the same 
phenomenon has been observed in other PBD thioamides in the presence of base28. 
The convergent route to fuligocandin B proves superior to that of Arai, however. 
Furthermore, it was found when converting the intermediate sulfide 32 to 33, the  




episulfide contraction happened without the need for a base or sulfur scavenger, the 
first reported example of this reaction under such conditions. Due to the absence of 
base in this step, compound 33 retained its chirality. However, the racemic product 
was still observed after deprotection with Cs2CO3, but this could be overcome by 
carrying out the deprotection using 1 equivalent of sodium hydride and 2 equivalents 
of thiophenol. The thiophenol acts as a Brønsted acid, neutralising the basic species 
generated by the deprotection, providing a route to an optically active fuligocandin B 
in better yield than previously reported.  
The final reported synthesis leading to the fuligocandin series was reported by Sorra 
et al, using a one-pot reductive cyclodehydration, resulting in optically pure 
fuligocandin A29. Beginning in a similar way to the pathway published by Arai, L-proline 
is coupled to 2-nitrobenzoyl chloride. A diazoketone 37 is then formed from the 
activated carbonyl using trimethylsilyl diazomethane, as shown in scheme 1.1.2.7. 
Scheme 1.1.2.6: Direct synthesis of fuligocandin B from thioamide 29. 
 




The diazoketone is then treated with acetaldehyde and tin(II) chloride, affording 
diketone 38, which was reacted without purification due to instability, with zinc powder 
and acetic acid to facilitate the reduction of the nitro group and subsequent 
cyclodehydration. This process is detailed in scheme 1.1.2.8. 
Furnishing with enantiopure fuligocandin A in the Z configuration over 5 steps in an 
overall yield of 29%, the route as reported by Sorra et al provides an excellent route 
to fuligocandin A, with the possibility of transformation to fuligocandin B by way of the 




aldol condensation as reported by Arai et al24. In addition to fuligocandin A, the 
reductive cyclodehydration as detailed by Sorra was also used to synthesise a series 
of homologues of fuligocandin A, which may prove biologically interesting. 
 The Circumdatin Series 
The circumdatins are a class of molecules in the benzodiazepine family, first 
documented in 1999 by Rahbæk et al30,31 as isolates from Aspergillus circumdati. 
Rahbæk detailed six novel compounds, circumdatins A-F (40 - 45 respectively in figure 
1.1.3.1). 
Containing both benzodiazepine and pyrrolobenzodiazepine moieties across the 
series, the assumption that these molecules may possess some biological activity is 
relatively well-founded. In 2014, Zhang et al used circumdatin F, along with seven 
other marine fungus extracts to find potential anti-fouling agents that are 
environmentally friendly and with low toxicity. Circumdatin F performed well, showing 
good anti-larval settling activity with an EC50 of 8.81 µg/ml and LC50 of >200 µg/ml32.  
Since this initial discovery, seven other circumdatins have been isolated from marine 
fungi, three of which are pyrrolo-variants, circumdatins H, J, and M (46, 47, and 48 
respectively in figure 1.1.3.2). 




The applications of the circumdatins as a series remain relatively unexplored, with 
even fewer reports on the pyrrolo-circumdatins. The work reported however, suggests 
potential biological significance. López-Gresa et al demonstrated that circumdatins H 
and E were effective as NADH oxidase inhibitors, with IC50 values of 1.5 ± 0.1 µM and 
2.5 ± 0.3 µM respectively, which suggests circumdatins H and E could lead to 
developments in insect control, and elucidate defects associated with the 
mitochondrial respiratory chain, which lead to degenerative diseases such as 
Parkinson’s and Huntington’s33. More recently, circumdatin M was tested against cell 
lines A2780 and A2780CisR - a human ovarian cancer, and its cisplatin resistant 
variant; however, the compound proved inactive, and the instability of 47 prevented 
further investigation34. 
There have been myriad of reported synthetic approaches to furnish the circumdatins. 
Initially, these syntheses were focussed on circumdatin F35. One of the first synthetic 
pathways to other pyrrolo-circumdatins was reported by Zhichkin et al, furnishing 










Beginning with the formation of PBD 28/51 in ~90% recovery from isatoic anhydride 
and L-proline, amides 54-56 were synthesised. Due to the poor solubility of 28, a 
variety of solvents and reaction conditions were attempted, and optimal conditions 
were found using N,N’-dimethylacetamide (DMAC), previously reported by Cvetovich 
and DiMichele to afford amides at low temperature in high yields37. Nitroamides 54-56 
were then converted directly into circumdatins E and H, and the J precursor 57 via 
reductive cyclization using zinc and acetic acid at -20 °C. Mechanistic detail is shown 
in scheme 1.1.3.2. An additional step in this synthesis was required for the conversion 
of precursor 57 to circumdatin J 44. Boron tribromide was used in 10% excess and the 
reaction quenched before completion to avoid double deprotection. With overall yields 
varying between 21 and 65% over 3/4 steps, the route as reported by Zhichkin 
provides a facile and relatively high yielding synthesis to previously unsynthesised 
natural products. 
  
Scheme 1.1.3.1: Route to circumdatins E, H, and J as reported by Zhichkin. 
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Bose et al reported a separate synthetic pathway to circumdatin H within months of 
Zhichkin. The approaches, although similar, differ at the final step with Bose utilising 
an aza-Wittig approach from an azide precursor37. The route in entirety is shown in 
scheme 1.1.3.3. 
Scheme 1.1.3.2: Mechanism for N-arylation and subsequent cyclisation, furnishing circumdatin species. 
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Furnishing optically pure circumdatin in good yield over the final step, and an overall 
yield of 46% over 4 steps, the route reported by Bose is an excellent route to 
circumdatin H 46 and analogue 68, which could lead to new developments in the 
synthesis and structure-activity relationships of quinazolino benzodiazepines38. 
In a similar fashion to Zhichkin and Bose, wherein the PBD backbone is synthesised 
first, Sorra, Mukkanti, and Pusuluri are responsible for a similar synthesis, utilising a 
palladium catalysed N-arylation followed by intramolecular cyclization to furnish 
enantiopure circumdatins and other analogues39, as shown in scheme 1.1.3.3. PBD 
28 (see above) is synthesised from isatoic anhydride and L-proline and subsequently 
thionated to give the thioamide 29. It is interesting to note here the use of Lawesson’s 
reagent as the thionating agent, as previous reports28 indicate that dithionation occurs 
with Lawesson’s reagent, and as such, more selective thionating agents are required.  
Thiomide 29 is then treated with mercury(II) chloride and anhydrous gaseous 
ammonia to form amidine 70. This and subsequent steps are shown in scheme 
1.1.3.4. Amidine 71 was synthesised in the same way from thioamide 69. 
 




After extensive optimisation of the Pd-catalysed N-arylation by Sorra and co-workers, 
the conditions detailed in scheme 1.1.3.4 were found, resulting in an efficient formation 
of circumdatins H and J 68 and 46, along with analogues 47, 73, and 74. This novel 
approach could be further utilised in the synthesis of analogues of circumdatins H and 
J, as bromides 72a-c could be substituted in a variety of ways.  
In previous examples of routes to pyrrolo-circumdatins, the PBD backbone 29 was 
synthesised first, and the quinazolinone moiety is then introduced. Kshirsagar and 
Argade were the first to report a synthesis wherein the 
quinazolinone moiety is first synthesised, followed by 
the synthesis of the characteristic PBD backbone40. 
Conducting a pseudo-biosynthesis, Kshirsagar began 
the synthesis of the quinazolinone moiety using 
anthranilamide and N-boc-L-proline, resulting in 
intermediate 75a over several steps, via the 
intermediate 76 as seen in red, in scheme 1.1.3.5. Upon isolating 75a, it was found 
that the deprotection of the N-boc group had resulted in complete racemisation of the 
resulting product, most likely due to the presence of the adjacent imine moiety. 
Following the deprotection and subsequent addition of the bromobenzoic acid, a 
variety of N-arylation procedures for racemic compound 75a were investigated, 
beginning with a combination of palladium catalyst, phosphine ligand, and base, in a 
similar manner to Sorra et al. These attempts proved unsuccessful, as it is known that 
palladium catalysed N-arylation reactions have limitations41. After isolating the desired 
products in low yields using a copper iodide catalyst, the reaction to form compound 
68 was optimised using the conditions shown in scheme 1.1.3.5. 




The issues with the de-boc racemisation were resolved by using a route (blue, scheme 
1.1.3.5) based on proline methyl ester 77, thus eliminating the need for boc 
deprotection. This route focused on the cyclisation of precursor 80 rather than 
precursor 76. The optimised copper catalysed N-arylation then furnished the 
circumdatin analogue 68. Kshirsagar went on to report an effective and novel synthetic 
pathway to other circumdatins, such as H and J, using the precursors 75b-d (see 
above), offering a previously unreported route, which could prove useful in analogue 
synthesis, where other annulations prove unsuccessful. 
In a similar fashion, Mekala et al reported a synthesis of circumdatin H42, along with 
other quinazolinones by way of a copper catalysed N-arylation and utilising a novel 
iron(III) chloride catalysed approach to afford intermediate quinazolinone 75e43. 75e 




was synthesised from 2-iodobenzoic acid and L-proline methyl ester, followed by a 
series of facile functional group interconversions as shown in scheme 1.1.3.6.  
More recently, Mahajan and Mhaske reported a previously unprecedented route to 
circumdatin alkaloids44. The oxidative decarboxylative coupling (ODC) (scheme 
1.1.3.7) utilised by Mahajan and Mhaske was also the first reported example of an 
oxidative decarboxylative coupling that shows memory of chirality (MOC).  
Scheme 1.1.3.6: Synthesis of circumdatin H as reported by Mekala et al. 
 




The protocol designed by Mahajan and Mhaske is mild and works with generally 
inexpensive reagents and catalyst, resulting in both naturally occurring circumdatins, 
along with the potential for myriad synthetic analogues. Over four steps and overall 
yields of 30 and 24% respectively for circumdatins H and J 46 and 47, Mahajan and 
Mhaske offer an excellent synthetic strategy, and opportunity for further study of the 
memory of chirality phenomena. 
Liu et al reported a unique microwave assisted synthesis of several 
quinazolinobenzodiazepine alkaloids including circumdatin F, and analogues of 
circumdatin E45. The route to circumdatin F, a microwave assisted domino reaction, 
and the route to circumdatin E analogues, a microwave assisted three component one-
pot reaction, are both shown in scheme 1.1.3.8. 
The ease of synthesis coupled with promising yields reported - typically between 25 
and 55%, suggests that these microwave-assisted syntheses could open many doors 
to synthetically produced quinazolinobenzodiazepine alkaloids and their possible uses 
in pharmaceutical applications. 
  




 An Overview of Pyrrolobenzothiadiazepines. 
A similar, yet relatively unexplored subspecies of the PBD family are the 
pyrrolobenzothiadiazepines (PBTDs). While the PBTDs have received much less 
attention than the PBDs, PBTDs are still an attractive class of molecules both 
synthetically and biologically.  
Zidovudine (ZDV, 96) was the first drug to be clinically approved to treat acquired 
immune deficiency syndrome (AIDS). The efficacy of ZDV was marred by side effects 
such as the development of drug-resistant variants and the suppression of bone 
marrow production. 2',3'-Dideoxyinosine, didanosine (DDI, 97) was later approved in 
order to treat those with ZDV resistances, however, DDI also showed side effects 
leading to the development of drug resistant mutants. Artico et al developed 
precedented work on tricyclic systems acting as non-nucleoside reverse transcriptase 
inhibitors46 (NNRTIs) such as nevirapine (98) and the dibenzothiazepine 99, shown in 
figure 1.1.4.1 .  
Artico and co-workers set out to search for new NNRTIs incorporating tricyclic 
benzodiazepines and thiadiazepines. Of the many compounds synthesised and 
screened, two variants, 100 and 101 showed potent and specific activity towards HIV-
1 with EC50 and IC50 comparable to 
nevirapine47. It was found that the 
PBTD derivatives synthesised also 
inhibited HIV-1 reverse transcriptase, 
therefore introducing PBTDs as a new class of NNRTI. 
 
 
Figure 1.1.4.1: A selection of NNRTIs, including thiazepine 99. 
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Marfe et al reported on the potential anti-cancer properties of PBTDs, when three 
PBTDs (102 – 104) were tested against human K562 cells – a form of acute myeloid 
leukaemia, to moderate success48. The PBTDs were chosen with structural elements 
thought necessary to control apoptosis, including a sulfone group, benzofused 
heterocyclic ring, short side chains containing carboxylic acid or ester functionality, 
and in one case, an 
N-aroyl group at 
position 10. It was 
discovered that 
PBTDs 102 and 104 
caused 60 and 65% apoptosis in K562, respectively. Apoptosis was characterised by 
DNA fragmentation associated with poly(ADP-ribose)polymerase (PARP) cleavage. It 
was also found however, that proteins Bcl-2 and Bcl-xl negatively impact the apoptosis 
rate of PBTD treated cells, suggesting further developments would require Bcl-2 and 
Bcl-xl downregulation and the upregulation of Bax protein to maximise the efficiency 
of the apoptosis. 
PBTDs have also been reported as potential anti-schistosomal 
agents. This is an important development, as, over the past 40 
years, praziquantel (PZQ – 105) has been the only effective 
drug to treat schistosomiasis49. With no alternatives or back up 
drugs to treat schistosomiasis, should resistances be 
developed, there will be an urgent need for new anti-schistosomal agents. Chen et al 
reported on a series of PBTDs (figure 1.1.4.2) and related compounds and assessed 
their efficacy as anti-schistosomal agents.  
While none of the molecules tested by Chen showed activity close to PZQ, it was found 
that the chlorination of the pyrrole ring as displayed in 106 increased the worm killing 
capabilities in comparison to the parent molecule, providing an interesting 
development of the structural activity relationship of these PBTDs50. 
Figure 1.1.4.2: PBTD and related compounds as reported by Chen et al. 
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Synthetically, PBTDs should be just as accessible as PBDs, however, due to the 
overall lack of research on the PBTDs, reported synthetic pathways to PBTDs are 
comparatively sparse. In the early 1990s, tetracyclic diazepines were of great interest, 
as 111 and 112 were of clinical interest as antidepressant and anxiolytic respectively 
(figure 1.1.4.3).  
Compounds 113 – 115 were synthesised by Artico et al in an effort to develop 
approaches to pyrrole-containing tetracycles. Compound 115 was reported as a 
completely novel, medically interesting PBTD tetracycle. 115 was synthesised from 
PBTD 116 in the presence of TosMIC and n-butyllithium. There are two possible routes 
to PBTD 116, both detailed by Artico and co-workers51, and shown in scheme 1.1.4.1. 
Figure 1.1.4.3: A Series of tetracyclic PBDs, including some PBTDs. 
Scheme 1.1.4.1: Synthesis of tetracyclic PBTD 115 Using TosMIC and n-BuLi. 
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With both routes to 116 being both concise and with relatively good yields, the only 
shortcoming of this synthesis is the transformation of 116 to 115. Using a modified 
Van Leusen protocol, the imidazole moiety was introduced using TosMIC and n-BuLi 
over 60 hours. The synthesis of 115 established a series of syntheses targeting 
PBTDs, reported by Artico et al. While attempting the synthesis of aptazapine 
analogue 122 by treating 123 with an excess of methylamine, unexpected product 124 
was instead observed. Upon treatment with 2-hydroxypyridine, compound 125 was 
recovered, a novel tetracyclic spiro-PBTD as shown in scheme 1.1.4.2.  
Artico et al then developed a practical synthesis of compound 124 as detailed in 
scheme 1.1.4.3. Interestingly, 2-nitrobenzenesulfenyl chloride was used, over the 
corresponding sulfone, and the sulfone moiety is introduced later in the synthesis. 
Schemes 1.1.4.3 and 1.1.4.2 detail a synthesis to furnish a novel family of tetracyclic 
spiro-PBTDs, with the possibility of expanding the pyrrolidine ring, or changing the 
functionality at several possible sites. The investigation of any medical properties 
these molecules may hold would also be a useful endeavour due to the structural 
similarity to known PBTDs with medicinal activity.  
Scheme 1.1.4.3: Synthesis of diamide 124 from 1H-pyrrole and 2-nitrobenzenesulfenyl chloride. 
 
Scheme 1.1.4.2: Formation of novel spiro-PBTD from unexpected diamide 124. 
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Previously, all noted examples of PBTDs feature the pyrrole ring fused into the 
sulfonamide (114, 115, 115, 122, etc), however, a new structural analogue was 
reported by Artico et al wherein the pyrrole is incorporated into the 5N position, as 
shown by structure 131 in scheme 1.1.4.4. The PBTDs of this variety were tested for 
activity against HIV-1, and while none bore a competitive activity to nevirapine, an 
interesting synthetic approach was established to access these PBTDs52. The key step 
of this synthesis is the reaction of the arylamine 129 with 2,5-dimethoxytetrahydrofuran 
in glacial acetic acid at reflux via the Clauson-Kaas method. The synthesis in its 
entirety is shown in scheme 1.1.4.4. 
More recently, Hemming and co-workers have contributed several synthetic 
approaches targeting PBTDs, including tetracyclic 
aziridinopyrrolobenzothiadiazepines, oxadiazolopyrrolobenzothiadiazepines, and 
triazolopyrrolobenzothiadiazepines, along with analogues of more ‘traditional’ tricyclic 
PBDs53,54. These routes centre around azide based 1,3-dipolar cycloadditions. 
The 1,3-dipolar cycloaddition (1,3-DC) is an extremely well documented reaction 
involving a 1,3-dipole and a dipolarophile. Mechanistically, a 1,3-DC happens in a 
similar manner to the Diels-Alder reaction, wherein a heterocyclic ring is formed via a 
concerted π4s + π2s transition state, as shown in scheme 1.1.4.5.  
Scheme 1.1.4.4: Synthesis of alternate-structure PBTDs as reported by Artico et al. 
 




While the mechanism detailed in scheme 1.1.4.5 is widely accepted, there are 
examples of 1,3-DC reactions that occur over two steps. Huisgen, Mloston, and 
Langhals demonstrated that the final product of 1,3-DC reactions using thiocarbonyl 
ylides as the 1,3-dipole showed evidence of cis-trans isomerisation, suggesting an 
intermediate state wherein the configuration of the molecule could change55, as a 
concerted reaction would not allow opportunity for isomerisation. Huisgen proposed 
the mechanism shown in scheme 1.1.4.6 in explanation to this fact. 
Additionally, Siadati showed through computational methods that the reaction 
between nitrile oxides and electron rich alkenes proceeded via the intermediate 
species shown in scheme 1.1.4.756. 
The approaches to the triazolo and aziridinopyrrolobenzothiadiazepines reported by 
Hemming et al rely on the intramolecular reaction between an azide moiety and a 
dipolarophile53. Both approaches can be seen in scheme 1.1.4.8. 
Scheme 1.1.4.8: Routes to Triazolo and Aziridinopyrrolobenzothiadiazepines 
 
Scheme 1.1.4.6: Mechanistic detail explaining isomerisation in 1,3-DC products from thiocarbonyl ylides. 
 




As shown in scheme 1.1.4.9, the route to oxadiazolopyrrolobenzothiadiazepines is 
more complex than that of the triazolo and aziridinopyrrolobenzothiadiazepines, 
beginning with the formation of sulfinylimine 145, and subsequent Diels-Alder reaction 
with isoprene, furnishing the corresponding 1,2-thiazine-1-oxide53. The sulfur was 
extruded in the presence of trimethyl phosphite, forming the pyrrole ring, and the azide 
reduced to the primary amine. N-formylating the amine followed by a Bischler-
Napieralksi reaction afforded the PBTD 148. 1,3-Dipolar cycloaddition with nitrile 
oxides then gave the desired oxadiazolo-PBTDs (149 etc) in moderate yields.  
There is still much work to be done in the area of PBTDs, in both synthesis, and 
potential applications. The reported literature sets a strong precedent for potential 
biological and medicinal significance, and as such, effective syntheses will be 
required. 
  




1.2 An Introduction to Homotropane Alkaloids 
 Homotropane Alkaloids and the azabicyclo[4.2.1]nonane System 
Homotropanes first piqued the interest of synthetic chemists after the isolation of 
anatoxin-a (150), a neurotoxin present in blue-green algae Anabaena flosaquae. 
Analysis of the N-acetyl analogue (151) elucidated the structure57, shown in figure 
1.2.1.1, and interest built, because at the time, anatoxin-a was the only naturally 
occurring alkaloid containing the 9-azabicyclo[4.2.1]nonane ring system.  
Anatoxin-a 150 and analogues 151-154 (see figure 1.2.1.1) are all biologically 
potent58a-d, binding to the nicotinic acetylcholine receptor (nAChR), with anatoxin-a 
itself reported to be in the area of eight times as potent as acetylcholine itself59. The 
potency of this molecule lends itself to its informal name “very fast death factor”, 
causing death by respiratory paralysis in animals and humans. 
There are several well-documented synthetic routes to these homotropane nuclei, 
including ring expansion of a tropane nucleus60, intramolecular cyclisation of iminium 
salts61, and through the cyclisation of allenes62. One particularly curious synthesis of 
a related system was reported by Hemming et al, when diphenylcyclopropenone 155 
was reacted with a 4-vinyl-1-azetine 156. In this reaction, the expected cycloadduct 
157 was not obtained, and instead, a bicyclo-nonane 158 was obtained63, as shown 










It was postulated that cycloadduct 157 did indeed form via the expected mechanism, 
however, upon formation of 157, an aza-Cope [3,3]-sigmatropic rearrangement 
occurs, rearranging the cycloadduct 157 to the 7-azabicyclo[4.2.1]nonane 158, as 
shown in scheme 1.2.1.2.  
The aza-Cope rearrangement is postulated to occur in these molecules due to ring 
strain, and the “half open book” structure at the junction of the two rings in structure 
(161), which allows the vinyl moiety to overlap with the cis-aryl alkene. This implies 
that the vinyl and sulfide groups adopt a trans configuration in order to facilitate the 
overlap. While similar sigmatropic rearrangements have been reported64a-b which also 
support strain relief being a driving factor in the rearrangement, the bicyclic 
rearrangement as reported by Hemming et al was previously unreported. It is worth 
noting that the 7-azabicyclo[4.2.1]nonane system present in 158 occurs naturally. 
Scheme 1.2.1.2: Mechanism of the formation of cycloadduct 269 and subsequent aza-Cope rearrangement. 
 




Thus, recently, Takayama et al have reported on the total synthesis of (-)-14-
hydroxygelsenicine 162, which is one of several related alkaloids possessing the 7-
azabicyclo[4.2.1]nonane system65, as seen in figure 1.2.1.2. 
Alkaloids of this type have been shown to have potent cytotoxicity against A431 human 
epidermoid carcinoma cells at the nanomolar level, with some surpassing the cisplatin 
used to standardise66. However, at the time, a comprehensive biological profile could 
not be compiled due to the small quantities of the alkaloids available. The total 
syntheses reported by Takayama et al aimed to resolve this. 
The synthesis of the 7-azabicyclo[4.2.1]nonane nucleus was achieved by an 
intramolecular aza-Michael addition on a cyclohepata-2-6-dien-one system, as 
described in scheme 1.2.1.3.  
 
 
166 was synthesised from commercially available materials over several steps. 
LiHMDS was then used, deprotonating the amide, and forming the N-PMB pyrrolidone 
ring system seen in 167. L-selectride, followed by PhNTf2 reduces the ketone and 
abstracts the remaining double bond. The triflate group is then introduced onto the 
newly formed alcohol. 
Figure 1.2.1.2: (-)-14-Hydroxygelsenicine and other related alkaloids. 
 




Bromophenyl compound 169 was introduced to form intermediate 170, after 
carbonylation of triflate 168. However, the TBDPS group prevented the reaction going 
to expected product 172. Following deprotection, Pd(0) was used to form the spiro-
compound 172 as shown in  scheme 1.2.1.4. 
From 172, the caged system 173 was formed through an ether linkage using mercuric 
chloride. The HgCl2 residue was then removed to form alcohol 174, and the removal 
of the PMB group followed, resulting in the amino form of (-)-14-hydroxygelsenicine 
175. 175 was converted to the title compound (-)-14-hydroxygelsenicine, over 4 steps 
shown in scheme 1.2.1.5. 
Takayama has thus reported not only a novel synthetic route to the 7-
azabicyclo[4.2.1]nonane nucleus, but has also provided it alongside pharmaceutical 
context, portraying 7-azabicyclo[4.2.1]nonane containing molecules as very strong 
candidates for pharmaceutical breakthrough. 
Scheme 1.2.1.4: Synthesising spiro compound 172 from the 7-azabicyclo[4.2.1]nonane core. 
 




1.3 – An Overview of Cyclopropenones and a Brief Review of Azetines. 
 Chemical and Biological Applications of Cyclopropenones. 
First reported in 1959 by Breslow, Haynie, and Mirra67, the synthesis of 
diphenylcyclopropenone (155) represented an important development in aromatic 
chemistry, as diphenylcyclopropenone was the first stable compound containing a 
carbonyl moiety in a three membered ring. Combining a paradoxical combination of 
ring strain and inherent stability, the cyclopropenone category of molecule led to an 
almost 25-year debate on the nature of its aromaticity68. It is now known that 
cyclopropenones exist in a resonance form, wherein a negative charge is held on the 
oxygen atom, rendering the propene ring an aromatic cation, adhering to Hückel’s rule 
of aromaticity69 as shown in figure 1.3.1.1. Interestingly, studies on the microwave 
spectra of cyclopropenones show the aromatic cation is not classically delocalised, 
and instead, exists as a mixture of both the neutral and cationic form70. 
As a result of their unusual structural and electronic properties, cyclopropenones can 
act both electrophilically and nucleophilically, allowing them to partake in a wide array 
of reactions. In the presence of Meerwein’s reagent, the carbonyl is alkylated, which, 
when reacted with dimethylamine, affords the dimethylamino adduct 178. 
Interestingly, upon reaction with bromine in chloroform, cyclopropenone 179 reacts 
first, to form a bromide salt, then, opening the ring, affords the trans alkene 181 without 
addition to the double bond. Both transformations are detailed in scheme 1.3.1.1. 
Figure 1.3.1.1: Resonance of the aromatic cyclopropenone. 
 




Cyclopropenones can also undergo hydrolysis in the presence of base, affording a 
ring-opened α,β-unsaturated carboxylic acid. In the case of asymmetric 
cyclopropenones, Bird and Harmer have reported that non-symmetric diaryl systems 
undergo hydrolysis affording the corresponding acids 186 and 187 in quantities 
relative to the respective rates of formation (scheme 1.3.1.2). Hammett studies 
indicated intermediate 183 preferentially cleaved to yield the more stable carbanion, 
followed by protonation. Interestingly, when Ar was ortho substituted, 183 would 
exclusively cleave to afford the trans acid, postulated to be due to steric interference 
as opposed to electronic interference71. 
Breslow and Altman have reported similar findings regarding the hydrolysis of non-
symmetric alkyl cyclopropenones. Treating methylcyclopropenone with base afforded 
the corresponding α,β-unsaturated acids in a 3:1 (E : Z) mixture, again, suggesting 
preferential cleavage to the more stable carbanion72. Scheme 1.3.1.3 shows a 
selection of other nucleophilic additions cyclopropenones can undergo73,74,75,76. 
Scheme 1.3.1.3: Various reactions of cyclopropenones. 
 




In addition to the addition reactions detailed in the schemes above, cyclopropenones 
have been reported to have catalytic properties. A prominent and important example, 
reported by Nacsa and Lambert, was the discovery that functionalised 
diphenylcyclopropenones can facilitate nucleophilic substitution in alcohols, while 
inverting stereochemistry. This development offers an alternative to the widely used 
Mitsunobu reaction, which is plagued with shortcomings, such as the toxic and 
explosive nature of the characteristic dicarboxylate reagents, difficulty of product 
separation, and excess use of reagents, which significantly lowers yield and reaction 
efficiency77. Nacsa and Lambert effectively demonstrated this new technique (scheme 
1.3.1.4) on a range of alcohols. 
To further improve this procedure, a cyclopropenone scavenging work-up was 
employed. Using the tendency of cyclopropenones to undergo a nucleophilic ring 
opening, tetraethylenepentamine (TEPA) was added to a mixture of the resultant 
mesylate and cyclopropenone, and following a 1 N HCl wash, quantitative removal of 
the cyclopropenone was observed, postulated to be due to conversion to acrylamide 
204 (scheme 1.3.1.5). This scavenging technique was used successfully in several 
other reported syntheses78. 
Scheme 1.3.1.4: Cyclopropenone catalysed alcohol conversion using methanesulfonic anhydride. 
 




In addition to developing a cyclopropenone catalysed Mitsunobu alternative, Nacsa 
and Lambert have reported cyclopropenones are also suitable catalysts in several 
dehydration reactions, such as with alcohols79, carboxylic acids80, and the Beckmann 
rearrangement81, as shown in scheme 1.3.1.6. 
Typically generated by treating diphenylcyclopropenone with thionyl/oxalyl chloride,  
the activated cyclopropene 205 is then treated with the desired alcohol/acid/oxime, 
generating the intermediate 212. The nucleophile is then free to attack, affording the 
desired substituted product 209-211.  
The cyclodehydration of diols by way of a cyclopropenium intermediate has also been 
reported by Kelley and Lambert, resulting in a novel cyclodehydration of 1,4- and 1,5-
diols82 by the mechanism shown in scheme 1.3.1.7. 
 
Scheme 1.3.1.7: Mechanism of dehydrative cyclization of a 1,4-diol. 
 




In addition to the work reported by Lambert et al, Matsuda and Sakuri have also 
reported on the reaction of cyclopropenones with enynes, resulting in a ring expanding 
spiroannulation83, as shown in scheme 1.3.1.8. Mechanistically, the reaction between 
the enyne 217 and cyclopropenone 155 occurs after the intermediate 219 is formed 
upon reaction with the gold catalyst84, where the cyclopropenone opens the 
cyclopropane ring, generating the oxocarbenium intermediate 220. The spirocyclic 
221 is formed after the alkenyl-gold(I) attacks the cyclopropene ring, then the sp2 
carbon of the cyclopropene ring migrates, resulting in the ring expansion to 222, which 
is then hydrolysed, regenerating the gold catalyst, and furnishing compound 218. 
Aside from myriad synthetic uses, cyclopropenone-containing compounds have also 
been shown to have biological properties. Naturally occurring penitricin 223 – figure 
1.3.1.2 has been reported to show gram-negative anti-bacterial activity85. Compounds 
224 and 225 are also naturally occurring, however, they show no biological properties. 
Penitricin analogues 226 and 227 were later synthesised by Nakamura et al and were 




shown to have significant antibacterial properties86. Kogen et al synthesised 
cyclopropenone 228, a compound showing useful factor XIIIa inhibition87. 
 
 Synthesis of Cyclopropenones 
The first cyclopropenone syntheses were reported simultaneously and independently 
by Breslow, Haynie, and Mirra, and Vol’pin, Koreshkov, and Kursanov in 1959. The 
method reported by Breslow et al was based on ketene and carbene chemistry, 
precedented by McElvain and Venerable88. Breslow detailed the reaction between 
(2,2-dimethoxyvinyl)benzene 229, and (dichloromethyl)benzene 230 with potassium t-
butoxide53. The (dichloromethyl)benzene adds across the ketene double bond, 
forming the cyclopropane intermediate 231. HCl was then eliminated, and 232 
hydrolysed to afford diphenylcyclopropenone as the sole product (scheme 1.3.2.1).  
Vol’pin et al reported a similar synthesis, generating dibromocarbene 233 in situ from 
potassium t-butoxide and tribromomethane 234, which then reacts with 
diphenylacetylene 235. Cyclopropene intermediate 236 forms, and is then hydrolysed, 
furnishing diphenylcyclopropenone 155, shown in scheme 1.3.2.289. 
Scheme 1.3.2.1: Synthesis of diphenylcyclopropenone as reported by Breslow. 





The use of tetrachlorocyclopropene 237 is widespread in the synthesis of 
cyclopropenones, when used in conjunction with aluminium(III) chloride. Lambert et al 
used such a method to synthesise dithioanisylcyclopropenone (239, scheme 1.3.2.3) 
among other similar symmetrical cyclopropenones90.  
Mechanistically, these reactions occur in the expected manner for a Friedel-Crafts 
acylation, so that aluminium chloride creates a trichlorocyclopropenium ion (240), 
which is then substituted onto the 4-position of the thioanisole to form species 241, 
followed by loss of HCl and hydrolysis, as detailed in scheme 1.3.2.4.  
Using this method, a plethora of symmetrical cyclopropenones have been 
synthesised, some of which are shown in figure 1.3.2.191. 
Scheme 1.3.2.2: Diphenylcyclopropenone synthesis as reported by Vol'pin. 
Scheme 1.3.2.3: An example of Friedel-Crafts acylation furnishing cyclopropenones. 
 
Scheme 1.3.2.4: Mechanism for the formation of cyclopropenones via a Friedel-Crafts route. 
Figure 1.3.2.1: A Selection of symmetrical cyclopropenones. 
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In addition to providing a facile route to symmetrical cyclopropenones, West et al have 
reported that, if carried out at low temperatures, the cyclopropenium ion will add to just 
one aromatic moiety, allowing for a different second aromatic group to be added in a 
subsequent reaction92, as displayed in scheme 1.3.2.5. 
Aside from the use of aluminium(III) chloride, diarylcyclopropenones can be accessed 
via the symmetrical bromination of an appropriate diaryl ketone. Reported by 
Matsumoto et al, the desired ketone species 254 is the product of the reaction between 
the corresponding benzyl bromide 255 and Fe(CO)5, later improved by Vanos and 
Lambert by using the corresponding phenylacetic acid 256 and coupling with N,N′-
dicyclohexylcarbodiimide (DCC)76. The ketone 254 undergoes a dibromination 
Scheme 1.3.2.5: Symmetrical and non-symmetric cyclopropenone syntheses using AlCl3. 




affording dibromoketone 257. The cyclopropenone 249/258 is then formed through an 
intramolecular elimination reaction93 as displayed above in scheme 1.3.2.6. 
Non-symmetric cyclopropenones can also be made in this fashion, as Wender, 
Paxton, and Williams detail, synthesizing 2-methyl-3-phenylcycloprop-2-en-1-one 261 
from 1-phenyl-2-butanone 259 via dibromo intermediate 260 as scheme 1.3.2.794 
shows. It is reasonable to assume similar cyclopropenones would be accessible 
through this approach. 
Another route to non-symmetric cyclopropenones, optimized by Netland, Gundersen, 
and Rise, sees the reaction of carbenoid LiCCl3•3THF with an appropriate alkyne, 
forming intermediate dichlorocyclopropene 263. The dichlorocyclopropenone is then 
hydrolyzed to afford the desired cyclopropenone e.g., 264, as shown in scheme 
1.3.2.895. In this process, the method of hydrolysis is deemed an important factor, as 
when hydrolysis was carried out as per Gleiter and Merger96, a significant amount of 
ynone 265 and 2-(dichloromethyl)tetrahydrofuran 266 was observed. When 
hydrolyzed with conc. hydrochloric acid at -78 °C, the amount of the ynone 265 and 
tetrahydrofuran 266 were significantly reduced. 
The use of acetals has also been shown to be an effective route to asymmetric 
cyclopropenones, and both aryl and alkyl cyclopropenones have been synthesized in 
this manner. Ando et al reported on the use of acetal 267 and the subsequent 
conversion to 2-phenylcyclopropenone acetal 269, which could easily undergo 
hydrolysis to afford the respective cyclopropenone. Beginning from phenylacetone, 
Scheme 1.3.2.8: Synthesis of cyclopropenones and optimisation as reported by Gundersen et al. 
 




which is chlorinated at the benzyl position, the acetal is formed using neopentyl glycol 
and p-TsOH. The terminal carbon is then brominated to afford the starting acetal 26798. 
From the acetal, the benzylic position is deprotonated, resulting in the intramolecular 
cyclisation to afford cyclopropane 268. The chlorine is extruded, affording 
cyclopropane acetal 26997, which is then hydrolyzed to the cyclopropenone 270, as 
seen in scheme 1.3.2.9. 
Another concise synthesis of cyclopropenones by way of cyclopropene acetals comes 
courtesy of Isaka, Ejiri, and Nakamura. In this approach, 1,3-dichloroacetone is used 
as the starting material, and the acetal is formed from neopentyl glycol. Sodium amide 
is then used to cyclize the cyclopropane. The sodium salt 275 formed in the presence 
of the intermediate  274 was then alkylated with a primary alkyl halide through slow 
addition at -78 °C. Fast addition of the alkyl halide was reported to result in furnishing 
the 2,3-dialkylated product. The alkylated cyclopropene 276 was then hydrolyzed, to 
afford the cyclopropenone 277 in good yields, as shown in scheme 1.3.2.1098. 
 
 
Scheme 1.3.2.9: Synthesis of cyclopropene acetals, and subsequent hydrolysis. 
 




  Formal (3+2) Cycloadditions Involving Cyclopropenones 
Since their discovery, it has been well-documented that cyclopropenones partake in 
reactions with electron rich imines. Eicher et al prolifically published reports on this 
phenomenon, initially reacting N,N,N’,N’-tetraalkylguanidines 278 with 
diphenylcyclopropenone to afford functionalised 3H-pyrrol-3-ones- 280, or 1H pyrrole-
2,3-diones-282, see Scheme 1.3.3.199. 
Mechanistically, reactions of this type are described as “formal [3+2] cycloadditions”, 
with the cyclopropenone acting as an all carbon 1,3-dipole equivalent. Heimgartner 
detailed this mechanism in a later publication100, as seen in scheme 1.3.3.2. 
Since then, the reactivity of cyclopropenones and cyclic imines have been further 
investigated by Aly102, Eicher99, Yoshida101, Heimgartner100, and Hemming. Aly et al  
strengthened the notion of the reaction occurring via a formal [3+2] cycloaddition when 
investigating the synthesis of pyrrolo[2,1-b]1,3,4-oxadiazoles via the proposed 
mechanism in scheme 1.3.3.3102. 
Scheme 1.3.3.1: Reaction of diphenylcyclopropenone with an electron rich imine. 
 




Other examples, reported by Kascheres103, Heimgartner, and Hemming104 concern 
the reaction between cyclopropenones and cyclic imines, creating a variety of 
functionalised heterocycles as shown in scheme 1.3.3.4. 
 
Scheme 1.3.3.3: Mechanistic formation of pyrrolo[2,1-b]1,3,4-oxadiazoles. 
 




 A Brief Review of 1-Azetines 
The reaction between cyclopropenones and 1-azetines is an important part of this 
thesis, and as such, a brief review of 1-azetines and their chemistry will be reported. 
Initial reports of the structures of 1-azetines were deemed “improbable” by 
contemporary literature105, and the only real interest in such molecules was generated 
when it was suggested that a 1-azetine related molecule (297) was involved in the 
biosynthesis of azetidine-2-carboxylic acid (298)106 (scheme 1.3.4.1) 
Denis et al isolated 1-azetine 300 from the dehydrohalogenation of N-chloroazetidine 
299 via vacuum assisted gas-phase elimination in the presence of t-BuOK•SiO2107- 
(scheme 1.3.4.2). 
It was reported by Denis et al that 1-azetine was relatively unstable at room 
temperature, so that in sealed, degassed tubes, 300 polymerised at 20 °C, and in 
solution (CFCl3) the half-life of 300 was reported to be 90 minutes. Amatatsu et al took 
advantage of this instability, by carrying out gas-phase FTIR spectroscopy on 1-
azetine generated in situ, with results consistent108 with previously reported work109. 
In the same publication, modified neglect of diatomic overlap (MNDO) calculations 
were carried out on 1-azetine, and again, proved to be compliant with previous 
reports98. These results show the bond between C2 and C3 is significantly longer than 
noncyclic hydrocarbons - up to 0.1 Å, significantly contributing to the ring strain in 
these molecules.  
The stability of 1-azetines can be increased through adding substituents across the 
carbon backbone, with stabilisation effects increasing in number of substitutions and 
in passing from alkyl to aryl groups.  
Scheme 1.3.4.2: Synthesis of 1-azetine from N-chloroazetidine. 
Scheme 1.3.4.1: Simplified transformation from 1-azetine to azetidine-2-carboxylic acid. 
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There are several established synthetic options when targeting 1-azetines. 4-Alkylthio-
2-vinyl azetines can be synthesised through thionation and subsequent alkylation of 
the β-lactam, offering additional functionality at the 2- and 4- positions94. Hassner et 
al reported on the use of trichloromethyllithium on azirine 301 to afford azetine 304110, 
which then in turn can be alkylated at the 4- position, or, converted to the β-lactam 
306, as detailed in scheme 1.3.4.3. 
Rinck et al reported on the synthesis of simple 1-azetines by the thermolysis of 
cyclopropyl azides111. Similarly, 2-alkylthio-1-azetines may be formed by the 
thermolysis of 1-alkylthio cyclopropyl azides112, presenting a possible alternative route 
to 2-alkylthio-1-azetines than that previously mentioned94. Both thermolyses are 
shown in scheme 1.3.4.4. 
A route to 2-amino-1-azetines has been reported by Ghosez et al, wherein 
dimethylamides are treated with phosgene and base, furnishing 1-chloroenamine 315, 
Scheme 1.3.4.3: Synthesis of 1-azetine as reported by Hassner109. 
Scheme 1.3.4.4: Thermolysis of cyclopropyl azides to furnish 1-azetines. 
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which, when reacted with a benzhydryl imine 316, gives the 2-amino-1-azetine after 
workup113, shown in scheme 1.3.4.5. 
There are other interesting synthetic applications for molecules in the azetine series 
in addition to the formation of the 7-azabicyclo[4.2.1]nonanes reported by Hemming 
et al59, and detailed above in schemes 1.2.1.1, and 1.2.1.2. A novel route towards 
oxazepines and diazepines was reported by Tsuchiya et al114, by treating tricyclic 
azetines 321 with ultraviolet frequencies, affording the corresponding ring system after 
rearrangement as shown in scheme 1.3.4.6. 
 Novikov et al made an interesting development in azetine chemistry by reporting a 
method for synthesising functionalised azetines 328 via  the ring-expansion of 2-
bromo-azirines 323, or ring-contraction of 4-bromo-isoxazoles 324 using the same 
conditions115 (scheme 1.3.4.7). 
Scheme 1.3.4.5: Synthesis of azetines via a protected azetidine. 
Scheme 1.3.4.6: Formation of oxazepines and diazepines from tricyclic azetines. 
Scheme 1.3.4.7: Synthesis of azetines from both azirines and isoxazoles. 
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The series of compounds synthesised using the 328 backbone were tested against 
THP-1 cells in vitro, and results showed a wide range in the apoptotic/necrotic 
difference test (AND) in these species. The most promising of these was 328 when R1 
= Ph, R2 = CO2Me, R3 = Me, with an AND of +20%113.  
Hemming et al have also demonstrated that the cycloadduct formed from 4-aryl-2-
thioalkyl-1-azetines and symmetrical cyclopropenones undergo a [2+2]-
retrocycloaddition, in refluxing toluene. The resulting fragments then take part in a 
[4+2] cycloaddition, affording a proposed bridged cycloimine 333, which loses CO, 
furnishing the aromatized thiopyridines 334 as shown in scheme 1.3.4.8116. 
Similarly, Hemming et al reported that 4-aryl-1-azetines react with nitrile oxides and 
undergo cycloaddition to form bicyclic systems such as 337a/b, which also undergo a 
[2+2]-retrocycloaddition, affording 1,2,4-oxadiazoles 338, a moiety contained in a 
variety of biologically active molecules117a-b (scheme 1.3.4.9118). 
  
Scheme 1.3.4.8: Synthesis of pyridines from azetines. 
 




Chapter 2  – Results and Discussion 
This chapter details the findings and an exploration of the results from the approaches 
to synthesise sulfonyl analogues and homologues of the natural products fuligocandin 
A and B, (section 2.1), the synthetic approaches towards the synthesis of sulfonyl 
analogues and homologues of the natural product circumdatin H, (section 2.2). The 
results of in vitro testing of a selection of molecules synthesised in sections 2.1 and 
2.2 is shown in section 2.3. Section 2.4 details the investigation into the reaction of 4-
vinyl-1-azetines and diarylcyclopropenones, and section 2.5 explores a similar 
reaction of diarylcyclopropenones and polycyclic imines. A selection of products 
synthesised in section 2.4 were subjected to in vitro testing, the results of which are 
shown in section 2.6.  
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2.1  The Synthesis of Sulfonyl Analogues of the Fuligocandins 
 The Synthesis of the Sulfonyl Fuligocandin Precursor 1,2,3,11a-
tetrahydrobenzo[f]pyrrolo[1,2-b][1,2,5]thiadiazepin-11(10H)-one 5,5-dioxide. 
The Eschenmoser episulfide contraction was chosen as the initial route towards the 
sulfonyl analogue fuligocandins due to its relatively mild conditions and reported 
efficiency26. In the reported procedure26 for fuligocandin A itself, the precursor dilactam 
28 was synthesised (see scheme 1.1.2.3) via the reaction between isatoic anhydride 
and L-proline, however, since the sulfonyl analogue of 28 cannot be accessed in this 
manner, a different route to this precursor was required. Using a route optimised by 
Hamasharif119, and based upon previous work37a, precursor sulfonamide 339 was 
synthesised over three steps as detailed in scheme 2.1.1.1.  
The coupling between L-proline and sulfonyl chloride 341 proved facile and high 
yielding, affording the desired sulfonamide without need of purification. These 
characteristics made scaling up this reaction attractive, and when scaled up to multi-
gram scale, the reaction proceeded as expected without any noticeable drop in 
efficiency. The reduction of nitro compound 342, under the indicated conditions in 
scheme 2.1.1.1 furnished the desired amine 343 without the need for purification after 
thorough work-up. This step proved to be incredibly capricious regarding yields 
however, with recoveries ranging between 15% and 80%. After failed attempts to 
maximise yields through altering the reaction conditions, it was postulated that material 
was being lost during the work-up. Several variations of the work-up were utilised; 
however, none of these attempts made a noticeable change. The conditions for this 
reaction also made carrying out the reduction on larger scales impractical and 
unpleasant due to the large volume of acetic acid needed, and interference caused 




between the iron powder and magnetic stir bars. The final step in synthesising 
precursor 339 was the intramolecular amidation, which proceeded smoothly, affording 
the required amide in consistently good yields without the need for purification after 
the solid was dried under vacuum. 
In an attempt to maximise the efficiency and workability of the synthesis of PBTD 339, 
several different approaches were trialled. The first option was to ensure that the 
reduction of nitro compound 342 produced consistently good yields. A reduction using 
hydrazine and palladium120 was initially used. The reaction itself proved much cleaner, 
with the lack of iron, and lack of the gummy deposits occurring during the work-up. 
One drawback however was the reaction conditions - hydrazine hydrate and carbon-
bound palladium in refluxing ethanol bore inherent dangers and would need careful 
monitoring if the reaction were scaled up. While advantageous in terms of workability, 
the hydrazine proved difficult to remove during work-up, and ofttimes, the product was 
completely lost during the work up. A third reduction procedure was therefore 
employed. Reported by Lin and Snyder121, ammonium formate and zinc were 
employed to reduce 342, as shown in scheme 2.1.1.2. 
The conditions in scheme 2.1.1.2 resulted an excellent reduction strategy, providing a 
clean, mild reaction that was also reasonably fast. The only caveat to this reaction was 
the excess of reagents needed to facilitate the reaction, making larger-scale reactions 
impractical.  
A slightly different route to sulfonamide 339 was also attempted, taking initial steps 
from a report by Sanjayan et al122. In this iteration, ((2-nitrobenzene)sulfonyl)chloride 
341 was coupled with L-proline methyl ester 344. The nitro group was reduced using 
the ammonium formate and zinc method and was followed by ring closure with 
diphenyl ether (DPE) in 2-hydroxypyridine, as seen in scheme 2.1.1.3.  





The coupling of sulfonyl chloride 341 and proline methyl ester 344 was facile and 
relatively high yielding, as was the reduction, similar in both cases to the L-proline 
approach (shown in scheme 2.1.1.1). The final step, using 2-hydroxypyridine in DPE 
at 205 °C, as previously utilised by Artico et al123 proved very problematic. Following 
extreme reaction conditions and a difficult work-up, post-purification afforded the 
desired product 399 in yields typically less than 15%. Compound 346 could however, 
be hydrolysed, e.g., using LiOH and a mixture of THF and water, affording carboxylic 
acid 343, which could then undergo the ring closure using DCC as previously shown 
in scheme 2.1.1.1. The drawbacks of the 2-hydroxypyridine step in this approach, 
combined with the need of adding in an unnecessary step from the alternative, L-
proline route (scheme 2.1.1.1), meant the approach shown in scheme 2.1.1.3 was 
disadvantageous.  
 Attempted Syntheses of Fuligocandin A Analogue from 1,2,3,11a-
tetrahydrobenzo[f]pyrrolo[1,2-b][1,2,5]thiadiazepin-11(10H)-one 5,5-dioxide. 
As precursor PBTD 339 bears only a single carbonyl group, the threat of dithionation 
as reported for the diamide analogue by Bergman et al26 was not present. Thus, 
Lawesson’s reagent 347 was employed as previously reported,120 and shown in 
scheme 2.1.2.1 along with the reaction mechanism. As the reaction progressed, a 
precipitate formed, and upon completion of the reaction this precipitate was filtered 
and, fortuitously, found to be the desired thioamide 350 in average yield. More 




precipitated product could be obtained by concentrating the reaction mixture and 
dissolving the residue in CHCl3. 
With thioamide 350 in hand, the Eschenmoser reaction was attempted. Following the 
conditions reported by Bergman26  - (scheme 2.1.2.2), the reaction was carried out 
using DACBO and trimethylphosphite, as shown in scheme 2.1.2.2, and the recovered 
material was purified.  
Scheme 2.1.2.1: Formation of thioamide 350 using Lawesson's reagent. 




Upon analysis, it was apparent the desired product was not present in any of the crude 
components, as the characteristic alkene signal was missing at ~5.5 ppm in the 1H 
NMR spectrum. What was observed however, was a low ppm methyl singlet. With no 
traces of the expected alkene present, it remains unclear by what means this moiety 
was inserted. Carbon NMR and mass spectral analysis confirmed that the desired 
product was not synthesised. Interestingly, only one oxygen atom was observed in the 
isolated product, thus, the observed product is believed to be compound 353a.  
It is speculated that compound 353a is formed through the mechanism shown in 
scheme 2.1.2.3 below. The expected imine 353 is formed by the 
reaction of 352 with chloroacetone, and after base treatment, the 
resultant terminal carbanion attacks at the imine carbon, to give spiro 
intermediate 353b. Spiro compound 353b extrudes 
thioformaldehyde and carbon monoxide, furnishing terminal alkene 
353c, where subsequent tautomerization affords compound 353d. Finally, the 
formation of trimethyl phosphate drives the conversion of the sulfone 353d into the 
sulfoxide, affording the observed compound 353a. 
In their synthesis of fuligocandin itself, Bergman et al reported26 that the use of 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) as a base rather than DABCO furnished the 
desired compound with a lower yield. This was also attempted in order to synthesise 
fuligocandin analogue 354; however, this proved fruitless. Next, the intermediate 
sulfide 353 was targeted, in the hope that the problem in the two-step sequence could 
be identified. Thioamide 352 was treated with NaH and chloroacetone, in dry DMSO, 
and the reaction was left to progress until the starting materials were consumed. Ethyl 




acetate was used to dilute the mixture, and the DMSO was removed with sequential 
water washes. The remaining material was purified, and analysis showed intermediate 
353 was successfully synthesised. This suggests that the first reaction shown in 
scheme 2.1.2.2 is not problematic, and the problem lies in the sulfur extrusion step. 
This also suggests that the proposed intermediate 353b in scheme 2.1.2.3 arises from 
an intermolecular cyclisation of intermediate 353. 
Several failed attempts were made to convert the intermediate 353 into the desired 
vinyl ketone 354, including attempting the reaction with several bases in other high-
boiling solvents. After these attempts, the Eschenmoser approach was deemed 
unsuccessful. 
The next attempt at synthesising 354 came via a Wittig olefination, by treating PBTDs 
339/352 with the chloroacetone derived ylide 355, which was easily synthesised from 
a reported procedure124. After attempting the reaction several times, varying conditions 
such as temperature, time, and solvent, this route was also abandoned, with the only 
identifiable product being the methyl ester 356,  the product of amide bond cleavage 
by methanol, as shown in scheme 2.1.2.4. 
 Synthesis of Fuligocandin A Sulfonyl Analogue via Diazoketone. 
After the unsuccessful attempts at converting PBTD 339 into the fuligocandin 
analogue 354, it was clear that a different approach was needed. The synthesis of 
fuligocandin reported by Sorra28 was selected, as precursor 36 (see scheme 1.1.2.5 
in the Introduction), is an analogue of our readily available sulfonamide 342, a 
compound used in the synthesis of PBTD 339. 




Precursor 342 was synthesised under the conditions described in  scheme 2.1.1.1. 
The carbonyl was activated following the procedure reported by Sorra, using 
triethylamine and ethyl chloroformate, as displayed in scheme 2.1.3.1. 
The mixed anhydride 357 was reacted without purification and was treated with a 2 M 
solution of TMS-diazomethane in hexanes which was then warmed to ambient 
temperature overnight. Upon isolation and purification of the diazoketone 358, over 
several attempts, the isolated yields ranged between 15 and 20%. Thus, the reaction 
was left after the addition of the diazomethane solution for 72 hours in an attempt to 
maximise conversion. This had little to no impact on the recovery of compound 358. 
Due to the safety concerns using TMS-diazomethane125, any form of additional heating 
was avoided. 
Previous work had reported the formation of diazoketones from acid chlorides126; as 
such, acid 342 was converted to acid chloride 359 using DMF and oxalyl chloride at 
room temperature, as shown in scheme 2.1.3.2. Intermediate 359 was cooled to -20 
°C and the TMS-diazomethane was added as per the original method. 
Following the use of intermediate 359, it was immediately clear that the reaction was 
occurring at a much faster rate, as the diazomethane solution was visibly consumed 
upon addition to the stirring acid chloride, which was previously not seen with the 
mixed anhydride intermediate. The reaction was left to stir for a total of 72 hours, and 
Scheme 2.1.3.1: Formation of mixed anhydride 357 and subsequent diazotisation. 
 




upon purification the isolated yield of compound 358 was found to be 48%, over double 
the observed yield following the use of ethyl chloroformate. 
Finally, the diazoketone 358 was treated with acetaldehyde in the presence of tin(II) 
chloride, affording intermediate β-diketone 360. Subsequent treatment with activated 
zinc and acetic acid resulted in the reductive cyclodehydration of diketone 360 to afford 
the target compound 354, shown in scheme 2.1.3.3,  in relatively low yields of typically 
between 15 and 20% starting from diazoketone 358. 
Following the successful synthesis of the fuligocandin analogue 354, attempts were 
made to optimise the conditions shown in scheme 2.1.3.3 by substituting activated 
zinc with iron and allowing the reductive cyclodehydration to progress over a longer 
period of time. Both of these strategies proved unsuccessful at improving the yield of 
354. Future optimisation attempts could include attempting the reduction using the 
zinc/ammonium formate conditions that more efficiently reduced compound 342,  
and/or heating the reaction mixture after complete consumption of diazoketone 358, 
resulting in either a refluxing DCM system, or, after the evaporation of the DCM, the 
use of acetic acid as the reaction solvent. 




 Attempted Synthesis of Fuligocandin B Analogue 
With an effective route to fuligocandin A analogue 354, the next logical step was to 
synthesise fuligocandin B analogue 361, shown in figure 2.1.4.1.  
The first attempt at this transformation came directly from precedented work26, wherein 
the 3-vinyl-1H-indole moiety is introduced from a protected 3-formylindole 363. This 
was synthesised from 3-formylindole 362 in the presence of triisopropylsilyl (TIPS) 
chloride and sodium hydride127 as shown in scheme 2.1.4.1. 
The attempt at protecting the 3-formylindole as described in scheme 2.1.4.1 proved 
unsuccessful. The presence of 363 was undeniable, but a side-product, believed to be 
triisopropylsilanol, indicated by a broad singlet at 2.66 ppm, and a total of 21 protons, 
was also formed in significant quantities. The mixture was progressed to the next stage 
Scheme 2.1.4.1: Formation of N-protected 3-formylindole 363. 
Scheme 2.1.4.2: Attempted aldol condensation to furnish 361. 
Figure 2.1.4.1: Structures of fuligocandin B (11) and its sulfur analogue 361. 
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in the hope that the protected indole would react as expected. The aldol condensation 
was attempted as reported by Arai et al26, as shown above in scheme 2.1.4.2. 
The reaction failed when the LDA used was generated as required from DIPA and n-
BuLi, or when commercial LDA was used. The only recovered compounds were the 
starting material 354 and the deprotected 3-formylindole 362. In another attempt to 
successfully carry out the aldol condensation, the reaction was repeated with N-boc 
and N-nosyl protected 3-formylindoles, both of which proved unsuccessful. An 
alternative route to the N-protected 3-formylindole would be to first N-protect the 
indole, and then lithiate at C3, followed by electrophilic addition of the aldehyde128 
shown in scheme 2.1.4.3. However, lack of time prevented this route from being 
explored. 
Next, an opportunity was seen to modify the reductive cyclodehydration seen in 
scheme 2.1.3.3 above, that successfully afforded 354. As  such, aldehyde 366 was 
synthesised from indole 363 and acrolein 365 in the presence of morpholine-TFA and 
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), as reported by Jiao et al129, shown 
in scheme 2.1.4.4. The synthesis of aldehyde 366 proved to be facile, with NMR data 
consistent with previously reported entries127. 
Scheme 2.1.4.4: Synthesis of unsaturated indole aldehyde 366. 
 
Scheme 2.1.4.3: TIPS protection of indole and subsequent electrophilic addition at C3. 
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The diazoketone 358 was prepared in the manner previously described (scheme 
2.1.3.2) and treated with tin(II) chloride and aldehyde 366 in an attempt to introduce 
the vinyl indole moiety prior to the reductive cyclodehydration, displayed in scheme 
2.1.4.5. 
TLC showed that starting materials 358 and 366 were consumed, showing a single 
new spot present following the first step; as such, the intermediate, assumed to be 
compound 368 was progressed without isolation. Following the attempted reductive 
cyclodehydration, the crude analyte contained promising signals; however, after 
purification, none of the isolates were successfully identified as the desired product 
361. Future work should focus on the  optimisation of these reaction conditions in order 
to allow a successful synthesis of the fuligocandin B analogue 361, following the 
successful synthesis of fuligocandin A analogue 354. 
 Attempted Synthesis of a Sulfonyl Fuligocandin A Homologue 
With a successful route now available to the fuligocandin A sulfonyl analogue 354, the 
opportunity was taken to explore the synthesis of other possible analogues. L-
piperidine-2-carboxylic 369 acid was chosen as a homologue to L-proline. The initial 
coupling proved challenging, with the previously used procedure proving ineffective, 
with no evidence of the coupling occurring. Several other coupling protocols were 
attempted, before finding success with conditions (reported for a different substrate) 
by Sorra et al28, shown in scheme 2.1.5.1. 
Scheme 2.1.4.5: Attempted synthesis of fuligocandin B sulfonyl analogue 361 using indole aldehyde species 367. 
 




Following this, the sulfonamide 370 was converted to the diazoketone 371 in the usual 
manner, with yields similar to that seen with proline. Compound 371 was then treated 
with acetaldehyde and tin(II) chloride, followed by treatment with activated zinc and 
acetic acid, as detailed in scheme 2.1.5.2. 
Upon completion of the reaction and subsequent purification, the proton NMR of one 
isolate proved promising, with key signals - a broad singlet at 12.32 ppm, and a sharp 
singlet at 5.46 ppm, both integrating to one proton, suggesting the presence of the 
vinyl amide, and a singlet showing three protons at 2.00 ppm, implying the presence 
of the terminal methyl group. While these proton signals alone were encouraging, both 
the aromatic and the aliphatic regions contained an excess of signals, suggesting the 
presence of impurities. The small quantities of this isolate were insufficient to obtain a 
carbon NMR spectrum, and further purification of the species was not possible. The 
synthesis of homologues of this type may prove to be a worthwhile area of research 
in the future, given the absence of research on fuligocandin analogues. 
 Summary 
A reductive cyclodehydration reaction was employed to synthesise the sulfonyl 
analogue of the natural product fuligocandin A (FCA). Homologue synthesis of the 
sulfonyl analogue of FCA was also explored, with the precursor of a six-membered 
homologue successfully synthesised. Future work in this area should include 
optimisation of the reaction conditions that were found to furnish the sulfonyl analogue 
of FCA. Optimisation of such conditions would allow the synthesis and study of more 
diverse homologues, and also allow increased access to the sulfonyl analogue of  FCA 
which would then facilitate a more detailed exploration of the conversion of sulfonyl 
analogue of FCA into the respective fuligocandin B analogue. 




2.2 – The Synthesis of Sulfonyl Circumdatins and Related Compounds. 
 The Attempted Synthesis of benzo[c][1,2,5]oxathiazin-3(4H)-one 1,1-
dioxide 
Of the reported circumdatins containing a pyrrolidine moiety, circumdatin H (46) [see 
introduction] was selected as the first target for sulfonyl analogue synthesis, due to the 
relative simplicity in comparison with other entries in the “pyrrolo-circumdatin” series. 
With three precedented routes to circumdatin H proceeding via 1,2,3,11a-tetrahydro-
5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H)-dione 28, and a reliable synthetic 
strategy to the sulfonamide analogue 339 already in place, a circumdatin H analogue 
was the logical starting point. 
Before these syntheses were attempted however, it was apparent that any advances 
towards a more efficient synthesis of 339 would greatly improve throughput to the 
circumdatin analogues. Precedented literature35,37,38 shows the reaction between 
isatoic anhydride and L-proline (scheme 1.1.2.3) to be the ubiquitous route to the 
circumdatin precursor 28,  and as such, an analogous route to the sulfonyl-precursor 
339 was extremely attractive. 
A route to 7-methylbenzo[c][1,2,5]oxathiazin-3(4H)-one 1,1-dioxide 374 was reported 
by Dieterich et al, wherein 4-methylbenzene isocyanate 375 was treated with gaseous 
sulfur trioxide, to afford the oxathiazinone dioxide 374 (scheme 2.2.1.1)130. 
While reported to be an effective route to the compound of interest, the cost and safety 
risks of working with gaseous SO3 proved too severe, and while various sulfur trioxide 
complexes are available commercially, the risks associated with using these were also 
undesirable, and existing in solid form, there was no evidence showing such 
complexes would successfully promote the desired reaction. 




Instead, a well-documented131 synthesis of isatoic anhydride was employed, adapted 
to potentially furnish the desired analogue 381. Treatment of the aryl amine with 
triphosgene converts the amine into the isocyanate, which then cyclises with the 
existing sulfonic acid, as shown in scheme 2.2.1.2, in essence, mirroring the synthesis 
in scheme 2.2.1.1. 
The reaction progressed without any real problems, and upon removal of the reaction 
solvent, a solid was afforded that bore an acrid odour and a similar appearance to 
isatoic anhydride. Proton NMR spectroscopy showed a correct number of signals in 
the expected areas, however, due to the low solubility of the recovered solid, 13C NMR 
spectra were not able to be obtained. A small-scale reaction between the suspected 
product 381 and L-proline (scheme 2.2.1.3 above) was attempted using conditions 
previously reported26; however, upon completion of the reaction, the expected product 
was not recovered. The analytical data collected for 381 was insufficient to conclude 
whether this was due to the changed reactive properties of compound 381, or if 
compound 381 was or was not the observed isolate of the reaction shown above in 
scheme 2.2.1.2. 
 Attempted Synthesis of Circumdatin Analogues via Reductive Cyclisation 
The first attempt to synthesise a sulfonyl circumdatin analogue came by utilising the 
strategy reported by Zhichkin36. With a source of 339 already established, the only 
component needed to employ this strategy was the second aryl unit utilised in forming 
Scheme 2.2.1.2: Synthesis of isatoic anhydride analogue 381 using aniline-2-sulfonic acid and triphosgene. 
 




the quinazolinone moiety. The desired compound 51 was synthesised by forming the 
acid chloride of 5- methoxy-2-nitrobenzoic acid35, shown in scheme 2.2.2.1. 
The reaction in scheme 2.2.2.1 proved to be a consistently efficient route to 51, 
affording the desired acid chloride in quantitative yield without the need for purification. 
Following concentration, acid chloride 51 was usually recovered as a viscous oil. 
However, allowing slow evaporation afforded large crystals of 51, although this was 
usually avoided due to the immediate use of compound 51 in the next step.  
PBD 28 was synthesised from isatoic anhydride and L-proline as reported by 
Bergman27 in order to carry out the synthesis of circumdatin H 46 as shown in scheme 
1.1.3.1 in the introduction. The naturally occurring circumdatin was synthesised as an 
informal “test run” of the published method36, allowing the reaction to be carried out as 
needed without the potential waste of the comparably more difficult to synthesise 
PBTD 339, and also allowing access to the actual natural product for later biological 
testing. Carrying out the reaction as published36 resulted in isolating the desired 
product in 20% yield - significantly lower than the reported recovery. However, physical 
properties and spectral analysis proved consistent. A point to be made about the 
published conditions was the vexatious nature of the cooling process throughout the 
reaction. Using solvent baths and coolant proved challenging as the fluctuations in 
temperature were unpredictable when trying to increase or decrease the temperature 
of the reaction vessel. After this, an acetone bath was used alongside an electric 
immersion cooler. This solved the immediate problem of unreliable cooling, as 
temperature was measured and controlled within a tenth of a degree, although the rate 
of heating could still be inconsistent.  
Scheme 2.2.2.1: Synthesis of acid chloride 51 as a circumdatin precursor. 
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With the model reaction complete, the reaction between acid chloride 51 and amide 
339 was carried out following the precedented method35- illustrated in scheme 2.2.2.2. 
Whilst TLC indicated a transformation after the first step, after purification, two 
products (not 383 or 384) were isolated in small quantities with unexpected 1H NMR 
signals. The first signals, manifesting as two broad singlets at 9.75 and 8.95 ppm, 
respectively, were deemed of interest due to the definition and relative integrations 
compared to the rest of the spectrum. 
It was thought that this unexpected product was compound 385, a product of the 
reduction that had failed to cyclize, shown in figure 2.2.2.1. Another unexpected 
product was observed, showing a broad singlet in the aromatic region. This product 
was proposed to be amine 385a, an over-reduced product of the cyclisation, also 
shown in figure 2.2.2.1. 
 
Scheme 2.2.2.2: Attempted synthesis of circumdatin H analogue via  reductive cyclodehydration. 
Figure 2.2.2.1: Theorised structures of the unexpected products furnished by the reaction in scheme 2.2.2.2. 
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This result could not be replicated, and a well-resolved carbon NMR spectrum was 
unable to be collected due to the low mass recovery from the initial reaction. However, 
a consistent high resolution [M+H] m/z for compound 385 was found (expected to be 
402.1118 and found to be 402.1127). While not  conclusive proof, this strongly 
suggests compound 385 was the observed product. 
While it seemed that the reductive cyclization was unable to furnish the PBTD 
circumdatin analogue 384, there are two other possible sites for sulfonyl analogues to 
be formed, resulting in three analogue possibilities, shown in figure 2.2.2.2. As such, 
the possibilities of such syntheses were explored. 
The substrate needed to produce analogues 386 and 387 was synthesised over two 
steps, following procedures by Tietze et al132 and Buhr et al133. Beginning with 3-fluoro-
4-nitrophenol 389, the phenoxide anion 390 was formed through reaction with base, 
with subsequent nucleophilic substitution in the presence of iodomethane, giving the 
methyl ether, as shown in scheme 2.2.2.3. 
After purification, 391 was obtained in good yields, and was therefore progressed to 
the next stage. Treatment of 391 with sodium sulfite in water/EtOH afforded the 
desired sulfonic acid after work-up without the need for purification. A method also 
detailed by Buhr et al131 was then used to convert sulfonic acid 392 to the sulfonyl 
chloride 393, as shown in scheme 2.2.2.4.  
Figure 2.2.2.2: Possible Sulfonamide Analogues of Circumdatin H. 
 
Scheme 2.2.2.3: Formation of phenoxide ion and subsequent alkylation. 
 




With the sulfonyl chloride synthesised without the need for purification, sulfonyl 
chloride 393 was taken and used in place of 51 in the amide formation and reductive 
cyclisation reactions as detailed in scheme 2.2.2.2, the result of this reaction was 
unsuccessful, as was the attempted synthesis of 386, as shown in scheme 2.2.2.5. 
It may be pertinent to repeat the reactions between 392 and 
28/339 and attempt to isolate intermediate 54/383 before the 
addition of acetic acid and zinc powder. If observed, the 
intermediate could be progressed to circumdatin analogue 
386/387 using an optimised reduction protocol, or the reduction 
using the conditions published by Zhichkin, could be attempted 
to confirm the synthesis of the reduced uncyclized compound 
385 and produce amide analogue 388. 
 Synthesis of Circumdatin Analogues via an Aza-Wittig Approach 
Following the lack of success in synthesising circumdatin analogues using the 
reductive cyclodehydration approach, attention was turned to utilising an aza-Wittig 
reaction in the attempt to synthesise the target circumdatin. The nucleophilicity of the 
intermediate phosphazene and the general efficiency of the aza-Wittig reaction made 
this route promising.  
PBTD 339 was again a logical starting point, and as such, the corresponding azide 
partner 63 required synthesis. Following Bédard et al, azide 61 was synthesised from 
the aryl amine using sodium nitrite and sodium azide134. The azido carboxylic acid was 
Scheme 2.2.3.1: Azide formation and subsequent acid chloride synthesis. 
 




then converted to the acid chloride as reported by Bose et al by using thionyl 
chloride38, as shown above in scheme 2.2.3.1.  
With azide 63 in hand, the synthesis of circumdatin H itself was repeated as published 
(see scheme 1.1.3.2 in the introduction), affording the desired circumdatin in very low 
yields, typically less than 10%. The reaction was repeated using triphenylphosphine 
rather than the original tributylphosphine, however, this failed to give any positive 
result, as the crude material recovered was unable to be purified. The low yield of this 
approach was seen as an aspect of the reaction that could be optimised through future 
iterations, and the relatively low maintenance conditions made this strategy preferable 
to the reductive cyclodehydration. 
Following this approach, the coupling reaction was attempted with PBTD 339, 
however, from TLC analysis, it was apparent that under the published conditions, 
azide 63 and PBTD 339 would not form the intermediate imide bond. A protocol, also 
reported by Bose et al38 utilising DCC and HOBt to form an imide link with carboxylic 
acid 61 was also attempted; however, this also proved fruitless - scheme 2.2.3.2. 
Although it was unsuccessful in synthesising the desired sulfonyl analogue of the 
circumdatin H species described above, the aza-Wittig approach did prove to be a 
successful route to other analogues of the natural product circumdatin H. Using 
syntheses reported by Dyatkin and Maryanoff135, and Jadidi et al136, two 









Benzodiazepines 391 and 393 were then taken, and reacted further with azide 63, 
followed by the aza-Wittig formation of circumdatin analogues 396 and 397, as shown 
in scheme 2.2.3.4, showing that the aza-Wittig route was a valid approach. These new 
analogues were both successfully characterised with proton, and carbon NMR, and 
high-resolution mass spectrometry. 
Scheme 2.2.3.3: Synthesis of benzodiazepines  391 and 393. 
 




 Attempted Conversion of Thioamide to an Amidine 
With two unsuccessful attempts at N-linkage and subsequent reaction at C11, a 
different approach was required. Utilising an approach detailed by Sorra et al39, and 
discussed below in schemes 2.2.4.1 and 2.2.4.2, this strategy seemed attractive, as 
the first step would be forming the amidine at C11, then reacting at the exocyclic N 
position. Conveniently, the starting material for this process was one already used in 
the attempted synthesis of the sulfonyl analogue of fuligocandin A, namely thioamide 
352. With this, the thioamide would be treated with mercury(II) chloride, and gaseous 
ammonia to desulfurize the thioamide and install the amidine - via the theorised 
mechanism137 shown below in scheme 2.2.4.1. 
From here, as shown in scheme 2.2.4.2, the amidine 399 is introduced to a reaction 
mixture containing a palladium-ligand complex inserted into aryl bromide 72a, 
coordination occurs, followed by deprotonation and reductive elimination to furnish the 
substituted amidine 404. Deprotonation then triggers the intramolecular cyclization to 




give the desired product 384. In order to attempt the reaction shown in scheme 2.2.4.1, 
gaseous ammonia was generated by boiling concentrated aqueous ammonium 
hydroxide. The resulting gas was passed through two nitrogen flushed Dreschel flasks 
containing freshly dried molecular sieves, then directly into the reaction mixture via 
Pasteur pipette. Initially, the reaction seemed promising, with the reaction mixture 
gradually turning black, indicating the formation of mercury sulfide. The reaction was 
left overnight, but TLC indicated no change in the starting material, despite the visible 
colour difference. It was thought a combination of the non-laminar flow of ammonia 
gas and the slow rate at which it was introduced into the reaction was responsible for 




the very low rate of reaction. As such, the reaction was worked up and purified, with 
no detectable trace of the desired amidine 399. A cannister of ammonia was 
uneconomical for a single reaction with no evidence of prior success, and therefore, 
this route was abandoned. 
  Circumdatin Analogue Synthesis via Copper Catalysed Intramolecular N-
Arylation 
The lack of success in the above three different strategies towards the sulfonyl 
circumdatin analogues prompted investigation into an approach that was sufficiently 
different from the previous attempts that were focussed on installing the quinazolinone 
moiety onto an existing PBTD ring. A procedure detailed by Mekala et al,42 and 
detailed in scheme 1.1.3.5 in the Introduction, gave such an opportunity, and the 
results are detailed below. 
2-Iodobenzenesulfonic acid is a key starting material for this approach and was made 
in two steps by the diazotization and subsequent iodation of aniline-2-sulfonic acid, as 
reported by Tan et al138 and shown in scheme 2.2.5.1. 
The transformation detailed in scheme 2.2.5.1 required some optimisation to provide 
a reliable route to the iodo-compound 408. Initially, it was noted that the mass recovery 
inferred yields from this reaction were far surpassing 100%, showing that impurities 
were present. To overcome this, after the addition of KI, the temperature was 
increased to 100 °C, in an attempt to reduce the chance of iodine vapour being re-
introduced into the reaction vessel. Once all vapours were colourless, the work-up 
continued, and once the precipitate was isolated, it was suspended in chloroform and 
stirred vigorously. The chloroform was decanted off and the process repeated until the 
chloroform remained colourless. These additions to the work-up resulted in a purer 
product. The acid was then progressed, using the method detailed by Mekala et al42 
and converted into the sulfonyl chloride 409. Monitoring the conversion via TLC 
showed the presence of starting material even after four hours in refluxing DCM. 
Scheme 2.2.5.1: Synthesis of 2-iodobenzenesulfonic acid 408. 
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Column chromatography was employed, providing a method of isolating some pure 
sulfonyl chloride. Subsequently, commercial 2-iodobenzenesulfonyl chloride was used 
to enable faster throughput. 
With the required sulfonyl chloride in hand, the synthesis was continued. L-proline 
methyl ester hydrochloride was reacted with acid chloride 409 in the presence of base, 
furnishing the sulfonamide 410 in modest yields without the need for purification. The 
methyl ester 410 was then converted to the amide 411 using concentrated ammonium 
hydroxide in n-butanol as shown in scheme 2.2.5.2.  
The reaction with aqueous ammonia was incomplete after 96 hours, however; when 
taken through the work-up,  the desired amide was recovered as a pure, crystalline 
solid without the need for chromatography.  The long reaction time was avoided by 
coupling acid chloride 409 with prolinamide under the same conditions. This afforded 
the desired amide 411 in a single step, also shown in scheme 2.2.5.2. The observed 
yield of this reaction was almost twice that of the two-step equivalent, with the only 
negative point being that the coupling reaction now required purification via flash 
chromatography. 
With a streamlined route to amide 411, a two-step conversion to amidoxime 413 was 
next carried out, via nitrile 412, as shown in scheme 2.2.5.3. 




Both steps had their yield maximised by allowing each to run overnight. The full 
mechanistic detail for these transformations is displayed in scheme 2.2.5.4. 
With an efficient and extremely reliable route to amidoxime 413, the synthesis was 
continued. 6-Methoxyisatoic anhydride 50 was synthesised following a reported 
synthesis by Carter et al139 using 5-methoxyanthranilic acid and triphosgene, a 
process akin to previously mentioned syntheses of isatoic anhydrides.  
  
Scheme 2.2.5.3: Formation of amidoxime 413 via nitrile 412. 
 




The iron(III) chloride catalysed synthesis of quinazolinones as reported by Mekala et 
al140 was carried out to afford the desired circumdatin analogue precursor 414, shown 
in scheme 2.2.5.5. 
While successful, the efficacy of this transformation was brought into question, with 
attempts to synthesise 414 consistently falling below 20% recovery. It was first thought 
that this may be due to the quality of the iron(III) chloride used, as an older, more 
degraded source of iron(III) chloride may hamper the catalytic properties. Using a new 
source of iron(III) chloride furnished the desired product, however, with no real 
improvement to yield. Unsuccessful attempts at optimisation by using anhydrous THF 
as the solvent was also made. The mechanism is shown in scheme 2.2.5.6.  
In the reported literature141, Mekala et al demonstrate the reaction with a wide variety 
of aromatic amidoximes, with a variety of activating and deactivating groups, including 
the amide analogue of sulfonamide 413 (86) in a separate publication42. This leads to 
the implication that the presence of the sulfonamide is the cause of the problems in 
this transformation. A possible solution to this problem, would be the use of an 
alternative Lewis acid, such as iron(III) fluoride. Iron(III) fluoride was used in the 
original publication138 with just a 5% reduction in yield, however, the main downside to 
using iron(III) fluoride, among several other catalysts, was the formation of the 
oxadiazole 415 alongside the desired product 417, shown in scheme 2.2.5.7. 
Scheme 2.2.5.5: Iron(III) chloride catalysed synthesis of circumdatin precursor 414. 
 
Scheme 2.2.5.6: Suspected mechanism of quinazolinone formation. 
 




After several repeats of the reaction detailed in scheme 2.2.5.5 were carried out, a 
sufficient amount of precursor 414 was in hand to progress to the final step of the 
reaction. Utilising the copper mediated approach detailed in scheme 1.1.3.5 in the 
introduction, the sulfonyl analogue was finally successfully synthesised, in 25% yield, 
as illustrated in scheme 2.2.5.8. 
While successful, the observed yield is an obvious target for improvement. One such 
avenue would be the variation of ligand and metal centre used in the reaction. Argade 
and Kshrisagar report the limited success of 416 and 41742, and other sources141 
report the use of ligands 418 – 420, shown in figure 2.2.5.1, as successful counterparts 
to the copper iodide catalyst. 
Palladium catalysts have also been explored in this reaction; however, none were 
reported to be successful42. The correct combination of catalyst and ligand may prove 
difficult to find, due to the relatively limited space created by the quinazolinone, aryl 
iodide, and the increased steric bulk of the sulfone, as seen in the mechanism shown 





Scheme 2.2.5.8: Copper mediated N-arylation used to furnish circumdatin analogue 384. 
 





  Steps Towards the Synthesis of Sulfonyl-Circumdatin Homologues 
Following the success of the copper mediated arylation in synthesising the sulfonyl 
analogue of circumdatin H, 384, attention was turned towards further applications of 
this approach. To compliment the analogues synthesised by the aza-Wittig approach 
in scheme 2.1.8.4, L-thiazolidine-4-carboxylic acid 390 and piperidine-2-carboxylic 
acid 392 were taken in attempt to synthesise the respective sulfonyl analogues (425 
and 426 respectively, shown in figure 2.2.6.1). 
Figure 2.2.6.1: Structure of target circumdatin analogues 425 and 426. 
 




Ideally, the first step in the synthetic route would feature direct coupling to the 
respective amides, as seen with the sulfur analogue of the natural product, shown 
using prolinamide in scheme 2.2.5.2, above. However, due to the commercial 
unavailability of such amides, the acid needed converting to the amide post-coupling. 
The first step in this process therefore, required the formation of sulfonamides 427 and 
428. These were easily synthesised utilising a previously successful coupling 
protocol28, using commercially sourced 2-iodobenzenesulfonyl chloride in the 
presence of base, as displayed in scheme 2.2.6.1. 
With excellent yields and no need to purify, attention was turned to the next step. Using 
(benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) 
and ammonium chloride in the presence of base was found to furnish the desired 
amides in good yields, shown in scheme 2.2.6.2. 
Following the efficient amide formation, amides 429 and 430 were subsequently 
converted to the respective nitriles using TFAA and triethylamine, the nitriles were then 
reacted with 50% aqueous hydroxylamine, affording the amidoximes in near 
quantitative yields, as scheme 2.2.6.3 shows.  
Scheme 2.2.6.1: Coupling of circumdatin homologue precursors 390/392 and 409. 
 
Scheme 2.2.6.1: Amide formation using BOP and ammonium chloride. 
 




With both functional group interconversions performing excellently, the stage was set 
to attempt the iron(III) chloride catalysed quinazolinone formation. Following the 
reaction on TLC, revealed the gradual fading of the amidoxime; however, the isatoic 
anhydride remained, with no sign of product formation. Following work-up and 
purification, the methoxyisatoic anhydride was recovered in part, with no other 
identifiable products. As such, different approaches to quinazolinones 435 and 436, 
shown in figure 2.2.6.2, were investigated. 
A strategy reported by Argade and Kshirsagar41 (see scheme 1.1.3.4) seemed an ideal 
strategy to utilise in the pursuit of compounds 435 and 436 as it not only utilises the 
same carboxylic acid precursors (427 and 428), but the approach also has fewer 
steps, and would see the avoidance of the relatively inefficient amide formation. 
Conveniently, 5-methoxyanthranilamide 437 was readily available through the 
nucleophilic substitution of 5-methoxyisatoic anhydride with ammonia as reported by 
Chamberlain et al142. Following this, amide formation was carried out following the 
protocol detailed by Argade and Kshirsagar39, displayed in scheme 2.2.6.4. 
While successful, the low yield of both species prompted investigation of other 
coupling strategies. An attempt was made to improve the yield of 438 by carrying out 
the synthesis using BOP and triethylamine. However, no improvements on the yield 
Figure 2.2.6.2: Target quinazolino- intermediates 453 and 436. 
 




were noted. An attempt at efficient amide formation was then attempted using a 
method reported by Moran et al143, utilising T3P and base, as illustrated in scheme 
2.2.6.5. This approach was also showed similar results, with a yield that was also very 
low (<10%.)  
Despite the poor yields observed over the various attempted amide formations, the 
proposed synthesis was continued. Treatment of amides 438 and 439 with aqueous 
lithium hydroxide resulted in formation of the desired quinazolino compounds 435 and 
436 in acceptable yields as scheme 2.2.6.6 shows.  
Only small amounts of 435 and 436 were recovered, and the final N-arylation was only 
attempted using the piperidine compound 436. The reaction was carried out on a 
similar scale to that which produced 384. Upon examining the proton NMR spectrum 
of the supposed product, it was observed that while not completely pure, the material 
recovered did bear certain characteristic signals that would be expected in the 
successful cyclisation product 426, such as the broad singlet at 3.90 ppm, pertaining 
to the aryl methyl ether, several signals between 5.00 and 5.80 ppm which could 
indicate the bridgehead CH between the diazepine and piperidine ring, and a number 
Scheme 2.2.6.4: Amide formation using T3P. 
 




of aromatic signals. While this is a promising result, there was insufficient material 
recovered from the column to reliably purify again, thus, hope of a successful synthesis 
of the sulfonyl-circumdatin homologues 425 and 426 will require future optimisation of 
the previous steps. 
 Summary 
A sulfonyl analogue of circumdatin H was synthesised using a copper catalysed N-
arylation. Some unsuccessful attempts to synthesise the sulfonyl analogue via other 
strategies afforded unexpected products which it may prove beneficial to explore 
further. An aza-Wittig approach was used to synthesise homologues of the natural 
product circumdatin H from a substituted 2-azidobenzoic acid and homologous 
benzodiazepine backbone. Progress has been made towards the synthesis of 
homologues of the sulfonyl analogue of circumdatin H; however, reaction efficiency 
has impeded progress towards the target compounds. Future work prospects include 
completing the synthesis of the sulfonyl analogue of the circumdatin H homologues, 
and a thiadiazine analogue of the natural product circumdatin H.  
2.3 Biological Test Results of Synthetic PBD and PBTDs 
Five compounds, shown in igure 2.3.1, synthesised in the previous section were taken 
and tested against human colon carcinoma cells and non-carcinoma colon cells. 
Of the compounds tested, only compound 385 showed any notable biological activity, 
inducing cytotoxicity in the carcinoma cells with an IC50 of 29.3 ± 5.3 µM. Interestingly, 
compound 385 showed a high selectivity towards cancer cells, with no significant 
toxicity induced towards non-cancerous cells. Compounds of this structure have been 
targeted for future development and attempts are being made to synthesise a range 
of functionalised N-aroyl compounds to explore the activity further. 




2.4 - Investigating the Aza-Cope Rearrangement Following the Reaction 
between 2-Vinylazetines and Symmetrical Di-aryl Cyclopropenones 
 Synthesis of the Homotropane Precursors 
This section will investigate the reaction shown in scheme 1.2.1.1, as discussed in the 
introduction. The first step in this investigation was to create an azetine backbone in 
which the target reactions could be executed. To afford such azetines, the route 
reported by Hemming et al60 was implemented. Isoprene 440 and 2,3-dimethyl-1,3-
butadiene 441 were selected due to previous successes when this reaction was 
previously carried out60. Reaction with chlorosulfonyl isocyanate (CSI) furnished the 
β-lactams 442 and 443 via the well-established cycloaddition to the alkene144 shown 
in scheme 2.4.1.1. 
The reaction between the dienes and CSI ran smoothly, affording the desired β-
lactams without need for purification. With the lactams in hand, they were thionated 
using Lawesson’s reagent, which again proved a reliable transformation, furnishing 
the thiolactams 444 and 445 in good yields after flash chromatography, detailed in 
scheme 2.4.1.2. 
The final step in generating the 1-azetine species came by treating the thiolactams 
444  and 445 with Meerwein’s reagent. It was decided to use both methyl and ethyl 
variations of the salt, which would in turn furnish four 1-azetines, shown in scheme 
2.4.1.3, to use in the investigation. 
Scheme 2.4.1.1: Cycloaddition of chlorosulfonyl isocyanate with isoprene and 2,3-dimethyl-1,3-butadiene. 





Due to the reported instability106 of these azetine species, azetines 446 – 449 were 
not stored for any length of time and were instead synthesised on an ad hoc basis. 
The simple reaction conditions and facile work-up, combined with no requirement for 
purification made this requirement feasible. It is of note that the pure 1-azetines were 
either volatile themselves, or were degrading to volatile species, as prolonged rotary 
evaporation with heat resulted in their loss. 
Literature60 reports only the use of diphenylcyclopropenone 155 to initiate the reaction 
that facilitates the aza-Cope rearrangement (see scheme 1.2.1.2 in the introduction), 
as such, a series of di-aryl cyclopropenones were synthesised to investigate the scope 
of this phenomenon, and to investigate its efficacy with other cyclopropenones. 
Two methods were utilised to furnish the range of cyclopropenones that were 
ultimately employed, the first of which resulted in the synthesis of cyclopropenones 
249, 258a, and 258c over three steps, as shown in scheme 2.4.1.4.  
Scheme 2.4.1.4: Three-step synthesis of di-aryl cyclopropenones. 
 




Beginning with the appropriately substituted phenylacetic acid, two molar equivalents 
are coupled together to form diarylketones 254a, b, and d. What is interesting to note 
here, is in the traditional Steglich approach, one would expect formation of the 
anhydride (450) form of the diaryl species, displayed in figure 2.4.1.1. 
Evidently, this is not what occurs in this instance, and instead, at the point where one 
phenylacetic acid molar equivalent has formed the intermediary ester linkage with the 
DCC, the second molar equivalent of the phenylacetic acid acts as a nucleophile at 
the alpha position, forming a pseudo-hemiacetal followed by the extrusion of 
dicyclohexylurea (DHU), and carbon dioxide, furnishing the diarylketone, as detailed 




Figure 2.4.1.1: Expected anhydride intermediate 450. 
 




From the diarylketone, both alpha positions are brominated using bromine and glacial 
acetic acid. Literature88 reported reaction times between 30 minutes and 4 hours, but 
it was found that when replicated, these times led to variable yields and in some cases, 
no product isolation at all. As a result, the bromination step was left overnight, resulting 
in consistent product recovery. In the literature procedures, it is indicated that the 
reaction mixture was poured into water. When carried out, ofttimes this would result in 
no precipitate forming, and after encouraging precipitate, after isolation and drying, it 
was confirmed the precursor diarylketone was recovered. It was found that if water 
was introduced into the reaction mixture at this point, precipitation was regular and 
was maximised after ~30 minutes of stirring. After bromination was confirmed via  
NMR spectroscopy, the final step sees the introduction of base, which deprotonates 
the alpha position, allowing backside attack from the remaining alpha position, forming 
an intermediary cyclopropanone 451. The final alkene formation then happens in an 
E2 fashion, as shown in scheme 2.4.1.6. 
Cyclopropenones 249 and 258a were isolated after three steps in yields slightly higher 
than the reported literature values (30 and 32% respectively). Conversely, 
cyclopropenone 258c was only isolated once following this approach, and then with a 
yield of only 0.7%. For this reason, cyclopropenone 258c was synthesised using a 
different strategy. 
The second strategy employed to synthesise cyclopropenones was a Friedel-Crafts 
reaction, utilising tetrachlorocyclopropene and aluminium chloride in the presence of 
an aromatic compound, followed by a geminal dihalide hydrolysis. The generic 
mechanism for the full transformation is shown in scheme 2.4.1.7. 





Cyclopropenone 258c, along with cyclopropenones 452, 453 and 454 were chosen 
for this approach (figure 2.4.1.2 shows these compounds). 
Synthesising 258c through this approach proved incredibly fruitful, with a recovery of 
80% via a simpler process, showing the Friedel-Crafts approach to this 
cyclopropenone was a superior option. Compounds 452 and 453 were also 
successfully synthesised, albeit with substantially lower yields than 258c, with 
recoveries of 18 and 24% respectively. Cyclopropenone 454 was also targeted using 
this approach; however, a pure form of this cyclopropenone could not be isolated. 
 Investigations into the Aza-Cope Rearrangement 
With a selection of 1-azetines and cyclopropenones available, the key reaction was 
initially carried out using 1-azetine 446 and diphenylcyclopropenone (155) following 
the literature methodology63. Initial reactions were carried out using the conditions 
described in the precedent literature63. A solution of 446 and 155 (see scheme 2.4.2.1) 
in acetonitrile was stirred for 10 days at room temperature in a sealed vessel. A gradual 
colour change was observed over the course of the reaction, leaving the reaction 
Figure 2.4.1.2: Cyclopropenones targeted via the Friedel-Crafts approach. 
 




mixture a faded orange colour by the time of completion. Upon removal of the solvent, 
the residue was purified over a column of silica.  
After analysing the recovered material, the desired azabicyclononane 456 (17% yield) 
was observed; however, a second major component was observed. Signals between 
5.2 and 5.6 ppm, and ~6.3 ppm were present in the spectrum. Totalling three protons, 
these signals were consistent with the vinylic CH=CH2 protons observed in the spectra 
of the azetine and related precursors. The presence of ten aromatic protons suggested 
that the other product was cycloadduct 455, thus suggesting the reaction proceeds via 
the mechanism postulated in the literature63, as shown below in scheme 2.4.2.2. 
Following this, the reaction was carried out using all possible combinations of the 
synthesised 1-azetine and cyclopropenones, the details of which can be seen in table 
2.4.2.1. It is interesting to note, while the reaction was carried out many times using a 
variety of cyclopropenone and azetine combinations, no successful products from 
cyclopropenones 452 or 454 were reported. 
Scheme 2.4.2.1: Observed isolates and proposed intermediate in the aza-Cope rearrangement. 
 




Of the reactions carried out between 1-azetines and cyclopropenones shown in table 
2.4.2.1, five compounds (see figure 2.4.5.1) were isolated and confirmed to be the 
respective primary cycloadducts as was shown generally in scheme 2.4.2.1 above. 
Such observations give further credence to the mechanism in scheme 2.4.2.2, which 
presumes the imine to cyclopropenone cycloaddition occurs first, and is followed by a 
strain-assisted aza-Cope rearrangement. 
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Table 2.4.2.1: Cyclopropenone and 1-Azetine combinations with resulting isolated products. 
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Traditionally, [3,3]-sigmatropic rearrangements occur through the overlap of the 
HOMO and LUMO orbitals in the molecule, as seen in figure 2.4.2.2. 
The molecular orbital overlap creates a chair-like transition state akin to that seen in 
the Zimmerman-Traxler model of the aldol condensation. Consequently, if the resulting 
terminal alkenes have non-hydrogen substituents, there will be multiple transition-
state conformations, and the favoured outcome will be the lower energy transition 
state, which can be seen in scheme 2.4.2.3. 
Strain relief is also a driving force for [3,3]-sigmatropic (Cope) rearrangements, as 
seen in the synthesis of dictyopterene C, reported by Jaenicke et al145 where the 
expansion of a cyclopropane ring in compound 476 facilitates the formation of the 
cycloheptadiene ring seen in compound 477, as detailed in scheme 2.4.2.4. 
The aza-Cope rearrangement from cycloadduct 455 to 456 is almost certainly driven 
by the alleviation of the strain around the azetidine ring and across the enamine 
moiety63, 64. Of the two “main” examples of aza-Cope rearrangements, shown in 
scheme 2.4.2.5 below, the assumption can be made that the synthesis of the 
azabicyclo[4.2.1]nonenes 456 - 475 proceeds via the non-cationic route, as cation 
formation is unlikely. Interestingly, Overman reported cationic cyclisations such as the 
aza-Cope, proceed much more quickly than the non-cationic concerted processes146, 
Figure 2.4.2.2: HOMO and LUMO overlap resulting in a [3,3] sigmatropic rearrangement. 
 
Scheme 2.4.2.4: Strain-driven Cope rearrangement of dictyopterene C. 
 




suggesting the reaction shown in scheme 2.4.2.1 could be accelerated in the future 
by allowing cationic formation, a process that was not investigated in this thesis.  
In an attempt to increase the speed of conversion, other reaction conditions were 
tested. Compounds 155 and 446 were reacted in refluxing acetonitrile under a positive 
pressure of nitrogen. It was quickly noted that the reaction reached a similar stage of 
conversion after 5-7 days in comparison to the reaction at room temperature. After 
purification, it was noted that the aza-Cope rearranged product was the only “product 
material” detected, with no trace of the initial cycloadduct. Presumably, the increased 
temperature has increased the rate of the aza-Cope rearrangement and prevented the 
isolation of the initial cycloadduct. Yields were not improved, however. This could be 
due to the stability/volatility of the 1-azetine, as discussed above. One possible 
solution to this is to repeat the reactions at high temperatures in a sealed tube 
(assuming the 1-azatines are volatile), or, as mentioned above, allow cation formation, 
which could be facilitated by the addition of a Lewis Acid. 
Whilst  no stereochemical analysis was carried out, the intermediate shown in scheme 
2.4.2.1 is suggested to be in the indicated “trans” configuration, as the vinylic moiety 
must be able to overlap the aryl-flanked double bond in the cyclopentenone ring. The 
inherent hindrance across the enamine reduces the possible conformations of the 
chain involved in the aza-Cope rearrangement (shown in red in scheme 2.4.2.6). This 
hindrance prevents the chain forming the favoured chair-like intermediate, however, a 
half-chair intermediate can be formed, as see in scheme 2.4.2.6, facilitating the FMO 
overlap required for the aza-Cope rearrangement.  
This also provides an explanation as to why the reaction both proceeds slowly at room 
temperature, and why the cycloadduct is not observed when the reaction is carried out 
at reflux. As the half chair is the most thermodynamically unstable conformer for six-
Scheme 2.4.2.5: Cationic and non-cationic aza-Cope rearrangements. 
 




membered rings, it is reasonable to apply kinetic theory and suggest the reaction 
proceeds slowly because of this, and the overall energy increase while the reaction is 
at reflux allows for the conformer to occur more readily. Aside from these assumptions, 
the true mechanism of the aza-Cope rearrangement from cycloadducts such as 
compound 455 to give azabicyclononenes such as compound 456 is unknown and will 
require both computational and kinetic studies to fully elucidate. 
 Summary 
A series of azabicyclo[4.2.1]nonenes were synthesised, along with the isolation of 
several of the proposed intermediate primary cycloadducts, supporting the mechanism 
proposed previously in the Hemming research group. Future work needs to focus upon 
improving the isolated yields and mass recovery of the target 
azabicyclo[4.2.1]nonenes, and into reducing the observed reaction times. 
2.5 Further Investigation into the Reaction Between Cyclopropenones and 
Cyclic Imines 
A brief investigation into the reaction of cyclopropenones and cyclic imines was also 
undertaken. Hemming147, 104, 118,  and others 100, 101, 103, building on the work of 
Eicher148, have reported extensively on such interactions, and more recently Cui et 
al149 have contributed. Cui149 and Eicher148 reported that dihydroisoquinolines react 
with cyclopropenones to form pyrroloisoquinolines, a process that was investigated 
simultaneously by the Cui149 and Hemming groups157. The polycyclic structures used 
by Cui et al have received much less attention than the isoquinoline derivatives that 
have historically been used to demonstrate the cycloaddition of cyclopropenones to 
cyclic imines. Some of the work in this thesis contributed to the findings reported by 
the Hemming group157. This work involved investigating the reaction between 
dihydropyridoindoles (derived from tryptamine) and cyclopropenones. 
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Tryptamine was used as the starting material for attempted conversions into the 
desired reaction scaffolds shown in figure 2.5.1 through two approaches, varying 
between two and five steps.  
Compound 478 was synthesised over two steps from tryptamine, shown in scheme 
2.5.1. Stirring tryptamine 481 for 24 hours in ethyl formate150 afforded N-
formyltryptamine 482 in quantitative yield, without the need for purification. Treatment 
of the intermediate 482 with phosphoryl chloride151 facilitated the Bischler-Napieralski 
cyclization, furnishing 478 without the need for purification.  
Compounds 479 and 480 are products of the same strategy, shown below in scheme 
2.5.2, wherein tryptamine (481) was acylated with acetyl chloride. After 90 minutes, N-
acyltryptamine 483 was afforded in 99% yield. The Bischler-Napieralski cyclization 
was attempted on compound 483, however, the reaction proved unsuccessful, 
resulting in a viscous mass from which the desired product could not be extracted. To 
overcome this issue, the aromatic amine was protected using benzyl bromide and 
sodium hydride. The protected species 479 was then subjected to the Bischler-
Napieralski protocol, affording the protected cyclised species 484 in good yields. De-
benzylation was then attempted. Literature reports152 the removal of benzyl groups 
using a variety of hydrogenolysis protocols. A triethylammonium formate 
hydrogenolysis reported by Heck, Patel, and Weir153 was modified to use ammonium 
formate and palladium on carbon. This attempt proved unsuccessful, with no 
identifiable material recovered. It may be pertinent to attempt the reaction as reported,  
Figure 2.5.1: Polycyclic imines synthesised from tryptamine. 




generating triethylammonium formate in situ with formic acid and triethylamine. 
Alternatively, the reaction could be attempted using palladium on carbon and a 
hydrogen balloon, or the hydrogen could be generated in situ using triethylsilane and 
Pd/C as reported by McMurray and Mandal154. Attempts to synthesise 
dihydropyridoindole 480 were abandoned at this point. 
With dihydropyridoindoles 478 and 484 in hand, the reactions with DPP were 
attempted. Protected imine 484 was reacted with diphenylcyclopropenone at room 
temperature for seven days (scheme 2.5.3), affording the expected cycloadduct 485. 
The reaction of compound 478 with DPP was also carried out, shown in scheme 2.5.4. 
Surprisingly, a precipitate was clearly visible after approximately 16 hours of stirring. 
Scheme 2.5.2: Synthesis of polycyclic Imine 485 and attempted deprotection. 
Scheme 2.5.3: Cycloaddition of DPP with polycyclic imine 484. 
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The reaction was allowed to stir for a total of four days before the solid was collected 
via vacuum filtration and the filtrate was concentrated under vacuum. 
The proton NMR spectrum of the precipitate showed a broad CH signal at 3.55 ppm, 
along with three other alkyl-proton signals in a 1:1:1:1 ratio. It was initially thought the 
bridgehead carbon would oxidise via the enol tautomer 487, forming a hydroperoxide 
488, which would then cleave, furnishing the alcohol 489, demonstrated in scheme 
2.5.5, as observed in several similar systems155. 
After further analysis, 2D NMR suggested compound 489 was not the observed 
product, with HSQC and HMBC spectra both indicating the broad signal at 3.55 ppm 
was a CH and that there was no C-OH present. Further analysis was needed and, as 
such, crystals of the recovered precipitate were grown in acetonitrile, using hexane as 
an anti-solvent. The crystals were analysed and found to be suitable for 
crystallographic analysis, and an X-ray structure was obtained, displayed in figure 
2.5.2. 
  
Scheme 2.5.4: Attempted cycloaddition of DPP with polycyclic imine 478. 
Scheme 2.5.5: Proposed mechanism of formation of alcohol 489. 
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The X-ray structure showed that the expected cycloadduct 486 had formed a dimer-
like product in situ, presumably though the radical species 486a possibly generated 
by the loss of a hydrogen radical (H•) from cycloadduct 486, as shown in scheme 
2.5.6.  
Radical 486a could also be formed from species 489/489a, shown in scheme 2.5.5 
above, with, for example, species 488a extruding a hydrogen radical from species 486. 
With multiple routes to radical 486a being possible, dimerization can occur. Radical 
486a is captodative and can be stabilised by the adjacent nitrogen and carbonyl. Such 
dimerization reactions are not unprecedented, as similar dimers have been reported 
Figure 2.5.2: X-Ray structure of the recovered precipitate. 
 




by McNab et al156, who also presented evidence that the mechanisms progress via 
free  radicals. 
Since the elucidation of the structure of 490, it has been attempted to create dimers 
from imine 478 and a several other diarylcyclopropenones, as shown in scheme 2.5.7. 
The attempted syntheses of dimers 491-493 returned mixed results, with compound 
491 showed to have proton and carbon NMR spectra similar to dimer 490, suggesting 
the reaction between imine 478 and cyclopropenone 249 did indeed afford the 
predicted dimer. The spectra produced by compound 492 were reasonably well-
resolved, however, they bore little similarity to those of dimer 490. Other than for 
compound 490 itself, HRMS spectra were not obtained for these compounds, so the 
structures of these compounds remain uncertain. The compound proposed to have 
structure 493 proved to be almost completely insoluble in all available deuterated 
solvents, and as such, no NMR spectra were collected. Attempts to collect a mass 
spectrum were also unsuccessful. 
Additionally, since the discovery of the formation of dimer 490, the filtrate from which 
the dimer precipitates has been analysed by Hemming et al157. After purification by 
column chromatography, an additional 6% of dimer 490, along with 13% of an 
unknown compound were isolated. The unknown compound lacked the expected 
bridgehead OH of compound 489 in the proton NMR spectrum, and in the carbon NMR 
spectrum, two carbonyl signals and non-aromatic CH signals were observed. The 




mass spectrum of the unknown compound also highlighted the loss of two hydrogen 
atoms, and, the addition of an oxygen atom. It was therefore postulated that the 
product was compound 495. In this case, it is possible that the captodative radical 491 
is formed and picks up oxygen (see also scheme 2.5.5), furnishing the alcohol 486a 
as an intermediate. Ring opening of aminol species 489 then occurs to give 
intermediate 494, followed by the loss of hydrogen and subsequent tautomerization, 
resulting in the tricyclic compound 495, as illustrated in scheme 2.5.8. 
 Summary 
The reaction between dihydropyridoindoles and cyclopropenones was explored. The 
dimerisation of the proposed intermediate cycloadducts was observed, and the 
structures of one such dimer was elucidated by X-ray crystallography. Future research 
should see the further investigation into the formation of such species using differently 
functionalised precursors to evaluate the reaction scope. 
2.6 Biological Testing Results For azabicyclo[4.2.1]nonenes 
Five azabicyclo[4.2.1]nonenes, displayed in figure 2.6.1, were selected and tested in 
vitro against cisplatin sensitive and resistant ovarian carcinoma cells (A2780 and 
A2780-CP70 respectively).  




Table 2.6.1 shows the results of these tests, with compounds 467 and 461 being the 
most active. Compound 467 is the most active against the cisplatin resistant line. With 
the ease of the aza-Cope reaction, and the possible variations across the molecule, 
this result shows that azabicyclo[4.2.1]nonenes show some potential as biologically 
significant molecules, and that a more detailed SAR study should be undertaken.  
 Summary 
Several azabicyclo[4.2.1]nonenes were selected for biological testing, with two of 
these having promising results. Further work could be carried out on similar species 
in an attempt to improve potency and to provide a more detailed SAR profile. 
  
 IC50 /µM 
Compound A2780 A2780-CP70 
456 >100 >100 
457 29.44 ± 4.81 >100 
467 4.05 ± 0.81 4.65 ± 0.36 
461 20.77 ± 4.57 89.26 ± 10.74 
458 64.02 ± 5.22 No effect 
Figure 2.6.1: Azabicyclo[4.2.1]nonenes submitted for biological testing. 
 




Chapter 3 – Experimental 
General Information 
All reagents, reactants and solvents were purchased from commercial suppliers and 
used without further purification unless stated otherwise. TLC was carried out using 
Merck 60 F254 silica gel plates and column chromatography was performed with Sigma 
Aldrich 40-63 µm or 63-200 µm silica gel. Pet ether refers to 40 – 60 °C petroleum 
ether. Melting points were obtained using a Stuart SMP 10 melting point apparatus 
and are uncorrected. Infrared spectra were collected on Thermo Nicolet 380 IR, NMR 
spectra were collected on Bruker Fourier 300 MHz, Ascend 400 MHz, and Avance 
Neo 600 MHz spectrometers. NMR frequency is indicated when reported, along with 
the NMR solvent used. Chemical shifts are reported in ppm relative  downfield to TMS. 
Mass spectrometry was carried out on an Agilent 6530 Q-TOF mass spectrometer, 




3.1 – Experimental for the Synthesis of Sulfonyl Analogues of the 
Fuligocandins. 
  ((2-Nitrophenyl)sulfonyl)proline 342 
To a stirred solution of 3 N sodium hydroxide (20 mL) was added L-proline 340 (5.00 
g, 43.48 mmol, 1.0 eq). The resulting solution was cooled in an ice bath and 2-
nitrobenzenesulfonyl chloride 341 (9.64 g, 43.48 mmol, 1.0 eq) was added portion-
wise over 5 minutes. After stirring at room temperature for 30 minutes, the reaction 
mixture was acidified with concentrated HCl (5.5 mL). The organic material was 
extracted with EtOAc (3 × 50 mL), the extracts were combined, dried, and 
concentrated under vacuum, affording the desired product as a dark yellow syrup of 
mass 11.46 g (80%). Product used further without purification. 
1H NMR (400 MHz, CDCl3) δ: 11.13 (bs, 1H, COOH), 8.06 (d, J = 7.0 Hz, 1H, ArH), 
7.69 – 7.61 (m, 2H, ArH), 7.57 (d, J = 7.0 Hz, 1H, ArH), 4.52 (d, J = 8.7 Hz, 1H, CH), 
3.60 – 3.52 (m, 1H, CH of CH2), 3.55 – 3.47 (m,  1H, CH of CH2), 2.28 – 2.16 (m, 1H, 
CH of CH2), 2.11 – 2.03 (m, 1H, CH of CH2), 1.97 – 1.85 (m, 2H, CH2). 13C NMR (100 
MHz, CDCl3) δ: 177.8 (q), 148.0 (q), 134.0 (CH), 132.2 (q), 131.9 (CH), 131.0 (CH), 
124.2 (CH), 60.7 (CH), 48.5 (CH2), 30.98 (CH2), 24.5 (CH2). FTIR νmax /cm-1: 3730.4, 
2981.7, 1716.7, 1540.9, 1354.7, 1160.3. In concordance with reported literature119.  
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 Methyl ((2-nitrophenyl)sulfonyl)prolinate 345 
To a stirred suspension of proline methyl ester hydrochloride 344 (7.58 g, 45.77 mmol, 
1.0 eq) in DCM (100 mL), was added triethylamine (16 mL, 114.4 mmol, 2.5 eq), and 
the mixture was left to stir for 5 minutes. The mixture was cooled to 0 °C and 2-
nitrobenzenesulfonyl chloride 341 (11.16 g, 50.34 mmol, 1.1 eq) was added and the 
reaction was allowed to warm to room temperature and stirred overnight. Water (20 
mL) was added, and the organic material was separated and washed with brine (50 
mL). The organic material was dried and concentrated under vacuum, and the crude 
residue was purified over a column of silica, eluted by 25% EtOAc in hexane, affording 
the desired product as a pale oil - 8.56 g (60%). 
1H NMR (400 MHz, CDCl3) δ: 8.13 – 8.08 (m, 1H, ArH), 7.72 – 7.67 (m, 2H, ArH), 7.66 
(m, 1H, ArH), 4.59 (dd, J = 3.0, 8.5 Hz, 1H, CH), 3.67 (s, 3H, OMe), 3.66 – 3.60 (m, 
1H, CH of CH2), 3.59 – 3.51 (m, 1H, CH of CH2), 2.33 – 2.22 (m, 1H, CH  of CH2), 2.13 
– 1.92 (m, 3H, CH  and CH2). Compliant with published data158. 
 ((2-Aminophenyl)sulfonyl)proline 343 
To a solution of ((2-nitrophenyl)sulfonyl)proline 342 (1.0 g, 3.33 mmol, 1.0 eq) in glacial 
acetic acid (50 mL), iron powder (1.0 g, 17.9 mmol, 5.4 eq) was added gradually over 
30 minutes. The reaction was allowed to stir at 60 °C for 3 hours, after which, the 
solvent was removed under vacuum, leaving a brown gummy residue. The residue 
was suspended in EtOAc (50 mL), stirred vigorously, and filtered under gravity. The 
remaining solid was extracted and filtered twice more with EtOAc (2 × 50 mL). The 
filtrates were combined and washed with saturated aqueous NaHCO3 (75 mL), and 
brine (75 mL). The organic material was then dried (MgSO4), and concentrated under 
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vacuum, leaving the desired product as a pale brown oil, 0.68 g (76%). The product 
was used without further purification.  
1H NMR (400 MHz, CDCl3) δ: 7.62 (d, J = 8.2 Hz, 1H, ArH), 7.25 (t, J = 7.6 Hz, 1H, 
ArH), 7.08 (bs, 3H, COOH and ArNH2), 6.71 – 6.65 (m, 2H, ArH), 4.46 (dd, J = 4.4, 
8.6 Hz, 1H, CH), 3.29 (t, J = 6.6 Hz, 2H, CH2), 2.16 – 2.04 (m, 2H. CH2), 1.93 – 1.72 
(m, 2H, CH2). 13C NMR (100 MHz, CDCl3) δ: 177.1 (q), 146.3 (q), 134.8 (CH), 130.3 
(CH), 118.8 (q), 118.1 (CH), 117.3 (CH), 59.7 (CH), 48.8 (CH2), 31.0 (CH2), 24.87 
(CH2). FTIR νmax /cm-1: 3468.6, 3373.8, 2980.3, 1716.4, 1616.8, 1380.3, 1140.9. In 
agreement with literature119. 
 1,2,3,11a-tetrahydrobenzo[f]pyrrolo[1,2-b][1,2,5]thiadiazepin-11(10H)-one 
5,5-dioxide 339 
To an ice cooled solution of ((2-aminophenyl)sulfonyl)proline 343 (0.68 g, 2.52 mmol, 
1.0 eq) in DCM (6 mL), a solution of DCC (0.52 g, 2.52 mmol, 1 eq) in DCM (4 mL) 
was added and the mixture stirred overnight at room temperature. The reaction 
mixture was filtered through Celite, and additional portions of DCM (3 × 20 mL) were 
used to rinse any remaining product into the filtrate. The filtrate was washed with 2 M 
HCl (25 mL), saturated NaHCO3 (25 mL), and water (25 mL). The organic layer was 
dried with MgSO4 and concentrated under vacuum, affording a pale, off-white solid – 
0.49 g (77%), mp 185 – 185 °C.  Lit mp: 292 – 293 °C124. When dry, no purification 
was needed.  
1H NMR (400 MHz, CDCl3) δ: 7.86 (dd, J = 1.4, 7.8 Hz, 1H, ArH), 7.71 (bs, 1H, NH), 
7.45 (td, J = 1.4, 7.8 Hz, 1H, ArH), 7.16 (t, J = 7.8 Hz, 1H, ArH), 6.94 (d, J = 7.9 Hz, 
1H, ArH), 4.58 (dd, J = 6.0, 8.0 Hz, 1H, CH), 3.48 – 3.40 (m, 1H, CH of CH2), 2.98 – 
2.90 (m, 1H, CH of CH2), 2.47 – 2.36 (m, 1H, CH of CH2), 2.17 – 2.07 (m, 1H, CH of 
CH2), 1.97 – 1.88 (m, 1H, CH of CH2), 1.83 – 1.74 (m, 1H, CH of CH2). 13C NMR (100 
MHz, CDCl3) δ: 177.0 (q), 146.5 (q), 133.8 (CH), 130.3 (CH), 118.8 (q), 118.1 (CH), 
117.7 (CH), 59.0 (CH), 47.8 (CH2), 31.0 (CH2), 24.7 (CH2). FTIR νmax /cm-1 3321.3, 
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3202.2, 3063.7, 2928.4, 2851.1, 2113.3, 1661.6, 1478.3, 1341.7, 1161.3, 1064.5. Data 
consistent with literature124. 
 1,2,3,11a-Tetrahydrobenzo[f]pyrrolo[1,2-b][1,2,5]thiadiazepine-11(10H)-
thione 5,5-dioxide 350 
To a solution of sulfonamide 339 (0.86 g, 3.41 mmol, 1.0 eq) in 25 mL dry THF, was 
added Lawesson’s reagent (0.69 g, 1.70 mmol, 0.5 eq). The suspension was allowed 
to stir at room temperature for 1 hour, then at reflux overnight. The reaction mixture 
was allowed to cool, and the precipitate was filtered under vacuum. The filtrate was 
concentrated under vacuum and the resulting residue was suspended in CHCl3. The 
resulting precipitate was filtered under vacuum and left to dry. Combined, the 
precipitates afforded the pure, desired product as a pale green solid – 0.30 g (32%). 
Mp: 172 – 175 °C. 
1H NMR (400 MHz, d6-DMSO) δ: 12.33 (bs, 1H, NH), 7.78 (d, J = 7.7 Hz, 1H, ArH), 
7.72 (t, J = 7.7 Hz, 1H, ArH), 7.45 (d, J = 7.9 Hz, 1H, ArH), 7.39 (t, J = 7.7 Hz, 1H, 
ArH), 4.80 (t, J = 7.8 Hz, 1H, CH), 3.39 – 3.33 (m, 1H, CH of CH2), 2.95 – 2.87 (m, 1H, 
CH of CH2), 2.38 – 2.30 (m, 1H, CH of CH2), 2.08 – 1.97 (m, 1H, CH of CH2), 1.93 – 
1.76 (m, 2H, CH2). 13C NMR (100 MHz, d6-DMSO) δ: 206.3 (q), 135.2 (q), 134.9 (CH), 
130.7 (q), 128.2 (CH), 125.7 (CH), 124.0 (CH), 70.7 (CH), 49.7 (CH2), 35.1 (CH2), 24.1 
(CH2). In agreement with previously reported data in the group159. 
 1-(Triphenylphosphaneylidene)propan-2-one 355 
To a suspension of triphenylphosphine (4.20 g, 16.0 mmol, 1.0 eq) in MeCN (15 mL), 
a solution of chloroacetone (1.28 mL, 16.0 mmol, 1.0 eq) in MeCN (5 mL) was added 
over 10 minutes. The reaction was heated to 100 °C and left overnight. After TLC 
showed complete consumption of starting material, the reaction mixture was cooled to 
room temperature, and then to 0 °C. The precipitate was filtered under vacuum and 
was washed with MeCN (2 × 15 mL) before being dissolved in water. The aqueous 
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solution was added to a solution of K2CO3, (1.76 g) and Na2CO3 (2.00 g) in water (20 
mL). The resulting precipitate was filtered under vacuum and washed with water (15 
mL). The precipitate was dissolved in DCM (25 mL), and the organic layer was washed 
with brine (20 mL). The organic phase was dried over MgSO4, and concentrated under 
vacuum, affording the desired ylide as a white solid – 3.57 g (70%), mp 205 – 207 °C, 
lit mp: 205-206 °C160. 1H NMR (400 MHz, d6-DMSO) δ: 7.71 – 7.62 (m, 6H, ArH), 7.60 
– 7.53 (m, 3H, ArH), 7.51 – 7.45 (m, 6H, ArH), 3.61 (bs, 1H, CH=PPh3), 2.11 (s, 3H, 
CH3). FTIR νmax /cm-1: 1536.7, 1477.9, 1434.5, 1383.7, 1150.1, 1105.8. Mild deviations 
from reported data161. 
 Attempted Syntheses of (Z)-1-(5,5-Dioxido-1,2,3, 11a-tetrahydrobenzo -
[f]pyrrolo[1,2-b][1,2,5]thiadiazepin-11(10H)-ylidene)propan-2-one 354 
 
3.1.7.1 Via Eschenmoser Episulfide Contraction 
To a stirred solution of thioamide 350 (300 mg, 1.12 mmol, 1.0 eq) in dry DMSO (20 
mL), NaH (60% in mineral oil) (0.08 g, 2.24 mmol, 2.0 eq) was added slowly. The 
mixture stirred at ambient temperature for 30 minutes before chloroacetone (0.23 mL, 
2.8 mmol, 2.5 eq) was added, and left to stir for a further 90 minutes. Upon 
consumption of starting material, trimethylphosphite (0.4 mL, 3.36 mmol, 3.0 eq) and 
DABCO (0.38 g, 3.36 mmol, 3.0 eq) were added, and the reaction mixture was stirred 
at 90 °C overnight. The reaction mixture was cooled to ambient temperature and the 
contents of the flask were poured into water (50 mL) and extracted with CH2Cl2 (4 × 
40 mL). The combined organic layers were washed with water (7 × 80 mL), dried, and 
concentrated under vacuum. The crude product was purified over a column of silica, 
eluted with 20% EtOAc in 40 – 60 °C petroleum ether. An unknown product was 
recovered as a pale brown residue.  
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1H NMR (400 MHz, CDCl3) δ: 10.02 (bs, 1H, NH), 8.35 (d, J = 8.1 Hz, 1H, ArH), 7.42 
(d, J = 8.1 Hz, 1H, ArH), 7.23 (t, J = 8.0 Hz, 1H, ArH), 7.01 (t, J = 8.1 Hz, 1H, ArH), 
4.06 (t, J = 7.4 Hz, 2H, CH2) 2.84 (t, J = 7.6 Hz, 2H, CH2), 2.33 (s, 3H, CH3), 1.97 (t, J 
= 7.6 Hz, 2H, CH2). 13C NMR (100 MHz, CDCl3) δ: 172.0 (q), 160.2 (q), 137.8 (q), 
133.0 (CH), 128.7 (CH), 126.0 (q), 124.5 (CH), 120.0 (CH), 62.1 (CH2), 33.7 (CH2), 
22.7 (CH2), 18.9 (CH3). FTIR νmax /cm-1: 3305.4, 2922.1, 1683.6, 1575.8, 1510.4, 
1428.9, 1338.4, 1295.5, 1058.8. HRMS m/z calcd. for C14H16N2O3S [M+Na+] required 
315.0774, found 257.0718. This agrees with HRMS m/z calcd. for C12H14N2OS (353a) 
[M+Na+] however.  
3.1.7.2 Via Wittig Reaction 
To a solution of thioamide 350 (0.56 g, 2.10 mmol, 1.0 eq), in MeOH (20 mL), 
(acetylmethylene)triphenylphosphorane 355 (1.0 g, 3.15 mmol, 1.5 eq) was added, and 
the mixture was stirred at reflux for 3 days. The solvent was removed under vacuum and 
the resulting residue was purified over a column of silica, eluted with 50% EtOAc in 40 – 
60 °C petroleum ether, affording the methyl ester 356 as a pale green oily residue ~ 15 
mg. 
1H NMR (400 MHz, CDCl3) δ: 7.61 (dd, J = 1.4, 8.0 Hz, 1H, ArH), 7.23 (td, J = 1.4, 7.6 
Hz, 1H, ArH), 6.70 (d, J = 8.0 Hz, 1H, ArH), 6.64 (t, J = 7.6 Hz, 1H, ArH), 5.30 (bs, 2H, 
ArNH2), 4.44 (dd, J = 4.2, 8.6 Hz, 1H, CH), 3.65 (s, 3H, OMe), 3.30 (t, J = 6.9 Hz, 2H, 
CH2), 2.14 – 2.05 (m, 1H, CH  of CH2), 1.98 – 1.84 (m, 2H, CH2), 1.81 – 1.72 (m, 1H, 
CH  of CH2). 13C NMR (100 MHz, CDCl3) δ: 172.9 (q), 146.6 (q), 134.5 (CH), 130.2 
(CH), 118.7 (q), 117.7 (CH), 116.6 (CH), 59.6 (CH), 52.4 (CH3), 48.6 (CH2), 30.9 (CH2), 




 2-Diazo-1-(1-((2-nitrophenyl)sulfonyl)pyrrolidin-2-yl)ethan-1-one 358 
To a stirred solution of ((2-nitrophenyl)sulfonyl)proline 342 (2.24 g, 7.47 mmol,1.0 eq) 
in dry THF (20 mL) was added oxalyl chloride (0.64 mL, 7.47 mmol, 1.0 eq) and DMF 
(5 drops). The mixture stirred overnight at room temperature, after which, the reaction 
mixture was cooled to 0 °C and a 2 M solution of TMS-diazomethane in THF (7.5 mL, 
15.0 mmol, 2.0 eq) was added dropwise, and the reaction was left at room temperature 
for 4 days. Water (5.0 mL) was added to quench the reaction and the organic material 
was extracted with EtOAc (3 × 50 mL). The organic phases were combined and 
washed with saturated NaHCO3 (30 mL), brine (30 mL), and dried over MgSO4. The 
organic material was purified over a column of silica, eluted by 65% EtOAc in 40 – 60 
°C petroleum ether, affording the desired diazoketone as a viscous red/brown oil – 
0.97 g (48%). 
1H NMR (400 MHz, CDCl3) δ: 7.98 (dd, J = 1.7, 7.2 Hz, 1H, ArH), 7.61 – 7.54 (m, 2H, 
ArH), 7.58 (dd, J = 1.7, 7.2 Hz, 1H, ArH), 5.72 (bs, 1H, CH=N2), 4.41 (d, J = 8.3 Hz, 
1H, CH), 3.57 – 3.50 (m, 1H, CH of CH2), 3.39 (q, J = 8.3 Hz, 1H, CH of CH2), 2.13 – 
1.98 (m, 2H, CH2), 1.96 – 1.79 (m, 2H, CH2). 
 (Z)-1-(4,4-Dioxido-2,3,3a,10a-tetrahydro-1H-
benzo[b]cyclopenta[f][1,4]thiazepin-10(9H)-ylidene)propan-2-one 354 
To a stirred solution of diazoketone 358 (0.36 g, 1.11 mmol, 1.0 eq) in dry DCM (20 
mL), was added tin(II) chloride (0.25 g, 1.33 mmol, 1.2 eq) and a solution of 
acetaldehyde (0.081 mL, 1.44 mmol, 1.3 eq) in dry DCM (2 mL). The mixture was 
stirred at room temperature for 4 hours. Once TLC indicated the consumption of 
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starting material, the reaction mixture was filtered through Celite and washed through 
with DCM (2 × 20 mL). The filtrate was cooled to 0 °C, and zinc powder (0.73 g, 11.1 
mmol, 10 eq), and glacial acetic acid (10 mL) were added. The mixture stirred at room 
temperature overnight, the reaction was filtered through Celite, and washed through 
with DCM (3 × 10 mL). The filtrate was washed with water (40 mL), saturated NaHCO3 
(40 mL), and brine (40 mL) before being dried over MgSO4 and concentrated under 
vacuum. The crude material was purified over a column of silica and eluted with 50% 
EtOAc in 40 – 60 °C petroleum ether, affording the desired product as a pale-yellow 
solid, 50 mg (15%). Mp: 127 – 130 °C. 
1H NMR (400 MHz, CDCl3) δ: 12.70 (bs, 1H, NH), 7.79 (d, J = 7.8 Hz, 1H, ArH), 7.48 
(t, J = 7.8 Hz, 1H, ArH), 7.14 – 7.08 (m, 2H, ArH), 5.54 (s, 1H, =CH), 4.25 – 4.19 (m, 
1H, CH), 3.52 – 3.45 (t, J = 7.7 Hz, 1H, CH of CH2), 3.04 – 2.96 (m, 1H, CH of CH2), 
2.21 – 2.17 (m, 1H, CH of CH2), 2.15 (s, 3H, CH3), 1.93 – 1.86 (m, 3H,  CH2 and CH 
of CH2). 13C NMR (100 MHz, CDCl3) δ: 198.8 (q), 160.1 (q), 136.7 (q), 134.1 (CH), 
129.13 (CH), 122.8 (CH), 122.6 (CH), 99.21 (CH) 77.3 (q), 64.8 (CH), 49.7 (CH2), 34.7 
(CH2), 29.72 (CH3), 24.6 (CH2). HRMS, m/z calcd. for C14H16N2O3S [M+H] reqd. 
292.0882, found 292.0878. 
 1-(Triisopropylsilyl)-1H-indole-3-carbaldehyde 363 
 To a stirred solution of indole-3-carbaldehyde 362 (1.00 g, 6.90 mmol, 1.0 eq) in dry 
THF (50 mL), was added NaH (60% in mineral oil) (0.33 g, 8.30 mmol, 1.2 eq) portion-
wise at room temperature, under a nitrogen atmosphere. After 90 minutes, the reaction 
was cooled to 0 °C in an ice bath, and TIPS chloride (2.0 mL, 9.00 mmol, 1.3 eq) was 
added dropwise over 5 minutes. The mixture stirred at 0 °C for 30 minutes, after which 
the reaction was allowed to warm to room temperature over 90 minutes. Water was 
added until effervescence was no longer observed, and DCM (50 mL) was added. The 
organic material was separated and washed with water (30 mL), and brine (30 mL). 
The organic material was dried over MgSO4 and was concentrated under reduced 
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pressure. The crude product was purified over a column of silica, eluted by 30% EtOAc 
in 40 – 60 °C petroleum ether, affording the desired TIPS-protected product as a green 
oil, 0.51 g, 24%. 
NMR (400 MHz, CDCl3) δ: 9.94 (s, 1H), 8.24 – 8.21 (m, 1H), 7.77 (s, 1H), 7.42 – 7.39 
(m, 1H), 7.17 – 7.14 (m, 2H), 1.61 (septet, J = 7.6 Hz, 3H), 1.03 (d, J = 7.6 Hz, 18H). 
In agreement with literature124. 
 (E)-3-(1H-Indol-3-yl)acrylaldehyde 366 
Morpholine trifluoracetic acid (0.34 g, 1.71 mmol, 0.2 eq) and indole 363 (1.00 g, 8.54 
mmol, 1 eq) were mixed in dry THF (60 mL). Acrolein 365 (1.7 mL, 25.6 mmol, 3 eq) 
was added to the reaction mixture, which was allowed to stir for 24 hours at 30 °C. 
DDQ (2.5 g, 25.6 mmol, 3 eq) was added and the reaction was stirred for 2 hours. The 
solvent was removed, and the product was dried under vacuum. 500 mg of the crude 
material was purified over a column of silica, eluted by a system of 30% acetone in 
hexane, with 10% v/v Et3N, affording the product as a brown syrup- 70 mg (30% from 
the 500 mg), mp 79-82 °C, lit mp127 is unreported. 
NMR (400 MHz, CDCl3) δ: 9.65 (d, J = 7.8 Hz, 1H, CH=O), 8.79 (bs, 1H, NH), 7.95 – 
7.91 (m, 1H, ArH) 7.72 (d, J = 15.6 Hz, 1H, C=CH), 7.63 (d, J = 2.5 Hz, ArH), 7.48 (dd, 
J = 2.2, 6.8 Hz, ArH), 7.33 (td, J = 1.4, 6.3 Hz, 2H, ArH), 6.81 (dd, J = 7.9, 15.7 Hz, 
1H, C=CH). Slight deviations from reported data127. 
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 Attempted Synthesis of (1Z,3E)-1-(5,5-dioxido-1,2,3,11a-
tetrahydrobenzo[f]pyrrolo[1,2-b][1,2,5]thiadiazepin-11(10H)-ylidene)-4-(1H-
indol-3-yl)but-3-en-2-one 361 
 Via Aldol Condensation  
To a solution of LDA (2.0 M in THF, 0.34 mL, 0.67 mmol, 4.0 eq) in dry THF (10 mL) 
cooled to -78 °C, was added a solution of PBTD 354 (50 mg, 0.17 mmol, 1.0 eq) in dry 
THF (1 mL). The mixture was allowed to stir at -78 °C for 30 minutes before being 
transferred to a solution of protected indole carbaldehyde 363 (0.25 g, 0.85 mmol, 5.0 
eq) in dry THF (5 mL) at -78 °C. The reaction stirred at -78 °C for 20 minutes before 
warming to 0 °C, where it remained for 60 minutes. Water (10 mL) was added, and 
the organic material was extracted with EtOAc (3 × 50 mL). The combined organic 
phase was washed with brine (30 mL) and dried over MgSO4 before being 
concentrated and purified over a column of silica, gradient eluted (30 – 70%) EtOAc 
in hexane. The white solid afforded from the column was dissolved in a solution of 
THF: 2 M HCl (1:1, 5 mL), and stirred overnight. Saturated aqueous NaHCO3 (5 mL) 
was added, and the mixture was extracted with EtOAc (3 × 20 mL). The organic extract 
was washed with water (50 mL) and brine (50 mL), before being dried over MgSO4 
and concentrated under vacuum. The crude residue was purified over a column of 
silica, eluted by 50% EtOAc in hexane, affording the de-protected indole-3-
carbaldehyde (~20 mg) as the only product. 
 Via Reductive Cyclodehydration  
To a stirred solution of diazoketone 358 (100 mg, 0.31 mmol, 1 eq), in dry DCM (20 
mL), was added tin(II) chloride (71 mg, 0.372 mmol, 1.2 eq), and a solution of indole 
species 366 (70 mg, 0.403 mmol, 1.3 eq) in dry DCM (2 mL) and the mixture was 
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allowed to stir at room temperature for 3 hours. The reaction mixture was filtered 
through celite and washed through with DCM (20 mL). The filtrate was taken and 
cooled in an ice water bath. After cooling, zinc powder (0.20 g, 3.1 mmol, 10 eq) and 
glacial acetic acid (20 mL) was added, and the mixture was allowed to stir overnight 
at room temperature. The reaction mixture was filtered through celite, and the filtrate 
was washed with water (2 × 50 mL), saturated sodium bicarbonate solution (50 mL) 
and brine (50 mL), before being dried and concentrated under vacuum. Purification of 
the crude product was then attempted over a column of silica, eluted by a solution of 
50% EtOAc in 40-60 °C petroleum ether. No identifiable products were recovered.  
 1-((2-Nitrophenyl)sulfonyl)piperidine-2-carboxylic acid 370 
To a solution of piperidine-2-carboxylic acid 369 (0.67 g, 5.0 mmol, 1.0 eq) in a mixture 
of THF (5 mL), water (10 mL) and triethylamine (1.75 mL, 12.5 mmol, 2.5 eq) at 0 °C 
was added ((2 nitrobenzene)sulfonyl)chloride 341 (1.11 g, 6.0 mmol, 1.2 eq) 
portionwise. The reaction mixture was stirred at room temperature for 4 hours. The 
reaction mixture was cooled to 0 °C and acidified to ~ pH 2 using conc. hydrochloric 
acid. The organic material was extracted using 10% MeOH in DCM (3 × 30 mL). The 
extracted material was washed with brine (50 mL), dried using MgSO4 and 
concentrated under vacuum. The desired product was triturated using chloroform and 
hexane, affording a pale green syrup, 0.66 g (42%). 
1H NMR (400 MHz, CDCl3) δ: 8.07 – 8.02 (m, 1H, ArH), 7.74 – 7.69 (m, 2H, ArH), 7.69 
– 7.65 (dd, 2.4, 6.2 Hz, 1H, ArH), 6.92 (bs, 1H, NH), 4.82 (d, J = 5.0 Hz, 1H, CH), 3.78 
(dd, J = 3.3, 13.2 Hz 1H, CH of CH2), 3.31 (td, J = 2.7, 13.0 Hz, 1H, CH of CH2), 2.27 
(d, J = 13.0 Hz, 1H, CH of CH2), 1.87 (tdd, J = 3.6, 6.0, 13.5 Hz, 1H, CH of CH2), 1.74 
(t, J = 14.1 Hz, 2H, CH2), 1.59 – 1.45 (m, 1H, CH of CH2), 1.37 – 1.27 (m, 1H, CH of 
CH2). 13C NMR (100 MHz, CDCl3) δ: 176.4 (q), 147.6 (q) 133.5 (CH), 133.0 (q), 131.7 
(CH), 130.7 (CH), 124.4 (CH), 55.7 (CH), 43.4 (CH2), 27.5 (CH2), 24.8 (CH2), 20.2 
(CH2). FTIR νmax /cm-1: 1732.3, 1540.1, 1473.6, 1370.6, 1343.0, 1159.5, 1023.4. 
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 2-Diazo-1-(1-((2-nitrophenyl)sulfonyl)piperidin-2-yl)ethan-1-one 371 
To a stirred solution of 2-nitrobenzenesulfonyl-piperidine-2-carboxylic acid 370 (1.40 
g, 4.46 mmol, 1.0 eq) in dry THF (20 mL) was added DMF (3 drops) and oxalyl chloride 
(0.38 mL, 4.46 mmol, 1.0 eq) and the mixture stirred for 3 hours at room temperature. 
The mixture was cooled to 0 °C and a  2 M solution of TMSCHN2 in THF (4.46 mL, 
8.92 mmol, 2.0 eq) was added dropwise and the reaction stirred overnight under a 
positive pressure of nitrogen. Water (5 mL) was added, and the organic material was 
extracted with EtOAc (3 × 50 mL). The organic extracts were combined and washed 
with a saturated sodium bicarbonate solution (70 mL), and brine (50 mL). The organic 
phase was dried and concentrated under vacuum. The crude residue was purified over 
a column of silica, eluted by 60% EtOAc in 40-60 °C pet ether. The product was 
recovered as a pale brown oil, 170 mg (11%).  
1H NMR (400 MHz, CDCl3) δ: 7.95 – 7.90 (m, 1H, ArH), 7.58 – 7.52 (m, 2H, ArH), 7.53 
– 7.50 (m, 1H, ArH), 5.60 (s, 1H, CH=), 4.46 (broad doublet, J = 5.0 Hz, 1H, CH), 3.71 
(d, J = 14.0 Hz, 1H, CH of CH2), 3.13 (apparent triplet, J = 12.7 Hz, 1H, CH of CH2), 
2.75 (d, J = 12.7 Hz, 1H, CH of CH2), 2.13 (d, J = 13.1 Hz, 1H, CH of CH2), 1.53 – 1.46 
(m, 2H, CH2), 1.27 – 1.18 (m, 2H, CH2). 
 Attempted Synthesis of (Z)-1-(4,4-Dioxido-2,3,3a,10a-tetrahydro-1H-
benzo[b]cyclopenta[f][1,4]thiazepin-10(9H)-ylidene)propan-2-one 373 
To a stirred solution of diazoketone 371 (0.17 g, 0.50 mmol, 1.0 eq), in dry DCM (20 
mL), was added tin(II) chloride (0.11 g, 0.60 mmol, 1.2 eq) and a solution of 
acetaldehyde (0.04 mL, 0.65 mmol, 1.3 eq) in dry DCM (2 mL). The mixture was stirred 
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at room temperature for 4 hours, and after TLC indicated complete consumption of 
starting material, the reaction mixture was filtered through a plug of celite, washed 
through with DCM (3 × 15 mL). The filtrate was cooled to 0 °C followed by the addition 
of zinc powder (0.33 g, 5.0 mmol, 10 eq) and glacial acetic acid (10 mL). The reaction 
was stirred overnight at room temperature and was filtered through celite, washed 
through with DCM (3 × ~20 mL). The filtrate was washed with water (50 mL), saturated 
NaHCO3 solution (50 mL), and brine (50 mL), before being dried and concentrated 
under vacuum. The crude isolate was purified over a column of silica, eluted by a 50% 
solution of EtOAc in 40-60 °C pet ether, yielding trace amounts of promising isolates 
(See discussion). 
3.2 Syntheses of Circumdatin H 
 1,2,3,11a-Tetrahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H)-
dione 28 
To a stirred solution of isatoic anhydride 27 (1.27 g, 11.00 mmol, 1.1 eq) in dry DMSO 
(20 mL) was added L-proline (1.63 g, 10.00 mmol, 1.0 eq). The mixture was heated at 
reflux for 18 hours, and after cooling, was poured into cold water (150 mL) and was 
stirred gently for 30 minutes. The precipitate was collected via vacuum filtration and 
was dried over vacuum, affording the desired product as colourless needles, 1.2 g 
(55%) mp: 208 – 210 °C (lit mp: 209 – 210 °C26). 
1H NMR (400 MHz, CDCl3) δ: 8.03 (dd, J = 1.3, 7.8 Hz, 1H, ArH), 7.96 (bs, 1H, NH), 
7.50 (td, J = 1.4, 7.7 Hz, 1H, ArH), 7.31 (d, J = 7.6 Hz, 1H, ArH), 6.99 (d, J = 8.0 Hz, 
1H, ArH), 4.10 (d, J = 6.2 Hz, 1H, CH), 3.89 – 3.80 (m, 1H, CH of CH2), 3.68 – 3.58 
(m, 1H, CH of CH2), 2.83 – 2.74 (m, 1H, CH of CH2), 2.12 – 1.99 (m, 3H, CH2 and CH 
of CH2) - consistent with literature26. 
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 5-Methoxy-2-nitrobenzoyl chloride 51 
To a stirred suspension of 5-methoxy-2-nitrobenzoic acid 382 (2.00 g, 10.14 mmol, 
1.0 eq) in anhydrous toluene (20 mL) was added thionyl chloride (2.40 mL, 33.04 
mmol, 3.25 eq) and DMF (3 drops). The mixture was stirred at ambient temperature 
for 5 minutes before being heated to reflux for 1 hour. The volatile materials were 
removed under reduced pressure and the resulting oil was dried under high-vacuum 
conditions to afford the desired acid chloride in quantitative yield and was used further 
without purification. 
1H NMR (400 MHz, CDCl3) δ: 8.15 (d, J = 9.1 Hz, 1H, ArH), 7.10 (dd, J = 2.6, 9.1 Hz, 
1H, ArH), 7.00 (d, J = 2.6 Hz, 1H, ArH), 3.96 (s, 3H, OMe).  
 2-Azido-5-methoxybenzoic acid 61 
To a stirred suspension of 2-amino-5-methoxybenzoic acid 59 (1.00 g, 5.98 mmol, 1.0 
eq) in a solution of conc. HCl (1.25 mL) and water (5.0 mL) at -5 °C, was added a pre-
cooled solution of sodium nitrite (0.45 g, 6.52 mmol, 1.2 eq) in water (1.2 mL) dropwise 
over 5 minutes. The reaction was left in the ice bath for 30 minutes and urea (0.45 g, 
7.50 mmol, 1.4 eq) was added. After 3 minutes, a pre-cooled solution of sodium azide 
(0.46 g, 6.52 mmol, 1.2 eq) in water (1.25 mL) was added dropwise over 5 minutes. 
After 10 minutes, the reaction was allowed to warm to room temperature and stirred 
overnight at ambient temperature. Water (50 mL) was added, and the precipitate was 
collected via vacuum filtration. The crude product was purified by flash 
chromatography, eluted by 10% MeOH in DCM, affording 0.6 g of the desired azide 
(52%), mp 106 – 109 °C (lit mp: 107 – 108 °C37). 
1H NMR (400 MHz, CDCl3) δ: 7.67 (d, J = 2.4 Hz, 1H,ArH), 7.20 (d, J = 3.1 Hz, 2H, 
ArH), 3.87 (s, 3H, OMe), in compliance with literature.37 
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 2-Azido-5-methoxybenzoyl chloride 63 
To a stirred solution of 2-azido-5-methoxybenzoic acid 61 (0.5 g, 2.59 mmol, 1.0 eq) 
in dry THF (10 mL), was added neat thionyl chloride (1.58 mL, 21.9 mmol, 1.0 eq). 
The mixture was heated at reflux for 2 hours, was allowed to cool, and the volatile 
components were removed under vacuum, affording the desired acid chloride as a 
dark brown oil in quantitative yields. The product was used without further purification.  
1H NMR (400 MHz, CDCl3) δ: 7.68 (bs, 1H, ArH), 7.27 (bs, 1H, ArH), 7.18 (s, 2H, 2 × 




 Method 1: Via reductive cyclodehydration 
PBD  28 (250 mg, 1.16 mmol, 1.0 eq), DMAP (52.3 mg, 0.46 mmol, 0.4 eq), and 
triethylamine (0.32 mL, 2.32 mmol, 2.0 eq) were dissolved in anhydrous DMAC (5 mL) 
and cooled to -10 °C. 5-Methoxy-2-nitrobenzoyl chloride 51 (250 mg, 1.16 mmol, 1.0 
eq) was added and the mixture was  stirred at -10 °C for 30 minutes. Glacial acetic 
acid (5 mL) was added, and the reaction mixture was cooled to -30 °C. Zinc powder 
(1.8 g, 27.5 mmol, 23 eq) was added, the reaction mixture was warmed to -20 °C and 
was left to stir for 90 minutes and then slowly warmed to -5 °C, over approximately 2 
hours. The reaction mixture was poured into a 10% aqueous solution of potassium 
carbonate (60 mL) and the organic material was extracted with EtOAc (3 × 50 mL). 
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The combined organic extracts were washed with water (2 × 50 mL), dried over 
MgSO4, and concentrated under vacuum. The crude material was purified over a 
column of silica, eluted by a 60% solution of EtOAc in hexanes, to afford the desired 
natural product as an off-white solid - 80 mg (20%), mp: 211 – 213 °C, decomposed > 
215 °C, disagreeing with that in the published literature 36, 38. 
1H NMR (400 MHz, CDCl3) δ: 7.90 (d, J = 7.6 Hz, 1H, ArH), 7.56 – 7.53 (m, 2H, ArH), 
7.50 – 7.46 (m, 2H, ArH), 7.45 – 7.40 (m, 1H, ArH), 7.28 (dd, J = 2.5, 8.7 Hz, 1H, ArH), 
4.45 (d, J = 7.6 Hz, 1H, CH of CH2), 3.82 (s, 3H, OMe), 3.73 – 3.66 (m, 1H, CH of 
CH2), 3.56 – 3.47 (m, 1H, CH of CH2), 3.10 – 3.03 (m, 1H, CH of CH2), 2.28 – 2.16 (m, 
1H, CH of CH2), 2.11 – 1.92 (m, 2H, CH2). 13C NMR (100 MHz, CDCl3) δ: 164.52, 
161.65, 158.95, 151.51, 140.56, 133.40, 132.43, 130.72, 129.87, 129.18, 128.64, 
128.44, 124.81, 122.31, 106.91, 58.80, 55.86, 46.52, 27.01, 23.71. FTIR νmax /cm-1: 
2950.0, 1685.5, 1645.3, 1617.8, 1489.5, 1357.8, 1234.7, 1022.4, 789.1. Consistent 
with previously reported data36. 
 Method 2: Via an aza-Wittig reaction 
To a stirred solution of triethylamine (0.2 mL, 1.43 mmol, 1.5 eq) and DMAP (80 mg, 
0.6 mmol, 0.7 eq) in dry THF (20 mL) was added PBD 28 (0.20 g, 0.95 mmol, 1.0 eq) 
portion-wise at 0 °C under a nitrogen atmosphere. The reaction stirred at 0 °C for 1 
hour, after which, 2-azido-5-methoxybenzoyl chloride 61 (0.25 g, 1.18 mmol, 1.25 eq) 
was added, and the reaction was stirred for a further 30 minutes, followed by 1 hour 
at room temperature. The solvent was removed, and the residue was dissolved in dry 
DCM (100 mL). The organic material was washed with water (2 × 60 mL), dried, and 
concentrated under vacuum. The crude intermediate (600 mg, 1.53 mmol, 1.0 eq) was 
dissolved in anhydrous toluene (25 mL) and Bu3P (0.39 mL, 1.53 mmol, 1.0 eq) was 
added. The reaction was heated at 70 °C overnight, the volatile components were 
removed under reduced pressure, and the resulting residue was taken up in DCM (100 
mL). The organic material was washed with 0.5 M HCl (3 × 60 mL), brine (2 × 30 mL), 
and dried over magnesium sulfate. The solvent was removed under reduced pressure 
and the residue was purified over a column of silica, eluted by 20% EtOAc in DCM, 
affording the desired product as a cream solid - 30 mg (6%), mp: 211 – 213 °C, 
decomposed > 215 °C, in disagreement with literature36, 38. 
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1H NMR (400 MHz, CDCl3) δ: 7.98 (d, J = 7.2 Hz, 1H, ArH), 7.67 – 7.61 (m, 2H, ArH), 
7.58 – 7.53 (m, 2H, ArH), 7.53 – 7.48 (m, 1H, ArH), 7.36 (dd, J = 2.8, 8.8 Hz, 1H, ArH), 
4.53 (d, J = 7.6 Hz, 1H, CH), 3.90 (s, 3H, OMe), 3.81 – 3.73 (m, 2H, CH2), 3.64 – 3.53 
(m, 1H, CH of CH2), 3.20 – 3.09 (m, 1H, CH of CH2), 2.35 – 2.22 (m, 2H, CH2). 
Consistent with literature38 and previous synthesis. 
3.3  Synthesis of Circumdatin H Homologues 
 7,8,9,10-Tetrahydrobenzo[e]pyrido[1,2-a][1,4]diazepine-6,12(5H,6aH)-
dione 393 
A solution of isatoic anhydride 27 (1.25 g, 10.0 mmol, 1.0 eq) and piperidine-2-
carboxylic acid 392 (1.63 g, 10.0 mmol, 1.0 eq) in dry DMSO (20 mL) was heated at 
reflux for 4 hours. The mixture was cooled to room temperature, diluted with water (80 
mL), and the organic material was extracted with toluene (3 × 10 mL). The combined 
organic phases were dried over magnesium sulfate, concentrated under vacuum and 
the desired product was left to crystallise by slow evaporation. 0.16 g (6.9%) of product 
was recovered, mp: 208 – 210 °C (lit mp: 226 – 228 °C 135). 
1H NMR (400 MHz, CDCl3) δ: 10.36 (bs, 1H, NH), 7.69 (d, J = 7.6 Hz, 1H, ArH), 7.47 
(t, J = 7.6 Hz, 1H, ArH), 7.19 (t, J = 7.5 Hz, 1H, ArH), 7.06 (d, J = 7.7 Hz, 1H, ArH), 
4.30 (d, J = 13.2 Hz, 1H, CH), 4.12 (dd, J = 2.8, 6.4 Hz, 1H, CH of CH2), 2.78 (td, J = 
3.5, 13.1 Hz, 1H, CH of CH2), 2.01 (apparent doublet, J = 12.8 Hz, 1H, CH of CH2), 
1.81 – 1.69 (m, 2H, CH2), 1.64 – 1.53 (m, 2H, CH2), 1.51 – 1.39 (m, 1H, CH of CH2).  





Isatoic anhydride 27 (1.63 g, 10.0 mmol, 1.0 eq) and thiazolidine-4-carboxylic acid 390 
(1.33 g, 10.0 mmol, 1.0 eq) were dissolved in a 20% solution of triethylamine in DMF 
(10 mL) in a sealed tube. The reaction mixture was heated to 120 °C and was stirred 
for 2 hours. After cooling, the contents of the tube were poured into ice-cold water (300 
mL). After 2 hours of gentle stirring, the precipitate was collected and dried through 
vacuum filtration, affording the desired compound as an off-white solid, 0.2 g (8%) mp: 
207-208 °C (lit: 208 – 210 °C133). 
1H NMR (400 MHz, CDCl3) δ: 10.64 (bs, 1H, NH), 7.79 (dd, J = 1.3, 7.8 Hz, 1H, ArH), 
7.53 (td, J = 1.2, 7.8 Hz, 1H, ArH), 7.23 (t, J = 7.7 Hz, 1H, ArH), 7.14 (d, J = 8.0 Hz, 
1H, ArH), 4.66 (dd, J = 3.0, 10.0 Hz, 2H, CH2), 4.44 (dd, J = 2.8, 7.0 Hz, 1H, CH of 
CH2), 3.58 (dd, J = 2.8, 11.8 Hz, 1H, CH of CH2), 3.22 (dd, J = 7.0, 11.7 Hz, 1H, CH 




To a solution of triethylamine (0.09 mL, 0.65 mmol, 1.5 eq) and DMAP (0.037 g, 0.30 
mmol, 0.7 eq) in dry THF (10 mL), cooled to 0 °C, was added dilactam 393 (0.1 g, 0.43 
mmol, 1.0 eq) over 2 minutes, and the solution was stirred for 1 hour at 0 °C. 2-Azido-
5-methoxybenzoyl chloride 63 (0.11 g, 0.54 mmol, 1.25 eq) was added dropwise and 
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the whole was stirred further for 30 minutes at 0 °C, before being warmed to room 
temperature and stirring for 1 hour. The solvent was removed, and the residue 
dissolved in DCM (~20 mL). The organic layer was washed with water (2 × 60 mL) 
before being dried and concentrated under vacuum. The crude residue (146 mg, 0.36 
mmol, 1.0 eq) was dissolved in toluene (25 mL) and tributylphosphine (0.88 mL, 0.36 
mmol, 1.0 eq) was added. The mixture was heated at reflux for 1 hour before stirring 
overnight at room temperature. The solvent was removed under reduced pressure and 
the resulting deposit was dissolved in DCM (~20 mL). The organic material was 
washed with 0.5 M HCl (3 × 40 mL) and brine (2 × 30 mL). The organic phase was 
dried and concentrated under vacuum, and the resulting crude material was purified 
over a column of silica, eluted by a 20% solution of EtOAc in DCM, to afford the desired 
product as an off-white solid, 34 mg (22%), mp: 171 – 174 °C – previously unreported. 
1H NMR (400 MHz, CDCl3) δ: 7.91 (dd, J = 1.1, 7.6 Hz, 1H, ArH), 7.69 – 7.65 (m, 2H, 
ArH), 7.62 – 7.55 (m, 2H, ArH), 7.52 (t, J = 7.1, 14.2 Hz, 1H, ArH), 7.38 (dd, J = 2.9, 
9.0 Hz, 1H, ArH), 4.63 (dd, J = 2.9, 7.1 Hz, 1H, CH of CH2), 4.53 (broad doublet, J = 
15.8 Hz, 1H, CH of CH2), 3.93 (s, 3H, OMe), 2.82 (td, J = 3.7, 13.2 Hz, 1H, CH of CH2), 
2.59 – 2.51 (m, 1H, CH of CH2), 2.38 – 2.25 (m, 1H, CH of CH2), 1.90 – 1.80 (m, 2H, 
CH2), 1.79 – 1.71 (m, 1H, CH of CH2), 1.65 – 1.55 (m, 1H, CH of CH2). 13C NMR (100 
MHz, CDCl3) δ: 167.19 (q), 161.31 (q), 158.97 (q), 151.26 (CH), 140.38 (q), 133.45 
(q), 131.75 (q), 130.62 (CH), 129.70 (CH), 129.30 (CH), 128.71 (CH), 127.50 (CH), 
124.85 (CH), 122.44 (q), 106.87 (q), 55.90 (q), 52.89 (CH2), 39.05 (CH2), 24.17 (CH2), 
23.30 (CH2), 19.32 (OCH3). FTIR νmax /cm-1: 3000.0, 1678.3, 1615.3, 1487.1, 1358.7, 






To a stirred solution of triethylamine (0.09 mL, 0.65 mmol, 1.5 eq) and DMAP (0.037 
g, 0.30 mmol, 0.7 eq) in dry THF (10 mL) was added dilactam 391 (0.10 g, 0.43 mmol, 
1.0 eq) slowly at 0 °C. The mixture was allowed to stir for 1 hour at this temperature. 
2-Azido-5-methoxybenzoyl chloride 63 (0.11 g, 0.36 mmol, 1.25 eq) was added 
dropwise over 5 minutes and the resulting mixture was stirred at 0 °C for 30 minutes. 
The reaction was warmed to room temperature and stirred for a further hour. The 
solvent was removed under reduced pressure and the residue was dissolved in DCM 
(~30 mL). The organic phase was washed with (2 × 60 mL), dried over magnesium 
sulfate and concentrated under reduced pressure. The residue (147 mg, 0.37 mmol, 
1.0 eq) was dissolved in anhydrous toluene (10 mL) and Bu3P (0.091 mL, 0.37 mmol, 
1.0 eq) was added directly to the solution and the whole was heated at reflux for 1 
hour. The heat was removed, and the reaction stirred overnight at room temperature. 
The solvent was removed, and the residue was dissolved in DCM (30 mL) and was 
washed with 0.5 M HCl (3 × 40 mL), and brine (2 × 40 mL), before being dried and 
concentrated. The crude material was purified over a column of silica, eluted by a 20% 
solution of EtOAc in DCM, affording the desired product as a cream solid - 28 mg 
(18%), mp: decomposition after 90 °C. Unreported compound. 
1H NMR (400 MHz, CDCl3) δ: 7.69-7.65 (m, 2H, ArH), 7.61-7.57 (m, 2H, ArH), 7.56-
7.52 (m, 2H, ArH), 7.38 (dd, J = 2.9, 9.0 Hz, 1H, ArH), 5.00 (d, J = 10.6 Hz, 1H, CH of 
CH2), 4.79 (dd, J = 4.5, 6.9 Hz, 1H, CH of CH2), 4.58 (d, J = 10.58 Hz, 1H, CH of CH2), 
4.42 (dd, J = 4.6, 11.0 Hz, 1H, CH of CH2), 3.92 (s, 3H, OMe), 3.37 (dd, J = 7.2, 14.4 
Hz, 1H, CH of CH2). FTIR νmax /cm-1: 2950.0, 1682.6, 1615.2, 1393.4, 1361.8, 1278.1, 




3.5 Synthesis of Sulfonyl-analogue Circumdatins 
 Synthesis of Benzo[c][1,2,5]oxathiazin-3(4H)-one 1,1-dioxide 381 
To a vigorously stirred suspension of aniline-2-sulfonic acid 377 (1.0 g, 5.77 mmol, 1.0 
eq) in dry THF (20 mL) was added triphosgene 378 (0.57 mmol. 1.92 mmol, 0.3 eq). 
The mixture was stirred at 45 °C overnight, followed by concentration under vacuum. 
The crude deposit was dissolved in a minimum volume of hot acetone and filtered 
under gravity. The filtrate was concentrated under vacuum affording the product as a 
pale brown powder, 0.64 g (55%).  
1H NMR (400 MHz, CDCl3) δ: 8.95 (bs, 1H, NH), 7.90 (d, J = 7.7 Hz, 1H, ArH), 7.71 (t, 
J = 7.7 Hz, 1H, ArH), 7.41 (t, J = 7.7 Hz, 1H, ArH), 7.21 (d, J = 7.9 Hz, 1H, ArH). 
 Attempted reaction between Benzo[c][1,2,5]oxathiazin-3(4H)-one 1,1-
dioxide and L-proline 
To a stirred suspension of benzo[c][1,2,5]oxathiazin-3(4H)-one 1,1-dioxide 381 (0.64 
g, 3.22 mmol, 1.0 eq) in DMSO (5 mL) was added L-proline 340 (0.37 g, 3.22 mmol, 
1.0 eq). The mixture was stirred at reflux overnight, was cooled to room temperature, 
and poured into ice water (150 mL). The organic material was extracted with EtOAc 
(5 × ~50 mL), dried, and concentrated under vacuum, affording a yellow/brown 





To an ice cooled solution of ((2-aminophenyl)sulfonyl)proline 343 (0.68 g, 2.52 mmol, 
1.0 eq) in DCM (6 mL), a solution of DCC (0.52 g, 2.52 mmol, 1 eq) in DCM (4 mL) 
was added and the mixture stirred overnight at room temperature. The reaction 
mixture was filtered through Celite, and additional portions of DCM (3 × 20 mL) were 
used to rinse any remaining product into the filtrate. The filtrate was washed with 2 M 
HCl (25 mL), saturated NaHCO3 (25 mL), and water (25 mL). The organic layer was 
dried with MgSO4 and concentrated under vacuum, affording a pale, off-white solid – 
0.49 g (77%), mp 185 – 185 °C.  Lit mp: 292 – 293 °C124. When dry, no purification 
was needed.  
1H NMR (400 MHz, CDCl3) δ: 7.86 (dd, J = 1.4, 7.8 Hz, 1H, ArH), 7.71 (bs, 1H, NH), 
7.45 (td, J = 1.4, 7.8 Hz, 1H, ArH), 7.16 (t, J = 7.8 Hz, 1H, ArH), 6.94 (d, J = 7.9 Hz, 
1H, ArH), 4.58 (dd, J = 6.0, 8.0 Hz, 1H, CH), 3.48 – 3.40 (m, 1H, CH of CH2), 2.98 – 
2.90 (m, 1H, CH of CH2), 2.47 – 2.36 (m, 1H, CH of CH2), 2.17 – 2.07 (m, 1H, CH of 
CH2), 1.97 – 1.88 (m, 1H, CH of CH2), 1.83 – 1.74 (m, 1H, CH of CH2). 13C NMR (100 
MHz, CDCl3) δ: 177.0 (q), 146.5 (q), 133.8 (CH), 130.3 (CH), 118.8 (q), 118.1 (CH), 
117.7 (CH), 59.0 (CH), 47.8 (CH2), 31.0 (CH2), 24.7 (CH2). FTIR νmax /cm-1: 3321.3, 
3202.2, 3063.7, 2928.4, 2851.1, 2113.3, 1661.6, 1478.3, 1341.7, 1161.3, 1064.5. Data 
consistent with literature124. 
 1,2,3,11a-Tetrahydrobenzo[f]pyrrolo[1,2-b][1,2,5]thiadiazepine-11(10H)-
thione 5,5-dioxide 350 
To a solution of 1,2,3,11a-tetrahydrobenzo[f]pyrrolo[1,2-b][1,2,5]thiadiazepine-
11(10H)-one 5,5-dioxide 339 (0.86 g, 3.41 mmol, 1.0 eq) in 25 mL dry THF, was added 
Lawesson’s reagent (0.69 g, 1.70 mmol, 0.5 eq). The suspension was allowed to stir 
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at room temperature for 1 hour, then at reflux overnight. The reaction mixture was 
allowed to cool, and the precipitate was filtered under vacuum. The filtrate was 
concentrated under vacuum and the resulting residue was suspended in CHCl3. The 
resulting precipitate was filtered under vacuum and left to dry. Combined, the 
precipitates afforded the pure, desired product as a pale green solid – 0.30 g (32%). 
Mp: 172 – 175 °C. 1H NMR (400 MHz, d6-DMSO) δ: 12.33 (bs, 1H, NH), 7.78 (d, J = 
7.7 Hz, 1H, ArH), 7.72 (t, J = 7.7 Hz, 1H, ArH), 7.45 (d, J = 7.9 Hz, 1H, ArH), 7.39 (t, 
J = 7.7 Hz, 1H, ArH), 4.80 (t, J = 7.8 Hz, 1H, CH), 3.39 – 3.33 (m, 1H, CH of CH2), 
2.95 – 2.87 (m, 1H, CH of CH2), 2.38 – 2.30 (m, 1H, CH of CH2), 2.08 – 1.97 (m, 1H, 
CH of CH2), 1.93 – 1.76 (m, 2H, CH2). 13C NMR (100 MHz, d6-DMSO) δ: 206.3 (q), 
135.2 (q), 134.9 (CH), 130.7 (q), 128.2 (CH), 125.7 (CH), 124.0 (CH), 70.7 (CH), 49.7 
(CH2), 35.1 (CH2), 24.1 (CH2). In agreement with previously reported data in the 
group162. 
 
 Attempted synthesis of 11-Amino-1,2,3,11a-
tetrahydrobenzo[f]pyrrolo[1,2-b][1,2,5]thiadiazepine 5,5-dioxide 399 
Ammonia gas, generated by boiling concentrated ammonia and passing it through 4 
Å molecular sieves, was bubbled into a solution of 1,2,3,11a-
tetrahydrobenzo[f]pyrrolo[1,2-b][1,2,5]thiadiazepine-11(10H)-thione 5,5-dioxide 350 
(85 mg, 0.32 mmol, 1.0 eq) and suspended mercury(II) chloride (104 mg, 0.38 mmol, 
1.2 eq) in dry THF (20 mL) heated at 50 °C. The reaction was left overnight, and TLC 
indicated the presence of starting material. The reaction was cooled and concentrated 
under vacuum, and the residue was purified over a column of silica, eluted with 50% 
EtOAc in hexane, affording no discernible new products. 
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 Attempted synthesis of 2-Methoxy-5b,6,7,8-tetrahydro-16H-
benzo[6,7]pyrrolo[1',2':2,3][1,2,5]thiadiazepino[4,5-b]quinazolin-16-one 10,10-
dioxide 384; synthesis of 10-(2-amino-5-methoxybenzoyl)-1,2,3,11a-
tetrahydrobenzo[f]pyrrolo[1,2-b][1,2,5]thiadiazepin-11(10H)-one 5,5-dioxide 385. 
 
 Method 1: Via reductive cyclodehydration 
To a stirred solution of PBTD 339 (200 mg, 0.76 mmol, 1.0 eq), DMAP, (37 mg, 0.30 
mmol, 0.4 eq), and triethylamine (0.21 mL, 1.51 mmol, 2.0 eq) in anhydrous DMAC 
(10 mL), cooled to -10 °C, was added 5-methoxy-2-nitrobenzoyl chloride 51 (200 mg, 
0.91 mmol, 1.2 eq), and the mixture was allowed to stir for 30 minutes. Glacial acetic 
acid (5 mL) was added, followed by zinc powder (1.00 g, 15.29 mmol, 20 eq), and the 
reaction was stirred for 90 minutes. The contents of the flask were poured into a 10% 
aqueous solution of potassium carbonate (60 mL), and the organic material was 
extracted with EtOAc (2 × 75 mL). The organic phases were combined, washed with 
water (2 × 50 mL), dried, and concentrated under vacuum. The crude residue was 
dissolved in EtOAc (10 mL) and after standing, a colourless precipitate was observed 
and collected via vacuum filtration, affording 10 mg of a crude solid. The filtrate was 
purified over a column of silica, eluted by 20% EtOAc in DCM. The recovered solid (~4 
mg) was thought to be compound 385, mp: decomposes >227 °C. 
1H NMR (400 MHz, CDCl3) δ: 9.48 (s, 1H, ArNH), 8.94 (s, 1H, ArNH), 8.63 (dd, J = 
0.7, 8.4 Hz, 1H ArH), 8.08 (dd, J = 1.6, 7.9 Hz, 1H, ArH), 7.95 (d, J = 8.9 Hz, 1H, ArH), 
7.72 (apparent triplet J = 7.8, Hz, 1H, ArH), 7.36 (dd, J = 1.0, 7.7 Hz, 1H, ArH), 7.34 
(d, J = 3.1 Hz, 1H, ArH), 7.10 (dd, J = 3.0, 8.9 Hz, 1H, ArH), 4.65 (dd, J = 5.8, 9.1 Hz, 
1H, CH), 3.88 (s, 3H, OMe) 3.51-3.44 (m, 1H, CH of CH2), 3.05 (dt, J = 4.5, 9.5 Hz, 
1H, CH of CH2), 2.55-2.45 (m, 1H CH of CH2), 2.23 (sextet J = 6.4 Hz, 1H, CH of CH2), 
2.11-2.07 (m, 2H, CH2). 13C NMR: Not recorded, insufficient compound. FTIR νmax /cm-
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1: 1665.5, 1526.0, 1315.4, 1219.8, 1148.3, 1123.9, 603.4. HRMS m/z calcd. For 
C19H19N3O5S (compound 385) [M+H] 402.1118, found 402.1114. 
 Method 2: Via aza-Wittig coupling 
To a stirred solution of triethylamine (0.123 mL, 0.89 mmol, 1.5 mL) and DMAP (50 
mg, 0.43 mmol, 0.7 eq) in anhydrous THF (10 mL), cooled to 0 °C in an ice bath was 
slowly added PBTD 339 (150 mg, 0.59 mmol, 1.0 eq). The mixture was left to stir at 0 
°C for 1 hour, after which, 2-azido-5-methoxybenzoyl chloride 63 (160 mg, 0.75 mmol, 
1.25 eq) was added gradually, and the reaction was left for a further 30 minutes. The 
whole was warmed to room temperature and stirred for one hour before the solvent 
was removed under vacuum. The resulting residue was dissolved in DCM (20 mL) and 
washed with water (2 × 60 mL) before concentration under vacuum. The crude 
intermediate (350 mg 0.82 mmol, 1.0 eq) was dissolved in dry toluene (50 mL) and 
Bu3P (0.2 mL, 0.82 mmol. 1.0 eq) was added dropwise. The reaction was heated at 
reflux for 1 hour, then left at ambient temperature overnight. The solvent was removed, 
and the residue was dissolved in DCM (100 mL) and subsequently washed with 0.5 M 
HCl (2 × 60 mL), and brine (2 × 30 mL). The organic material was dried over 
magnesium sulfate and concentrated under vacuum. The crude material was purified 
over a column of silica, eluted by a 20% solution of EtOAc in DCM, affording primarily 
the starting PBTD and other unidentifiable trace compounds. 
 Attempted Synthesis of aza-Wittig intermediate 10-(2-Azido-5-
methoxybenzoyl)-1,2,3,11a-tetrahydrobenzo[f]pyrrolo[1,2-b][1,2,5]thiadiazepin-
11(10H)-one 5,5-dioxide 389 
To a stirred solution of PBTD 339 (180 mg, 0.83 mmol, 1.0 eq) in dry DCM (5 mL), 
cooled to 0 °C was added a solution of DCC (170 mg, 0.83 mmol, 1.0 eq) in DCM (5 
mL) and 2-azido-5-methoxybenzoyl chloride 63 (160 mg, 0.83 mmol, 1.0 eq) in DCM 
(5 mL). The reaction stirred overnight, and TLC indicated no change in reaction 
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composition. Further DCC (42.5 mg, 0.21 mmol, 0.25 eq) was added and the reaction 
was left for 6 hours. TLC indicated no change in the reaction, and HOBt (11 mg, 0.083 
mmol, 0.1 eq) was added, and the mixture was left to stir overnight. The reaction 
mixture was filtered through celite, washed through with DCM (2 × 15 mL). The filtrate 
was washed with 2 M HCl (25 mL) and brine (25 mL), before being dried and 
concentrated under vacuum. The crude residue was purified using column 
chromatography (15% EtOAc in DCM), and no identifiable material was recovered. 
 2-Fluoro-4-methoxy-1-nitrobenzene 391 
To a stirred mixture of potassium carbonate (2.50 g, 18.1 mmol, 2.0 eq), and methyl 
iodide (1.15 mL, 18.1 mmol, 2.0 eq) in acetone (20 mL) was added 3-fluoro-4-
nitrophenol 389 (1.50 g, 9.05 mmol, 1.0 eq) and the mixture was left to stir overnight 
at room temperature. Water (25 mL) was added, and the organic material was 
extracted with DCM (3 × 50 mL). The combined extracts were dried over magnesium 
sulfate and concentrated under vacuum. The resulting residue was purified over a 
column of silica, eluted with a 10% solution of EtOAc in hexanes, affording the desired 
product as a pale solid - 1.0 g (64%). 
1H NMR (400 MHz, CDCl3) δ: 8.02 (t, J = 9.0 Hz, 1H, ArH), 6.72-6.64 (m, 2H, ArH), 
3.83 (bs, 3H, OMe). Consistent with literature163. 
 5-Methoxy-2-nitrobenzenesulfonic acid 392 
To a stirred suspension of Na2SO3 (0.835 g, 6.63 mmol, 2.3 eq) in a mixture of ethanol 
(8 mL) and water (10 mL) was added a solution of 2-fluoro-4-methoxy-1-nitrobenzene  
391 (0.5 g, 2.93 mmol, 1.0 eq), and the mixture was heated at 70 °C overnight. After 
cooling, the mixture was acidified to pH ~2 using conc. HCl, the solvent was removed 
under vacuum and the residue dissolved in brine (20 mL). The solution was refluxed 
for 2 hours, cooled to room temperature, and then cooled to 0 °C in an ice bath. The 
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resulting precipitate was collected and dried via vacuum filtration, affording the desired 
sulfonic acid as a pale green solid - 0.95 g (62%), which was used without further 
purification. 
1H NMR (400 MHz, CDCl3) δ: 7.59 (d, J = 8.8 Hz, 1H, ArH), 7.32 (d, J = 2.8 Hz, ArH), 
7.03 (dd, J = 8.7 , 2.8 Hz, 1H, ArH), 3.84 (s, 3H, OMe), matching published data133. 
 Attempted Synthesis of 3-Methoxy-13,14,15,15a-tetrahydro-11H-
benzo[e]benzo[5,6][1,2,4]thiadiazino[3,2-c]pyrrolo[1,2-a][1,4]diazepin-11-one 
5,5-dioxide 386 
5-Methoxy-2-nitrobenzenesulfonyl chloride was made by heating 5-methoxy-2-
nitrobenzenesulfonic acid 382 (25 mg, 0.10 mmol, 1.0 eq) in thionyl chloride (3.0 mL) 
and DMF (~3 drops) at reflux for 3 hours before being concentrated under vacuum. 
The resulting acid chloride (30 mg, 0.12 mmol 1.2 eq) was added to a stirred solution 
of PBD 28 (21 mg, 0.10 mmol, 1.0 eq), Et3N (0.028 mL, 0.20 mmol, 2.0 eq) and DMAP 
(5 mg, 0.04 mmol, 0.4 eq) in anhydrous DMAC (5 mL) cooled to 0 °C. The mixture was 
stirred for 30 minutes at this temperature, after which, glacial acetic acid (2.5 mL) was 
added and the reaction mixture was cooled to ~ -30 °C. Zinc (0.5 g, 6.75 mmol, 67.5 
eq) was added, and the reaction was stirred for 2 hours. The reaction warmed to -5 °C 
over 3 hours, and the reaction was poured into a 10% solution of potassium carbonate 
(60 mL) and was extracted into EtOAc (2 × 100 mL). The extracts were combined, 
dried, and concentrated under vacuum. The crude material was purified over a column 
of silica, eluted by 70% EtOAc in hexane, affording only the starting PBD. 
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 6-Methoxy-2H-benzo[d][1,3]oxazine-2,4(1H)-dione 50 
To a stirred suspension of 2-amino-5-methoxybenzoic acid 59 (0.5 g, 3.00 mmol, 1.0 
eq) in dry THF (100 mL) was added triphosgene 378 (0.3 g, 1.00 mmol, 0.33 eq) and 
the mixture stirred overnight at room temperature. The solvent was removed under 
vacuum, and the resulting residue was triturated with diethyl ether (50 mL). The 
precipitate was collected via vacuum filtration and dried over vacuum, affording the 
desired isatoic anhydride derivative as a grey/brown solid - 0.3 g (52%). 
1H NMR (400 MHz, DMSOd6) δ: 11.60 (bs, 1H, NH), 7.36 (dd, J = 2.9, 8.8 Hz, 1H, 
ArH), 7.31 (d, 2.9 Hz, 1H, ArH), 7.09 (d, J = 8.7 Hz, 1H, ArH), 3.78 (s, 3H, OMe). 
Compliant with literature reports164 
 2-Iodobenzenesulfonic acid 408 
To a homogeneous solution of aniline-2-sulfonic acid 377 (4.21 g, 21.3 mmol, 1.0 eq) 
and sodium carbonate (1.17 g, 11.0 mmol, 0.5 eq), in water (25 mL) was added sodium 
nitrite (1.67 g, 21.3 mmol, 1.0 eq), and the mixture was stirred at 0 °C for 30 minutes. 
Conc. HCl (4.2 mL) and crushed ice (~ 20 g) were added, and the mixture was left to 
stir for 30 minutes once precipitation started. A solution of potassium iodide (4.2 g, 
25.0 mmol, 1.2 eq) in water (4.2 mL) was added slowly, and the reaction stirred 
vigorously for 1 hour at 0 °C. The reaction was warmed to room temperature, and 
heated further to 95 °C. When visible generation of gas had ceased, the water was 
gradually removed under reduced pressure, and the resulting precipitate was collected 
via vacuum filtration. The solid was washed extensively with chloroform, until the 
added solvent remained colourless. The solid was left to dry over the vacuum, 
affording the desired compound as an off-white powder, 3.2 g (53%). 
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1H NMR (400 MHz, DMSOd6) δ: 7.89 (dd, J = 1.4, 7.7 Hz, 1H, ArH), 7.86 (d, J = 7.7 
Hz, 1H, ArH), 7.32 (t, J = 7.6 Hz, 1H, ArH), 6.98 (td, J = 1.4, 7.5 Hz, 1H, ArH). In 
agreement with literature54. 
 Methyl ((2-iodophenyl)sulfonyl)prolinate 410 
2-Iodobenzenesulfonic acid 409 (0.5 g, 1.76 mmol, 1.0 eq) was heated at reflux with 
thionyl chloride (0.24 mL, 3.3 mmol, 1.9 eq) and DMF (3 drops) in DCM (10 mL) for 2 
hours. The solvent was removed, and the residue (0.53 g, 1.76 mmol, 1.2 eq) was 
dissolved in DCM (10 mL) and was added dropwise to an ice-cooled solution of L-
proline methyl ester hydrochloride 344 (0.24 g, 1.40 mmol, 1.0 eq) and triethylamine 
(0.4 mL, 2.9 mmol, 2.0 eq) in DCM (10 mL). The mixture was stirred at room 
temperature overnight and was quenched with water (20 mL). The organic phase was 
separated and washed with 10% citric acid solution (20 mL), saturated sodium 
bicarbonate solution (20 mL), and brine (20 mL). The organic material was dried, and 
concentrated under vacuum, affording the desired product as a pale green oil, 0.28 g, 
(50%), partially characterised intermediate, previously unreported. 
1H NMR (400 MHz, CDCl3) δ: 8.17 (dd, J = 1.3, 8.0 Hz, 1H ArH), 8.09 (d, J = 8.0 Hz, 
1H, ArH), 7.48 (t J = 7.7, 15.1 Hz, 1H, ArH), 7.18 (td, J = 1.4, 7.5 Hz, 1H, ArH), 4.64 
(dd J = 2.7, 8.6 Hz, 1H, CH), 3.72 – 3.65 (m, 1H, CH of CH2), 3.60 (s, 3H, OMe), 3.49 
– 3.41 (m, 1H, CH of CH2), 2.33 – 2.21 (m, 1H, CH of CH2), 2.14 – 2.03 (m, 2H, CH2), 
2.00 – 1.91 (m, 1H, CH of CH2).  
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 1-((2-Iodophenyl)sulfonyl)pyrrolidine-2-carboxamide 411 
 Method 1: Via  Amination of the Methyl Ester 
To a stirred solution of methyl ((2-iodophenyl)sulfonyl)prolinate 410 (0.28 g, 0.71 
mmol, 1.0 eq) in n-butanol (10 mL) was added 25% aqueous ammonia (2.1 mL, 20.55 
mmol, 29.0 eq). The reaction stirred for 48 hours, and brine (10 mL) was added. The 
organic layer was separated and washed with brine (2 × 10 mL). The organic layer 
was dried, concentrated under vacuum, and the resulting residue was suspended in 
MTBE (15 mL). After 15 minutes of gentle stirring, a white precipitate formed and was 
collected via vacuum filtration, and dried, affording the desired product as an impure 
white solid (100 mg, 37%). 
1H NMR (400 MHz, DMSO D6) δ: 8.15 (d, J = 7.8 Hz, 1H, ArH), 7.97 (d, J = 7.8 Hz, 
1H, ArH), 7.59 (t, J = 7.8 Hz, 15.6 Hz, 1H, ArH), 7.35-7.28 (m, 1H), 7.27 (bs, 1H, 1 × 
CONH), 7.07 (bs, 1H, 1 × CONH), 4.53 (dd, J = 2.7, 8.9 Hz, 1H, CH), 3.51 – 3.45 (m, 
1H, CH of CH2), 3.27 – 3.19 (m, 1H, CH of CH2), 2.27 – 2.17 (m, 1H, CH of CH2), 2.00 
– 1.85 (m, 3H, CH of CH2 and CH2). 
 Method 2: Via Direct Coupling to Prolinamide 
2-Iodobenzenesulfonyl chloride 409 (0.63 g, 2.1 mmol, 1.2 eq) dissolved in DCM (15 
mL) was added dropwise to a cooled solution of prolinamide (0.20 g, 1.75 mmol, 1.0 
eq) and triethylamine (0.5 mL, 3.5 mmol, 2.0 eq) in DCM (15 mL). The reaction mixture 
was stirred overnight at room temperature, after which, the mixture was quenched with 
water (40 mL). The organic material was separated, washed with 10 % aqueous citric 
acid solution (15 mL), saturated sodium bicarbonate solution(15 mL), and brine (15 
m). The organic layer was dried and concentrated under vacuum, and the residue was 
purified via flash chromatography, eluted with EtOAc, furnishing the desired compound 
as a colourless syrup, 200 mg, (35%). 
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1H NMR (400 MHz, CDCl3) δ: 8.12 (dd, J = 1.6, 8.0 Hz, 1H, ArH), 8.11 (dd, J = 1.0, 
8.0 Hz, 1H, ArH), 7.52 (td, J = 1.0, 7.7 Hz, 1H, ArH), 7.22 (td, J = 1.5, 7.7 Hz, 1H, ArH), 
6.67 (bs, 1H, NH), 6.05 (bs, 1H, NH), 4.52 (dd, J = 2.3, 8.8 Hz, 1H, CH), 3.56 – 3.50 
(m, 1H, CH of CH2), 3.46 – 3.38 (m, 1H, CH of CH2), 2.30 – 2.23 (m, 1H, CH of CH2), 
2.11 – 1.99 (m, 1H, CH of CH2), 1.94 – 1.85 (m, 2H, CH2). 13C NMR (125 MHz, CDCl3) 
δ: 174.30 (q), 143.3 (CH), 140.2 (q), 134.1 (CH), 132.3 (CH), 128.7 (CH), 92.2 (q), 
62.7 (CH), 49.4 (CH2), 30.6 (CH2), 24.5 (CH2). FTIR νmax /cm-1: 1665.5, 1526.0, 
1315.4, 1219.8, 1148.3, 1123.9, 603.4. HRMS, m/z calcd. for C11H13IN2O3S [M+H] 
362.9659, found 362.9650. 
 1-((2-Iodophenyl)sulfonyl)pyrrolidine-2-carbonitrile 412 
Trifluoroacetic anhydride (0.10 mL, 0.625 mmol, 1.3 eq), added to a solution of amide 
411 (0.20 g, 0.525 mmol, 1.0 eq) and triethylamine (0.17 mL, 1.21 mmol, 2.3 eq) in 
dry THF (15 mL) stirring in a flame dried flask under an inert atmosphere. The reaction 
was stirred at 0 °C for 4 hours, and then overnight at room temperature. The reaction 
mixture was diluted with DCM (50 mL), and the whole was washed with water (20 mL), 
saturated sodium bicarbonate solution (20 mL), and brine (20 mL). The organic phase 
was dried and concentrated under vacuum, affording the desired nitrile as a yellowish 
syrup, 170 mg (89%). The crude material was reacted without further purification. 
1H NMR (400 MHz, CDCl3) δ: 8.20 (dd, J = 1.3, 8.0 Hz, 1H, ArH), 8.13 (d, J = 8.0 Hz, 
1H, ArH), 7.53 (t, J = 7.9 Hz, 1H, ArH), 7.25 (td, J = 1.3, 7.6 Hz, 1H, ArH), 4.74 (dd, J 
= 3.6, 7.0 Hz, 1H, CH), 3.70 – 3.64 (m, 1H, CH of CH2), 3.52 (apparent q, J = 8.2 Hz, 
1H, CH of CH2), 2.34 – 2.28 (m, 2H, CH2), 2.24 – 2.08 (m, 2H, CH2). 13C NMR Not 
recorded, poorly resolved spectrum. FTIR νmax /cm-1: 2251.1, 1334.3, 1195.0, 1157.3, 





To a stirred solution of nitrile 412 (170 mg, 0.47 mmol, 1.0 eq), in ethanol (10 mL) was 
added 50% (w/w) aqueous hydroxylamine (0.05 mL, 0.75 mmol, 1.6 eq). The mixture 
was stirred overnight, and after TLC indicated the completion of the reaction, the 
solvent was removed under vacuum, affording the desired amidoxime as a brownish 
yellow residue (200 mg crude, quantitative yield). The crude material was used without 
need for purification, mp 51 – 54 °C, unreported compound.  
1H NMR (400 MHz, CDCl3) δ: 8.14 (dd, J = 1.4, 8.0 Hz, 1H, ArH), 8.09 (dd, J = 1.0, 
7.9 Hz, 1H, ArH), 7.51 (td, J = 1.0, 7.8 Hz, 1H, ArH), 7.21 (td, J = 1.5, 7.7 Hz, 1H, ArH), 
4.70 (bs, 2H, NH2), 4.51 (dd, J = 4.0, 7.8 Hz, 1H, CH), 3.61 – 3.55 (m, 2H, CH2), 2.24 
– 2.16 (m, 1H, CH of CH2), 2.12 – 1.98 (m, 2H, CH2), 1.93 – 1.84 (m, 1H, CH of CH2). 
13C NMR (100 MHz, CDCl3) δ: 153.4 (q), 142.9 (CH), 140.8 (q), 133.7 (CH), 132.4 
(CH), 128.5 (CH), 92.3 (q), 59.6 (CH), 49.6 (CH2), 31.0 (CH2), 24.8 (CH2). FTIR νmax 
/cm-1: 3475.1, 3373.8, 1660.7, 1567.6, 1324.3, 1154.3, 1094.8, 639.6, 599.1. HRMS, 
m/z calcd. for C11H14IN3O3S [M+H], 395.9873, found 395.9876. 
 2-(1-((2-Iodophenyl)sulfonyl)pyrrolidin-2-yl)-6-methoxyquinazolin-4(3H)-
one 414 
To a stirred solution of amidoxime 413 (200 mg, 0.51 mmol, 1.0 eq) in 1,4-dioxane (10 
mL) was added 5-methoxyisatoic anhydride 50 (89 mg, 0.46 mmol, 0.9 eq) and iron(III) 
chloride (1.0 mg, 0.05 mmol, 0.1 eq). The reaction stirred at reflux for 3 hours and was 
144 
 
allowed to cool to room temperature. EtOAc (50 mL) was added, and the organic 
phase was washed with water (2 × 20 mL), dried, and concentrated under vacuum. 
The crude material was purified via flash chromatography, eluted by neat EtOAc, 
affording the desired compound as a dark residue, 50 mg, 19%. Partially characterised 
intermediate. 
1H NMR (400 MHz, CDCl3) δ: 9.66 (bs, 1H, NH), 8.13 – 8.08 (m, 2H, ArH), 7.57 (d, J 
= 2.9 Hz, 1H, ArH), 7.54 (d, J = 8.8 Hz, 1H, ArH), 7.38 (t, J = 7.6 Hz, 1H, ArH), 7.32 
(dd, J = 3.0, 8.9 Hz, 1H, ArH), 7.11 (t, J = 7.6 Hz, 1H, ArH), 5.02 (dd, J = 4.0, 8.3 Hz, 
1H, CH), 4.12 (q, J = 7.1 Hz, 1H, CH of CH2), 3.90 (s, 3H, OMe), 3.67 – 3.62 (m, 2H, 
CH2), 2.52 – 2.43 (m, 1H, CH of CH2), 2.35 – 2.25 (m, 1H, CH of CH2), 2.04 – 1.97 (m, 
2H, CH2). 
  Synthesis of 2-Methoxy-5b,6,7,8-tetrahydro-16H-
benzo[6,7]pyrrolo[1',2':2,3][1,2,5]thiadiazepino[4,5-b]quinazolin-16-one 10,10-
dioxide via  Copper Mediated N-Arylation 384 
A flame dried RBF under nitrogen was charged with quinazolinone 414 (50 mg, 0.11 
mmol, 1.0 eq), CuI (4.2 mg, 0.02 mmol, 0.2 eq), L-proline (3.8 mg, 0.33 mmol, 03 eq), 
NaH (60% in mineral oil) (8.4 mg, 0.21 mmol, 2.1 eq) and DMF (7 mL). The mixture 
was heated at reflux for 4 hours and cooled to room temperature. EtOAc (25 mL) was 
added and the whole was washed with water (2 × 10 mL) and brine (20 mL). The 
organic phase was dried, and concentrated under vacuum, and the resulting crude 
residue was purified over a column of silica, eluted by a 70% solution of EtOAc in 
hexane, affording the desired compound as a pale solid, 5 mg (11%). 
1H NMR (600 MHz, CDCl3) δ: 8.14 (d, J = 8.0 Hz, 1H, ArH), 7.81 (apparent t, J = 7.8 
Hz, 1H, ArH), 7.77 (d, J = 8.0 Hz, 1H, ArH), 7.72-7.67 (m, 3H, ArH), 7.40 (dd, J = 2.9, 
8.0 Hz, 1H, ArH), 3.94 (s, 3H, OMe), 3.90 (t, J = 6.7 Hz, 1H, CH of CH2), 3.71 (apparent 
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q, J = 7.8 Hz, 1H, CH of CH2), 3.44 – 3.38 (m, 1H, CH of CH2), 3.17 – 3.11 (m, 1H, 
CH of CH2), 2.39 – 2.32 (m, 1H, CH of CH2), 2.17 – 2.10 (m, 1H, CH of CH2), 2.04-
1.97 (m, 1H, CH of CH2). 13C NMR (150 MHz, CDCl3) δ: 160.8 (q), 159.2 (q), 148.24 
(q), 140.9 (q), 134.2 (q), 133.2 (CH), 132.4 (q), 129.9 (CH), 129.6 (CH), 129.4 (CH), 
127.1 (CH), 124.9 (CH), 122.9 (q), 107.0 (CH), 62.0 (CH), 55.8 (CH3), 45.8 (CH2), 27.7 
(CH2), 23.8 (CH2). HRMS, m/z calcd. for C19H17N3O4S [M+H] 384.1013, found 
384.1013. Unreported compound. 
3.6 Experimental Towards the Synthesis of Sulfonyl-Circumdatin 
Homologues 
 3-((2-Iodophenyl)sulfonyl)thiazolidine-4-carboxylic acid 427 
To a stirred solution of thiazolidine-4-carboxylic acid 390 (37 mg, 0.28 mmol, 1.0 eq) 
in a mixture of water (5 mL) and THF (2.5 mL), was added triethylamine (0.10 mL, 
0.69 mmol, 2.5 eq). The whole was cooled to 0 °C, and 2-iodobenzenesulfonyl chloride 
409 (100 mg, 0.33 mmol, 1.2 eq) was added slowly, and the reaction stirred at room 
temperature for 4 hours. The mixture was acidified with conc. HCl to ~ pH 2, and the 
organic material was extracted with 10% MeOH in DCM (3 × 15 mL). The combined 
organic extracts were washed with brine (25 mL) and dried before being concentrated 
under vacuum, affording the desired compound as an off-white gummy residue, 100 
mg (91%). The product was used without further purification. 
1H NMR (400 MHz, CDCl3) δ: 8.20 (dd, J = 1.5, 8.0 Hz, 1H, ArH), 8.12 (dd, J = 1.0, 
8.0 Hz, 1H, ArH), 7.52 (td, J = 1.0, 7.6 Hz, 1H, ArH), 7.25 – 7.21 (m, 1H, ArH), 5.21 
(dd, J = 3.3, 5.9 Hz, 1H, CH), 4.66 (d, J = 8.6 Hz, 1H, CH of CH2), 4.53 (d, J = 8.6 Hz, 
1H, CH of CH2), 3.39 – 3.36 (m, 2H, CH2). 13C NMR (100 MHz, CDCl3) δ: 173.8 (q), 
143.1 (CH), 141.1 (q), 134.0 (CH), 131.9 (CH), 128.5 (CH), 92.5 (q), 63.8 (CH2), 49.6 
(CH2), 34.3 (CH2). FTIR νmax /cm-1: 2919.8, 2850.6, 1724.3, 1336.0, 1225.6, 1157.1, 
1046.4, 591.6 HRMS, m/z calcd. for C10H10INO4S2 [M+H] 399.9169 found 399.9164 
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 1-((2-Iodophenyl)sulfonyl)piperidine-2-carboxylic acid 428 
To a stirred solution of piperidine-2-carboxylic acid 392 (36 mg, 0.28 mmol, 1.0 eq) in 
a mixture of water (5 mL), and THF (2.5 mL) was added triethylamine (0.1 mL, 0.87 
mmol, 2.5 eq). The mixture was cooled to 0 °C, and 2-iodobenzenesulfonyl chloride 
409 (100 mg, 0.33 mmol, 1.2 eq) was added. The reaction was stirred at room 
temperature for 4 hours, after which, conc. HCl (1 mL) was used to acidify the mixture 
to approximately pH 2. The organic material was extracted using 10% MeOH in DCM 
(3 × 20 mL), and the organic layers were combined, washed with brine (20 mL) and 
dried before concentration under vacuum. The desired product was recovered as a 
white solid - 90 mg (83%) mp 173 – 176 °C. Unreported compound. 
1H NMR (400 MHz, CDCl3) δ: 8.21 (dd, J = 1.6, 8.0 Hz, 1H, ArH), 8.09 (dd, J = 1.0, 
7.7 Hz, 1H, ArH), 7.49 (td, J = 1.0, 7.6 Hz, 1H, ArH), 7.19 (td, J = 1.6, 7.9 Hz, 1H, ArH), 
4.90 (broad doublet, J = 5.0 Hz, 1H, CH), 3.53 (d, J = 12.7 Hz, 1H CH of CH2), 3.86 
(td, J = 3.0 , 12.5 Hz, 1H, CH of CH2), 2.25 (d, J = 13.0 Hz, 1H, CH of CH2), 2.04 – 
1.94 (m, 1H, CH of CH2), 1.79 – 1.71 (m, 1H, CH of CH2), 1.68 – 1.61 (m, 1H, CH of 
CH2), 1.46 – 1.40 (m, 2H, CH2). 13C NMR (100 MHz, CDCl3) δ: 175.9 (q), 142.9 (CH), 
141.6 (q), 133.3 (CH), 132.0 (CH), 128.2 (CH), 92.3 (q), 55.5 (CH), 43.0 (CH2), 27.1 
(CH2), 24.5 (CH2), 20.1 (CH2). FTIR νmax /cm-1: 3000.0, 1702.0, 1336.2, 1321.1, 
1159.0, 1054.7, 602.1. HRMS, m/z calcd. for C12H14INO4S [M+H], 395.9761 found 
395.9756. 
 3-((2-Iodophenyl)sulfonyl)thiazolidine-4-carboxamide 429 
To a stirred solution of 1-((2-iodophenyl)sulfonyl)thiazolidine-4-carboxylic acid 427 
(0.49 g, 1.22 mmol, 1.0 eq) in dry DCM (10 mL) was added triethylamine (0.17 mL, 
1.22 mmol, 1.0 eq) and BOP (0.54 g 1.22 mmol, 1.0 eq). The reaction stirred for 5 
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minutes, after which ammonium chloride (0.10 g, 1.83 mmol, 1.5 eq) and triethylamine 
(0.26 mL, 1.83 mmol, 1.5 eq) were added. The mixture was stirred overnight at room 
temperature and was diluted with DCM (15 mL). The whole was washed with 2 M HCl 
(3 × 30 mL), saturated sodium bicarbonate (3 × 30 mL), and brine (3 × 30 mL). The 
organic material was dried and concentrated under reduced pressure, and the 
resulting residue was purified over a column of silica, eluted with EtOAc, affording the 
desired product as pale green syrup, 0.23 g (47%).  
1H NMR (400 MHz, CDCl3) δ: 8.21 – 8.12 (m, 2H, ArH), 7.57 (t, J = 7.8 Hz, 1H, ArH), 
7.32 – 7.26 (m, 1H, ArH), 6.62 (bs, 1H, CONH2), 5.56 (bs, 1H, CONH2), 4.93 (d, J = 
9.9 Hz, 1H, CH of CH2), 4.87 (dd, J = 2.0, 7.1 Hz, 1H, CH), 4.43 (d, J = 9.9 Hz, CH of 
CH2), 3.57 (dd, J = 2.0, 11.0, 1H, CH of CH2), 3.11 (dd, J = 7.0, 11.0 Hz, 1H, CH of 
CH2). 13C NMR (100 MHz, CDCl3) δ: 170.8 (q), 143.5 (CH), 140.0 (q), 134.6 (CH), 
132.5 (CH), 128.9 (CH), 92.4 (q), 65.1 (CH), 51.1 (CH2), 33.8 (CH2). FTIR νmax /cm-1: 
3450.0, 1675.2, 1568.3, 1329.8, 1155.3, 1120.6, 1015.4, 726.7, 588.2 HRMS, m/z 
calcd. for C10H11IN2O3S2 [M+H] 398.9329 found 398.9324. 
 1-((2-Iodophenyl)sulfonyl)piperidine-2-carboxamide 430 
To a stirred solution of 1-((2-iodophenyl)sulfonyl)piperidine-2-carboxylic acid 428 (90 
mg, 0.23 mmol, 1.0 eq) in dry DCM (10 mL) was added triethylamine (0.03 mL, 0.23 
mmol, 1.0 eq) and BOP (100 mg, 0.23 mmol, 1.0 eq). The mixture was stirred for 5 
minutes, and ammonium chloride (18 mg, 0.34 mmol, 1.5 eq) and triethylamine (0.05 
mL, 0.34 mmol, 1.5 eq) were added. The mixture was allowed to stir overnight and 
was diluted with DCM (15 mL). The whole was washed with 2 M HCl (3 × 10 mL), 
saturated sodium bicarbonate solution (3 × 10 mL), and brine (3 × 10 mL). The organic 
material was dried and concentrated under reduced pressure and the crude residue 
was purified over a column of silica, eluted by neat EtOAc, furnishing the desired 
compound as an off-white residue, 60 mg (66%).  
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1H NMR (400 MHz, CDCl3) δ: 8.21 (dd, J = 1.6, 8.0 Hz, 1H, ArH), 8.13 (dd, J = 1.0, 
7.8 Hz, 1H, ArH), 7.53 (td, J = 1.0 , 7.6 Hz, 1H, ArH), 7.24 (td, J = 1.6, 7.9 Hz, 1H, 
ArH), 6.70 (bs, 1H, CONH2), 5.51 (bs, 1H, CONH2), 4.57 (d, J = 5.0 Hz, 1H, CH), 3.78 
(d, J = 13.8 Hz, 1H, CH of CH2), 3.11 (t, J = 13.2 Hz, 1H, CH of CH2), 2.38 (d, J = 13.2 
Hz, 1H, CH of CH2), 1.79 – 1.66 (m, 2H, CH2), 1.52 – 1.38 (m, 3H, CH and CH2). 13C 
NMR (100 MHz, CDCl3) δ: 172.2 (q), 143.2 (CH), 140.8 (q), 133.8 (CH), 132.3 (CH), 
128.6 (CH), 92.0 (q), 56.4 (CH2), 43.8 (CH), 25.0 (CH2), 24.4 (CH2), 20.1 (CH2). FTIR 
νmax /cm-1: 3451.9, 3348.0, 1729.8, 1676.0, 1329.3, 1152.9, 588.7. HRMS, m/z calcd. 
for C12H15IN2O3S [M+H] 394.9921 found 394.9915. 
 3-((2-Iodophenyl)sulfonyl)thiazolidine-4-carbonitrile 431 
To a stirred solution of amide 429 (230 mg, 0.63 mmol, 1.0 eq) in dry THF (10 mL) 
and triethylamine (0.2 mL, 1.45 mmol, 2.3 eq) cooled to 0 °C was added trifluoroacetic 
anhydride (0.12 mL, 0.82 mmol, 1.3 eq). The reaction was stirred at 0 °C for 4 hours, 
then overnight at room temperature. DCM (20 mL) was added, and the whole was 
washed with water (20 mL), saturated sodium bicarbonate solution (20 mL), and brine 
(20 mL). The organic material was dried and concentrated under vacuum, affording 
the desired product as a pale green residue, 180 mg (75%). The recovered product 
was used further without purification. 
1H NMR (400 MHz, CDCl3) δ: 8.20 (dd, J = 1.3, 7.9 Hz, 1H, ArH), 8.16 (d, J = 7.8 Hz, 
1H, ArH), 7.56 (t, J = 7.8 Hz, 1H, ArH), 7.29 (td, J = 1.4, 7.6 Hz, 1H, ArH), 5.29 (dd, J 
= 2.2, 6.4 Hz, 1H, CH), 4.78 (d, J = 9.0 Hz, 1H, CH of CH2), 4.53 (d, J = 9.0 Hz, 1H, 
CH of CH2), 3.44 – 3.37 (m, 1H, CH of CH2), 3.31 (dd, J = 2.1, 11.6 Hz, 1H, CH of 
CH2). 13C NMR (100 MHz, CDCl3) δ: 143.3 (CH), 140.0 (q), 134.7 (CH), 131.9 (CH), 
128.7 (CH), 115.8 (q), 93.0 (q), 52.3 (CH2), 50.0 (CH2), 36.2 (CH2). FTIR νmax /cm-1:, 
1337.0, 1258.4, 1135.9, 1012.0, 286.9. HRMS not obtainable. 
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 1-((2-Iodophenyl)sulfonyl)piperidine-2-carbonitrile 432 
To an ice cooled solution of amide 430 (380 mg, 1.01 mmol, 1.0 eq) in dry THF (10 
mL) was added triethylamine (0.33 mL, 2.32 mmol, 2.3 eq) and trifluoroacetic 
anhydride (0.18 mL, 1.31 mmol, 1.3 eq). The reaction was stirred at 0 °C for 4 hours 
and then overnight at room temperature. The whole was diluted with DCM (20 mL), 
and the mixture was washed with water (20 mL), saturated sodium bicarbonate 
solution (20 mL), and brine (20 mL). The organic phase was dried and concentrated 
under vacuum, affording the product as a yellow oil, 290 mg (76%). 
1H NMR (400 MHz, CDCl3) δ: 8.14 (apparent dd, J = 7.9, 13.0 Hz, 2H, ArH), 7.53 (t, J 
= 7.7 Hz, 1H, ArH), 7.24 (apparent t, J = 7.7 Hz, 1H, ArH), 3.63 (broad doublet, J = 
13.1 Hz, 1H, CH), 3.12 (t, J = 12.5 Hz, 1H, CH of CH2), 2.03 – 1.96 (m, 2H, CH2), 1.87 
– 1.83 (m, 1H, CH of CH2), 1.76 – 1.70 (m, 2H, CH2), 1.63 – 1.50 (m, 2H, CH2). 13C 
NMR (100 MHz, CDCl3) δ: 143.2 (CH), 139.8 (q), 134.1 (CH), 132.1 (CH), 128.5 (CH), 
116.3 (q), 92.6 (q), 45.6 (CH2), 43.5 (CH), 28.8 (CH2), 24.3 (CH2), 19.9 (CH2). FTIR 
νmax /cm-1: 2925.7, 2855.1, 1736.3, 1369.9, 1343.5, 1219.9, 1160.6, 624.6, 600.0. 
HRMS not obtainable. 
 (Z)-N'-Hydroxy-3-((2-iodophenyl)sulfonyl)thiazolidine-4-carboximidamide 
433 
To a stirred solution of nitrile 431 (180 mg, 0.47 mmol, 1.0 eq) in ethanol (10 mL) was 
added a 50% solution of aqueous hydroxylamine (0.03 mL, 0.5 mmol, 1.05 eq). The 
reaction mixture was stirred at room temperature for 4 hours, and the solvent was 
removed under vacuum. Chloroform (10 mL) was added to the residue and the solvent 
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was removed under vacuum, then dried under high vacuum, affording the desired 
amidoxime as a pale gummy residue, 190 mg (98%). 
1H NMR (400 MHz, CDCl3) δ: 8.17 (dd, J = 1.5, 8.0 Hz, 1H, ArH), 8.11 (dd, J = 1.0, 
7.9 Hz, 1H, ArH), 7.52 (td, J = 0.9, 7.7 Hz, 1H, ArH), 7.24 (apparent td, J = 1.5, 7.6 
Hz, 1H, ArH), 4.93 (d, J = 9.8 Hz, 1H, CH of CH2), 4.84 (dd, J = 2.6, 7.3 Hz, 1H, CH), 
4.79 (bs, 2H, NH2), 4.55 (d, J = 9.8 Hz, 1H, CH of CH2), 3.37 (dd, J = 2.4, 11.2 Hz, 1H, 
CH of CH2), 3.16 (dd, J = 7.2, 11.3 Hz, 1H, CH of CH2). 13C NMR (100 MHz, CDCl3) 
δ: 150.9 (q), 143.1 (CH), 140.7 (q), 134.1 (CH), 132.3 (CH), 128.6 (CH), 92 (q), 61.4 
(CH), 51.4 (CH2), 34.3 (CH2). FTIR νmax /cm-1: 3473.5, 3366.8, 2924.4, 1660.1, 1332.2, 
1257.5, 1211.4, 1155.7, 1093.2, 1011.5, 588.0. HRMS, m/z calcd. for C10H12IN3O3S2 
[M+H] 413.9438 found 413.9428. 
 (Z)-N'-Hydroxy-1-((2-iodophenyl)sulfonyl)piperidine-2-carboximidamide 
434 
To a stirred solution of nitrile 432 (290 mg, 0.77 mmol, 1.0 eq) in ethanol (10 mL) was 
added a 50% solution of hydroxylamine in water (0.05 mL, 0.81 mmol, 1.05 eq) and 
the mixture was stirred overnight at room temperature. The reaction mixture was 
concentrated under vacuum, chloroform (10 mL) was added, and the solvent was 
removed under vacuum and the resulting residue was dried under high-vac, affording 
the product as a colourless syrup, 310 mg (98%). 
1H NMR (400 MHz, CDCl3) δ: 8.23 (ddd, J = 1.5, 4.0, 8.0 Hz, 1H, ArH), 8.15 (dt, J = 
1.3, 7.8 Hz, 1H, ArH), 7.57-7.51 (m, 1H, ArH), 7.27-7.21 (m, 1H, ArH), 6.73 (bs, 1H, 
NOH), 5.72 (bs, 1H, NH), 5.02 (bs, 1H, NH), 3.80 (d, J = 13.8 Hz, 1H, CH of CH2), 
3.12 (qd, J = 2.9, 13.5 Hz, 1H CH), 1.82 – 1.69 (m, 3H, CH and CH2), 1.66 – 1.50 (m, 
2H, CH2), 1.50 – 1.35 (m, 2H, CH2). 13C NMR (100 MHz, CDCl3) δ: 151.3 (q), 143.2 
(CH), 141.5 (q), 135.7 (CH), 132.0 (CH), 128.5 (CH), 91.7 (q), 45.0 (CH2), 42.9 (CH), 
28.5 (CH2), 24.8 (CH2), 19.0 (CH2). FTIR νmax /cm-1: 3472.6, 3367.2, 2926.2, 1660.3, 
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1332.0, 1257.5, 1155.4, 588.4. HRMS, m/z calcd. for C12H16IN3O3S [M+H] 410.0030 
found 410.0023. 
 2-Amino-5-methoxybenzamide 437 
5-Methoxyisatoic anhydride 50 (2.0 g, 10.4 mmol 1.0 eq) was dissolved in 35% 
aqueous ammonia (15 mL) and was stirred for 2 hours at room temperature. EtOAc 
(25 mL) was added, and the organic layer was separated. The organic layer was 
washed with saturated sodium bicarbonate solution (2 × 25 mL), and brine (2 × 20 
mL), before being dried and concentrated under vacuum, affording 0.19 g (11%) of the 
desired amide. 
1H NMR (400 MHz, CDCl3) δ: 6.93-6.89 (m, 2H, ArH), 6.67 (d, J = 8.3 Hz, 1H, ArH), 




 Method 1: Using EDCI and HOBt 
To an ice cooled, stirred suspension of 3-((2-iodophenyl)sulfonyl)thiazolidine-4-
carboxylic acid 427 (0.31 g, 0.77 mmol, 1.0 eq), 2-amino-5-methoxybenzamide 437 
(0.13 g, 0.77 mmol, 1.0 eq), and DIPEA (0.20 mL, 1.16 mmol, 1.5 eq) in DCM (20 mL), 
was added a solution of EDCI (0.16 g, 1.00 mmol, 1.3 eq) and HOBt (0.14 g, 0.92 
mmol, 1.2 eq) in DCM (15 mL) dropwise. The reaction was stirred at room temperature 
overnight and quenched with water (25 mL). The organic phase was separated, and 
the aqueous phase was extracted with DCM (2 × 25 mL). The combined organic 
phases were washed with brine (25 mL), dried, and concentrated under vacuum. The 
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crude residue was purified over a column of silica, affording 40 mg (9%) of the desired 
product as a pale brown residue. Partially characterised intermediate. 
1H NMR (400 MHz, CDCl3) δ: 11.85 (bs, 1H, ArNH), 8.48 (d, J = 9.1 Hz, 1H, ArH), 
8.16-8.11 (m, 2H, ArH), 7.52 (td, J = 1.0, 7.7 Hz, 1H, ArH), 7.23 (td, J = 1.6, 7.6 Hz, 
1H, ArH), 7.10 (d, J = 2.8 Hz, 1H, ArH), 7.03 (dd, J = 2.8, 9.0 Hz, 1H, ArH), 6.48 (bs, 
2H, CONH2), 5.16 (dd, J = 2.3, 7.1 Hz, 1H, CH), 5.00 (d, J = 10.1 Hz, 1H, CH of CH2), 
4.65 (d, J = 10.1 Hz, 1H, CH of CH2), 3.81 (s, 3H, OMe), 3.51 (dd, J = 2.4, 11.3 Hz, 
1H, CH of CH2), 2.96 (dd, J = 7.1, 11.3 Hz, 1H, CH of CH2). 
 Method 2: Using  Propylphosphonic anhydride 
A 50% solution of T3P in DMF (1.03 mL, 3.54 mmol, 3.0 eq) was added to DCM (5 mL) 
and the whole was cooled to 0 °C. Triethylamine (0.47 mL, 1.18 mmol, 1.0 eq) and 3-
((2-iodophenyl)sulfonyl)thiazolidine-4-carboxylic acid 427 (0.47 g, 1.18 mmol, 1.0 eq) 
were added, and the mixture stirred for 30 minutes at 0 °C. 2-Amino-5-
methoxybenzamide 437 (0.2 g, 1.18 mmol, 1.0 eq) was added, and the reaction was 
stirred overnight at room temperature. Water (25 mL) was added, and the organic 
material was extracted with EtOAc (3 × 15 mL). The combined organic material was 
dried and concentrated under vacuum. The resulting residue was purified over a 
column of silica, eluted with neat EtOAc, affording the desired product as a viscous 
film, 40 mg (6%). Partially characterised intermediate 
1H NMR (400 MHz, CDCl3) δ: 11.88 (s, 1H, ArNH), 8.49 (d, J = 9.1 Hz, 1H, ArH), 8.16-
8.13 (m, 2H, ArH), 7.5 (t, J = 7.7 Hz, 1H, ArH), 7.23 (td, J = 1.5, 7.6 Hz, 1H, ArH), 7.10 
(d, J = 2.8 Hz, 1H, ArH), 7.02 (dd, J = 2.8, 9.0 Hz, 1H, ArH), 6.53 (bs, 2H, CONH2), 
5.16 (dd, J = 2.4, 7.1 Hz, 1H, CH), 4.99 (d, J = 10.0 Hz, 1H, CH of CH2), 4.64 (d, J = 
10.0 Hz, 1H, CH of CH2), 3.80 (s, 3H, OMe), 3.50 (dd, J = 2.4, 11.4 Hz, 1H, CH of 





 Method 1: Using EDCI and HOBt 
To an ice cooled, stirred solution of 1-((2-iodophenyl)sulfonyl)piperidine-2-carboxylic 
acid 428 (0.47 g, 1.19 mmol, 1.0 eq), DIPEA (0.31 mL, 1.85 mmol, 1.5 eq), and 2-
amino-5-methoxybenzamide 437 (0.20 g, 1.20 mmol, 1.0 eq), was added a solution of 
EDCI (0.24 g, 1.55 mmol, 1.3 eq) and HOBt (0.22 g, 1.43 mmol, 1.2 eq) in DCM (15 
mL). The solution stirred overnight at room temperature and was quenched with water 
(25 mL). The organic material was collected, and the aqueous layer was extracted 
with DCM (3 × 20 mL). The combined organic material was washed with brine (40 mL) 
and dried. Concentration under vacuum afforded the crude material, which was in turn 
purified over a column of silica, eluted with EtOAc, affording the desired product as a 
dark orange residue, 96 mg (15%). Partially characterised intermediate 
1H NMR (400 MHz, CDCl3) δ: 11.63 (bs, 1H, ArNH), 8.52 (d, J = 9.1 Hz, 1H, ArH), 8.18 
(dd, J = 1.5, 8.0 Hz, 1H, ArH), 8.10 (dd, J = 1.1, 7.9 Hz, 1H, ArH), 7.50 (td, J = 1.1, 7.7 
Hz, 1H, ArH), 7.19 (td, J = 1.6, 7.7 Hz, 1H, ArH), 7.14 (d, J = 2.9 Hz, 1H, ArH), 7.00 
(dd, J = 2.9, 9.1 Hz, 1H, ArH), 6.78 (bs, 2H, CONH2), 4.86 (d, J = 4.1 Hz, 1H, CH), 
3.92 (broad doublet, J = 13.5 Hz, 1H, CH of CH2), 3.79 (s, 3H, OMe), 3.42 (td, J = 2.4, 
13.5 Hz, 1H, CH of CH2), 2.34 (broad doublet, J = 13.5 Hz, 1H, CH of CH2), 1.63 – 
1.38 (m, 5H, CH of CH2 and 2 × CH2). 
 Method 2: Using Propylphosphonic anhydride 
A 50% solution of T3P in DMF (0.59 mL, 2.00 mmol, 3.0 eq) in DCM (5 mL) was cooled 
in an ice bath, and triethylamine (0.58 mL, 4.05 mmol, 6.0 eq) and 3-((2-
iodophenyl)sulfonyl)thiazolidine-4-carboxylic acid (0.27 g, 0.68 mmol, 1.0 eq) were 
added, and the whole stirred for 5 minutes. 2-Amino-5-methoxybenzamide (0.21 g, 
0.68 mmol, 1.0 eq) was added and the reaction was stirred overnight at ambient 
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temperature. Water (20 mL) was added, and the organic phase was separated. The 
aqueous layer was extracted with EtOAc (3 × 10 mL) and the combined organic 
extracts were dried and concentrated under vacuum. The crude residue was purified 
over a column of silica, eluted by EtOAc, affording the desired product as a yellowish 
residue, 30 mg (8%). Partially characterised intermediate 
NMR identical to previous entry. 
 2-(3-((2-Iodophenyl)sulfonyl)thiazolidin-4-yl)-6-methoxyquinazolin-4(3H)-
one 435 
To a stirred solution of diamide 438 (40 mg, 0.08 mmol, 1.0 eq) in THF (5 mL) cooled 
to 0 °C was added a solution of LiOH•H2O (16 mg, 0.38 mmol, 5.0 eq) in water (2 mL). 
The reaction was stirred overnight at room temperature, and the organic material was 
extracted with EtOAc (3 × 20 mL). The combined organic extracts were washed with 
brine (20 mL), dried, and concentrated under reduced pressure. The resulting crude 
material was purified over a column of silica, eluted with neat EtOAc, affording the 
desired product as a pale green residue, 9 mg (22%). Partially characterised 
intermediate 
1H NMR (400 MHz, CDCl3) δ: 9.87 (bs, 1H, NH), 8.17 (dd, J = 1.5, 8.0 Hz, 1H, ArH), 
8.08 (dd, J = 1.0, 7.9 Hz, 1H, ArH), 7.59 (d, J = 3.0 Hz, 1H, ArH), 7.53 (d, J = 9.0 Hz, 
1H, ArH), 7.40 (td, J = 1.1, 7.7 Hz, 1H, ArH), 7.33 (dd, J = 3.0, 9.0 Hz, 1H, ArH), 7.11 
(td, J = 1.5, 7.6 Hz, 1H, ArH), 5.33 (dd, J = 2.5, 7.1 Hz, 1H, CH), 4.99 (d, J = 9.7 Hz, 
1H, CH of CH2), 4.71 (d, J = 9.7 Hz, 1H, CH of CH2), 3.93 (s, 3H, OMe), 3.72 (dd, J = 





To a stirred solution of diamide 439 (93 mg, 0.17 mmol 1.0 eq) in THF (5 mL) was 
added a solution of LiOH•H2O (36 mg, 0.86 mmol, 5.0 eq) in water (2 mL). The reaction 
was stirred overnight, and the organic material was extracted with EtOAc (3 × 20 mL). 
The organic extracts were combined and washed with brine (30 mL) before being dried 
and concentrated under vacuum. The crude material was purified over a column of 
silica, eluted by EtOAc, affording the desired product as a pale-yellow residue, 47 mg 
(53%). Partially characterised intermediate 
1H NMR (400 MHz, CDCl3) δ: 10.03 (bs, 1H, NH), 8.21 (dd, J = 1.2, 8.0 Hz, 1H, ArH), 
8.12 (d, J = 8.0 Hz, 1H, ArH), 7.62 (d, J = 2.8 Hz, 1H, ArH), 7.55 (d, J = 9.0 Hz, 1H, 
ArH), 7.49 (t, J = 7.6 Hz, 1H, ArH), 7.32 (dd, J = 3.0, 9.0 Hz, 1H, ArH), 7.19 (td, J = 
1.2, 7.6 Hz, 1H, ArH), 5.06 (broad doublet, J = 4.7 Hz, 1H, CH), 3.91 (s, 3H, OMe), 
3.20 (p, J = 7.5 Hz, 1H, CH of CH2), 2.58 (dd, J = 2.2, 13.4 Hz, 1H, CH of CH2), 1.94 
– 1.82 (m, 2H, CH2), 1.74 – 1.67 (m, 2H, CH2), 1.62 – 1.55 (m, 2H, CH2). 
 Attempted synthesis of 2-Methoxy-6,7,8,9-
tetrahydrobenzo[6,7]pyrido[1',2':2,3][1,2,5]thiadiazepino[4,5-b]quinazolin-
17(5bH)-one 11,11-dioxide 426 
A flame dried round bottomed flask was charged with L-proline (3.5 mg, 0.03 mmol, 
0.31 eq), 60% sodium hydride (7.5 mg, 0.2 quinazolinone 436 (50 mg, 0.095 mmol, 
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1.0 eq) and dry DMF (5 mL). The whole was stirred to homogeneity and then was 
heated at 130 °C for 3 hours. After cooling, EtOAc (20 mL) was added and the whole 
was washed with water (2 × 10 mL) and brine (10 mL). The organic material was dried 
and concentrated under vacuum; the crude material was purified over a column of 
silica, eluted by a 70% solution of EtOAc in hexane. The desired product was not able 
to be identified. 
3.7 Experimental for the Synthesis of Azabicyclo[4.2.1]nona-3,7-dien-9-
one Precursors 
 4-Methyl-4-vinylazetidin-2-one 442 
To a stirred solution of isoprene 440 (3.4 mL, 34.4 mmol, 1.01 eq) in dry diethyl ether 
(15 mL), cooled to -78 °C, was added a solution of chlorosulfonyl isocyanate (CSI) (3.0 
mL, 34.0 mmol, 1.00 eq) in dry diethyl ether (10 mL) over 1 hour. The reaction mixture 
was warmed to -10 °C, and the solution stirred for 30 minutes before being transferred 
dropwise to a stirred solution of sodium carbonate (9 g), sodium sulfite (6 g), and ice 
(30 g) in water (50 mL). The reaction was stirred in an ice bath for one hour before 
being allowed to warm to room temperature. The organic material was extracted with 
ether (6 × 20 mL), dried over MgSO4, filtered, and concentrated under vacuum, 
affording the desired product as a pale yellowish oil, 2.00 g (53%). 
1H NMR (400 MHz), CDCl3, δ: 6.24 (bs, 1H, NH), 6.06 (dd, J = 10.5, 17.1 Hz, 1H, 
CH2=CH), 5.27 (d, J = 17.1 Hz, 1H, CH=CHH), 5.15 (d, J = 10.5 Hz, 1H, CH=CHH) 




 4-Methyl-4-(prop-1-en-2-yl)azetidin-2-one 443 
To a stirred solution of 2,3-dimethylbuta-1,3-diene 441 (3.9 mL, 34.3 mmol, 1.0 eq) in 
dry diethyl ether (15 mL) at -78 °C, was added a solution of chlorosulfonyl isocyanate 
(3.0 mL, 34.3 mmol, 1.0 eq) in dry diethyl ether (10 mL) over 1 hour. The mixture was 
allowed to warm to -10 °C and was stirred for a further 30 minutes at this temperature. 
The whole was transferred dropwise to a solution of sodium carbonate (9 g), sodium 
sulfite (6 g), and ice (30 g) in water (50 mL) cooled in an ice bath. After addition, the 
reaction was left for 1 hour before being allowed to warm to room temperature. The 
organic material was extracted with ether (6 × 20 mL), dried over MgSO4, filtered, and 
concentrated under vacuum, affording the desired product as a colourless oil, 2.3 g 
(62%). 
1H NMR (400 MHz), CDCl3, δ: 6.43 (bs, 1H, NH), 4.93 (s, 1H, C=CHH), 4.87 (s, 1H, 
C=CHH), 2.85 (d, J = 14.3 Hz, 1H, CH of CH2),  2.85 (d, J = 14.2 Hz, 1H, CH of ring 
CH2), 2.76 (dd, J = 1.9, 14.2 Hz, 1H, CH of ring CH2), 1.79 (s, 3H, CH3), 1.53 (s, 3H, 
CH3). Data consistent with literature167 
 4-Methyl-4-vinylazetidine-2-thione 444 
To a stirred solution of 4-methyl-4-vinylazetidin-2-one 442 (1.04 g, 9.36 mmol, 1 eq) 
in dry THF (25 mL) was added Lawesson’s reagent (1.89 g, 4.68 mmol, 0.5 eq) and 
the whole was stirred at room temperature for 1 hour. The temperature was increased, 
and the reaction was left to reflux overnight. After cooling, the solvent was removed 
under reduced pressure, and the crude oil was purified over a column of silica, eluted 
by 50% EtOAc in hexane, affording the desired thiolactam as a viscous orange oil, 
0.75 g (63%). 
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1H NMR (400 MHz), CDCl3, δ: 8.41 (bs, 1H, NH), 6.06 (dd, J = 10.6, 17.3 Hz, 1H, 
CH=CH2), 5.28 (d, J = 17.3 Hz, 1H, CH=CHH), 5.22 (d, J = 10.6 Hz, 1H, CH=CHH), 
2.98 (s,  1H, CH of ring CH2), 2.97 (s, 1H, CH of ring CH2), 1.60 (s, 3H, CH3). In 
agreement with literature151. 
 4-Methyl-4-(prop-1-en-2-yl)azetidine-2-thione 445 
To a stirred solution of 4-methyl-4-(prop-1-en-2-yl)azetidin-2-one 443 (2.27 g, 18.14 
mmol, 1.0 eq) in dry THF (25 mL) was added Lawesson’s reagent (3.67 g, 9.07 mmol, 
0.5 eq). The mixture stirred at room temperature for 1 hour before being allowed to 
reflux overnight. The reaction mixture was cooled, and the solvent was removed under 
vacuum. The resulting residue was purified over a column of silica, eluted by 40%  
EtOAc in hexane, affording the desired product as a viscous dark red/orange oil, 1.8 
g (70 %). 
1H NMR (400 MHz), CDCl3, δ: 8.78 (bs, H, NH), 4.96 – 4.90 (m, 2H, C=CH2), 3.01 (d, 
J = 15.1 Hz, 1H, CH of ring CH2), 2.91 (dd, J = 15.1, 1.7 Hz, CH of ring CH2), 1.7 (s, 
3H, CH3), 1.61 (s, 3H, CH3). In good agreement with previous reports168 
 General procedure for azetine formation 
To a stirred solution of thiolactam (1 eq) in dry DCM (15 mL) was added the 
appropriate Meerwein salt, and the mixture was stirred under a nitrogen atmosphere 
overnight. The reaction was washed with saturated sodium bicarbonate solution (~20 
mL), water (~20 mL), dried over Mg2SO4, and carefully concentrated under vacuum, 
affording the desired azetine. 
159 
 
 4-(Ethylthio)-2-methyl-2-vinyl-2,3-dihydroazete 446 
Pale yellow film (112 mg, 89%). 1H NMR (400 MHz), CDCl3, δ: 6.06 (dd, J = 10.6, 17.2 
Hz, 1H, CH=CH2), 5.21 (dd, J = 1.2, 17.2 Hz, 1H, CH=CHH), 5.10  (dd, J = 1.2, 10.6 
Hz, 1H, CH=CHH), 3.06 – 2.85 (m, 4H, ring CH2 and SCH2CH3), 1.46 (s, 3H, CH3), 
1.37 (t, J = 7.4 Hz, 3H, SCH2CH3). In agreement with literature153. 
 4-(Ethylthio)-2-methyl-2-(prop-1-en-2-yl)-2,3-dihydroazete 447 
Pale yellow film (180 mg, 60%). 1H NMR (400 MHz), CDCl3, δ: 4.95 (s, 1H C=CHH), 
4.85 (s, 1H, C=CHH), 3.12 (m, 4H, ring CH2, SCH2CH3), 1.79 (s, 3H, CH3), 1.48 (s, 
3H, CH3), 1.38 (t, J = 7.4 Hz, 3H, SCH2CH3), consistent with literature153. 
 2-Methyl-4-(methylthio)-2-vinyl-2,3-dihydroazete 448 
Dark yellow/brown oil (120 mg, 97%) Rf = 0.2 with 10% MeOH in hexane. 1H NMR 
(400 MHz), CDCl3, δ: 6.05 (dd, J = 10.6, 17.2 Hz, 1H, CH=CH2), 5.21 (dd, J = 1.2, 17.2 
Hz, 1H, CH=CHH), 5.11 (dd, J = 1.2, 10.6 Hz, 1H, CH=CHH), 2.97 (d, J = 14.3 Hz, 
1H, CH of ring CH2), 2.87 (d, J = 14.3 Hz, 1H, CH of ring CH2), 2.41 (s, 3H, SMe), 1.46 
(s, 3H, CH3). 13C NMR (125 MHz), CDCl3 δ: 181.2 (q), 141.6 (CH), 113.7 (CH2), 66.9 
(q), 46.1 (CH2), 24.7 (CH3), 11.6 (CH3). HRMS m/z calcd. for C7H11NS [M+H], requires 
142.0614, found 142.0687. 
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 2-Methyl-4-(methylthio)-2-(prop-1-en-2-yl)-2,3-dihydroazete 449 
 
Dark yellow oil (113 mg, 83%). 1H NMR (400 MHz), CDCl3, δ: 4.95-4.93 (m, 1H, 
C=CHH), 4.86-4.83 (m, 1H, C=CHH), 2.98 (d, J = 13.8 Hz, 1H, CH2), 2.84 (d, J = 13.8 
Hz, 1H, CH2), 2.41 (s, 3H, SCH3), 1.79 (s, 3H, CH3), 1.47 (s, 3H, CH3). 13C NMR (125 
MHz), CDCl3 δ: 181.0 (q), 147.7 (q), 110.6 (CH2), 69.2 (q), 46.1 (CH2), 24.9 (CH3), 
18.3 (CH3), 11.5 (CH3).  FTIR  νmax /cm-1: 1644, 1530, 1437, 1226, 1076, 900. HRMS 
m/z calcd. for C8H13NS [M+H]: requires 156.0768, found 156.0840. 
 General Synthesis of Cyclopropenones via the Diarylketone 
To a stirred solution of N,N'-dicyclohexylcarbodiimide (1.05 eq) and 4-
dimethylaminopyridine (0.3 eq) in dry THF (25 mL) was added the required 4-
halophenylacetic acid (1.0 eq) and the reaction stirred for 2 hours. The contents of the 
flask were filtered through celite, washed through with DCM (3 × 25 mL), and 
concentrated under vacuum. The resulting material was purified via flash 
chromatography, eluted with EtOAc. The pure diarylketone was dissolved in glacial 
acetic acid (~100 mL) and a solution of bromine (3.0 eq) in acetic acid (10 mL) was 
slowly added dropwise. The reaction was stirred overnight at room temperature, and 
water (250 mL) was added. The mixture stirred gently until precipitation ceased, which 
was collected via vacuum filtration and dried overnight in a vacuum desiccator. The 
dry dibromoketone was dissolved in dry DCM (20 mL) and was slowly added to a 
solution of triethylamine (2.5 eq) in dry DCM (20 mL). The reaction was stirred for 1 
hour, and the contents of the flask were washed with 1 M HCl (35 mL), and brine (35 
mL). The organic phase was dried over magnesium sulfate and concentrated under 
reduced pressure. The crude residue was purified over a column of silica, eluted with 




 2,3-Bis(4´-chlorophenyl)cycloprop-2-en-1-one 258a 
Pale brown solid, (2.90 g, 30%). 1H NMR (400 MHz), CDCl3, δ: 7.89 (d, J = 8.5 Hz, 
4H, ArH), 7.57 (d, J = 8.5 Hz, 4H, ArH), in agreement with literature88 
 2,3-Bis(4´-fluorophenyl)cycloprop-2-en-1-one 249 
Pale orange/yellow solid (3.01 g, 32%). 1H NMR (400 MHz), CDCl3, δ: 7.98 (apparent 
q, J = 4.5 Hz, 4H, ArH) 7.28 (apparent t, J = 8.5 Hz,  4H ArH), in agreement with 
literature88. 
 2,3-Di-p-tolylcycloprop-2-en-1-one 258c 
Cream solid (54 mg, 0.7%). 1H NMR (400 MHz), CDCl3, δ: 7.88 (d, J = 8.1 Hz, 4H, 
ArH), 7.29 (d, J = 8.1 Hz, 4H, ArH), 2.48 (s, 6H, ArMe), In agreement with literature88 
 General Synthesis of Cyclopropenones Using AlCl3 
To a well-mixed suspension of tetrachlorocyclopropene (1.0 eq) and aluminium(III) 
chloride (1.05 eq) in dry DCM (10 mL) under an inert atmosphere, cooled to -78 °C, 
was added a solution of the required aromatic compound (2.0 eq) in dry DCM (5.0 mL) 
dropwise over 5 minutes. The reaction was stirred at -78 °C for two hours before 
warming to room temperature overnight. Water (10 mL) and DCM (20 mL) were added, 
and the organic material was separated and washed with water (2 × 40 mL) and brine 
(2 × 40 mL). The organic phase was dried and concentrated under vacuum, and the 
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resulting crude material was purified over a column of silica, eluted by a gradient of 5-
30% EtOAc in hexane, affording the desired cyclopropenone. 
 2,3-Di-p-tolylcycloprop-2-en-1-one 258c 
Pale cream solid (120 mg, 80%) 1H NMR (400 MHz), CDCl3, δ: 7.87 (d, J = 8.0 Hz, 
4H, ArH), 7.38 (d, J = 8.0 Hz, 4H, ArH), 2.47 (s, 6H, ArMe). In agreement with 
literature88 and previous synthesis (3.7.6.3) 
 2,3-Bis(4´-methoxyphenyl)cycloprop-2-en-1-one 453 
White solid (800 mg, 18%). 1H NMR (400 MHz), CDCl3, δ: 7.93 (d, J = 8.8 Hz, 4H, 
ArH), 7.07 (d, J = 8.8 Hz, 4H, ArH), 3.92 (s, 6H, OMe). In agreement with literature88. 
 2,3-Bis(2´,5´-dimethylthiophen-3-yl)cycloprop-2-en-1-one 454 
Brown solid (1.07 g, 24%). 1H NMR (400 MHz), CDCl3, δ: 6.96 (s, 2H, ArH), 2.82 (s, 





 Pale green crude solid. 1H NMR (400 MHz), CDCl3, δ: 7.08 (s, 2H, ArH), 3.75 (s, 6H, 
ArMe), 2.66 (s, 6H, ArMe). Unreported, but the carbon NMR could not be resolved. 
3.8 Experimental for Azetine and Cyclopropenone Cycloadditions and 
Aza-Cope Rearrangements 
 General Procedures to Afford Cycloadducts or Rearranged Systems 
Method 1 
To a stirred solution of azetine (1.0 eq) in dry acetonitrile (~10 mL) was added a 
solution of cyclopropenone (1.0 eq) in dry acetonitrile (~10 mL). The reaction vessel 
was sealed, and the reaction was left at room temperature for 7-10 days. The solvent 
was removed under reduced pressure and the resulting residue was purified over a 
column of silica, eluted with DCM to afford combinations of the cycloadduct and 
rearranged product.  
Method 2 
A solution of cyclopropenone (1.0 eq) in dry acetonitrile (10 mL) was added to a stirred 
solution of azetine (1.0 eq) in dry acetonitrile (10 mL) at room temperature. The 
reaction stirred at ~45 °C for 15 minutes and then at reflux for ~7 days. The reaction 
mixture was cooled to room temperature and the solvent was removed under vacuum. 
The crude material was purified over a column of silica, eluted with DCM, affording 





Off white solid from method 1: 113.7 mg (16.8%), mp 118 – 121 °C, Rf = 0.45 (DCM). 
1H NMR (400 MHz), CDCl3, δ: 7.66 (d, J = 8.0 Hz, 2H, ArH), 7.36 – 7.28 (m, 4H, ArH), 
7.27 – 7.19 (m, 2H, ArH), 7.14 (d, J = 8.0 Hz, 2H, ArH), 5.38 (d, J = 5.4 Hz, 1H, C=CH), 
3.12 (d, J = 16.8 Hz, 1H, CH of CH2), 2.98 (dd, J = 6.5, 16.8 Hz, CH of CH2), 2.77 (d, 
J = 17.2 Hz, 1H, CH of CH2), 2.70 – 2.50 (m, 3H, CH of CH2 and CH2CH3), 1.71 (s, 
3H, CMe), 1.26 (t, J = 7.4 Hz, 3H, CH2CH3). 13C NMR (100 MHz), CDCl3, δ: 214.7 (q), 
173.8 (q) 136.6 (q), 132.2 (q), 131.9 (CH), 131.0 (q), 129.1 (CH), 128.4 (CH), 128.3 
(CH), 128.0 (CH), 127.1 (CH), 118.5 (CH), 82.8 (q), 64.0 (CH2), 53.0 (q), 43.0 (CH2), 
35.0 (CH), 27.7 (CH2), 23.7 (Me), 14.3 (Me).  FTIR  νmax cm-1: 2970 (w), 2929 (w), 
1758 (s), 1588 (m), 1561 (m), 1444 (m), 1109 (m). 1073 (m), 731 (s), 701 (s). HRMS, 
m/z calcd. for C23H23NOS [M+H], reqd. 362.1583, found 362.1577. 
3.8.1.2 5-(Ethylthio)-7-methyl-2,3-diphenyl-7-vinyl-1-azabicyclo[3.2.0]hept-2-
en-4-one 456a 
Dark cream solid from method 1: 89 mg (13%), mp: 106-108 °C. 1H NMR (400 MHz), 
CDCl3, δ: 7.53 (d, J = 8.0 Hz, 2H, ArH) 7.43 – 7.23 (m, 8H, ArH), 6.32 (dd, J = 10.6, 
17.2 Hz, 1H, CH=CH2), 5.52 (dd, J = 0.9, 17.2 Hz, 1H, =CHH), 5.27 (dd, J = 0.9, 10.6 
Hz, 1H, =CHH), 2.63-2.49 (m, 2H, SCH2CH3), 2.48 (s, 1H, CH of ring CH2), 2.47 (s, 
1H, CH of ring CH2), 1.19 (t, J = 7.4 Hz, 3H, SCH2CH3), 0.87 (s, 3H, CCH3). 13C NMR 
(100 MHz), CDCl3, δ: 203.2 (q). 174.6 (q), 142.8 (CH), 132.9 (q), 131.5 (CH), 131.2 
(q), 129.6 (CH), 128.7 (CH), 128.6 (CH), 128.3 (CH) 127.0 (CH), 125.0 (q), 114.0 (CH), 
74.8 (q), 69.1 (CH2), 37.7 (CH2), 23.8 (CH2), 23.4 (CH3), 14.5 (CH3). FTIR νmax /cm-1: 
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1672, 1601, 1557, 1435, 1371, 1226, 1016, 916, 793, 697. HRMS m/z calcd. for 




Off-white solid from method 1: 50.4 mg (38%), mp: 149 – 151 °C, Rf = 0.43 (DCM). 1H 
NMR (400 MHz), CDCl3, δ: 7.64 (d, J = 8.0 Hz, 2H, ArH), 7.35 – 7.27 (m, 4H, ArH), 
7.23 (d, J = 7.8 Hz, 2H, ArH), 7.13 (d, J = 7.8 Hz, 2H, ArH), 3.20 (d, J = 16.3 Hz, 1H, 
CH of CH2), 2.95 (d, J = 16.3 Hz, 1H, CH of CH2), 2.78 (q, J = 16.8, 36.7 Hz, 2H, CH2), 
2.67 – 2.48 (m, 2H, CH2CH3), 1.67 (s, 6H, 2 × Me), 1.26 (t, J = 7.5 Hz, 3H, CH2CH3). 
13C NMR (100 MHz), CDCl3, δ: 215.1 (q), 173.7 (q) 136.7 (q), 132.2 (q), 130.8 (CH), 
129.0 (CH), 128.3 (CH), 128.2 (CH), 127.9 (CH), 127.1 (CH), 125.2 (q), 124.0 (q), 83.0 
(q), 63.5 (q), 46.0 (CH2), 42.5 (CH2), 23.8 (CH2), 23.6 (Me), 23.3 (Me), 14.3 (Me).  FTIR  
νmax cm-1: 2922 (w), 1766 (s), 1590 (m), 1562 (m), 1444 (m), 1319 (m), 1262 (m), 1081 
(m), 1028 (m), 788 (s), 703 (s). HRMS, m/z calcd. for C24H25NOS [M+H] reqd. 
376.1740, found 376.1734. 
3.8.1.4 5-(Ethylthio)-7-methyl-2,3-diphenyl-7-(prop-1-en-2-yl)-1-
azabicyclo[3.2.0]hept-2-en-4-one 457a 
Dark brown solid, from method 1: 33 mg (25%), mp: 84-86 °C. 1H NMR (400 MHz), 
CDCl3, δ: 7.53 (d, J = 7.8 Hz, 2H, ArH), 7.39 (t, J = 7.4 Hz, 1H, ArH), 7.35-7.26 (m, 
6H, ArH), 5.67 (s, 1H, =CHH), 5.12 (s, 1H, =CHH), 2.64-2.45 (m, 2H, SCH2CH3), 2.47 
(s, 1H, CH of ring CH2), 2.43 (s, 1H, CH of ring CH2), 1.82 (s, 3H, CH3), 1.18 (t, J = 
7.4 Hz, 3H, SCH2CH3), 0.90 (s, 3H, CH3). 13C NMR (100 MHz), CDCl3, δ: 203.3 (q), 
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175.2 (q), 147.4 (q), 133.1 (q), 131.3 (CH), 129.7 (CH), 128.7 (CH), 125.5 (CH), 128.3 
(CH), 126.9 (q), 125.4 (q), 112.6 (q), 74.6 (q), 72.4 (q), 37.5 (CH2), 23.8 (CH2), 23.4 
(CH3), 19.0 (CH3), 14.6 (CH3). FTIR νmax /cm-1: 1650, 1600, 1506, 1440, 1370, 1239, 




Yellowish brown solid from method 2: 27.3 mg (11%), mp: 164 – 168 °C, Rf: 0.32 
(DCM). 1H NMR (400 MHz), CDCl3, δ: 7.68 (d, J = 8.5 Hz, 2H, ArH), 7.40 – 7.32 (m, 
4H, ArH), 7.26 (t, J = 7.3 Hz, 2H, ArH), 7.18 (d, J = 7.9 Hz, 2H, ArH), 5.42 (d, J = 6.0 
Hz, 1H, CH=C), 3.15 (d, J = 17.0 Hz, 1H, CH of CH2), 3.01 (dd, J = 6.6, 17.0 Hz, 1H, 
CH of CH2), 2.81 (d, J = 17.0 Hz, 1H, CH of CH2), 2.67 (d, J = 17.0 Hz, 1H, CH of 
CH2), 2.14 (s, 3H, Me), 1.77 (bs, 3H, Me). 13C NMR (100 MHz), CDCl3, δ: 214.3 (q), 
174.3 (q), 136.5 (q), 132.3 (q), 131.9 (CH), 131.0 (CH), 129.1 (CH), 128.4 (CH), 128.3 
(CH), 127.1 (CH), 125.8 (q), 118.5 (CH), 82.3 (q), 64.1 (q), 42.7 (CH2), 34.9 (CH2), 
27.6 (Me), 12.5 (Me).  FTIR  νmax /cm-1: 2921 (m), 2850 (m), 1764 (m), 1561 (m), 
1443.2 (m), 1303 (w), 1094 (m). 7339 (s), 691 (s). HRMS, m/z calcd. for C22H21NOS 
[M+H] reqd. 348.1424, found 348.1417. 
3.8.1.6 3,4-Dimethyl-6-(methylthio)-1,8-diphenyl-7-azabicyclo[4.2.1]nona-3,7-
dien-9-one 459 
Off-white solid, from method 2: 59 mg (21%), mp: 190 – 193 °C, Rf: 0.35 (DCM). 1H 
NMR (400 MHz), CDCl3, δ: 7.66 (d, J = 7.6 Hz, 2H ArH), 7.39 – 7.31 (m, 4H, ArH), 
7.29 – 7.26 (m, 2H, ArH), 7.15 (d, J = 7.6 Hz, 2H, ArH), 3.22 (d, J = 16.1 Hz, 1H, CH 
of CH2), 2.98 (d, J = 16.1 Hz, 1H, CH of CH2), 2.82 (q, J = 16.6 Hz, 2H, CH2), 2.11 (s, 
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3H, SMe), 1.72 (s, 3H, CH3), 1.70 (s, 3H, CH3).13C NMR (100 MHz), CDCl3, δ: 214.8 
(q), 174.3 (q), 136.7 (q), 132.2 (q), 130.9 (CH), 129.0 (CH), 128.3 (CH), 128.2 (CH), 
127.9 (CH), 127.1 (CH), 125.3 (q), 123.9 (q), 82.6 (q), 63.5 (q), 45.7 (CH2), 42.4 (CH2), 
23.6 (Me), 23.2 (Me), 12.5 (Me).  FTIR  νmax /cm-1: 2915 (m), 2874 (m), 1761 (s), 1565 
(m), 1315 (m), 1081 (m) 760 (s), 738 (s). HRMS, m/z calcd. for C23H23NOS [M+H] 
reqd. 362.1587, found 362.1582. 
3.8.1.7 1,8-Bis(4-chlorophenyl)-6-(ethylthio)-3-methyl-7-
azabicyclo[4.2.1]nona-3,7-dien-9-one 460 
Brown residue from method 1: 35.0 mg (12%), Rf: 0.52 (DCM). 1H NMR (400 MHz), 
CDCl3, δ: 7.57 (d, J = 8.6 Hz, 2H, ArH), 7.33 (d, J = 8.6 Hz, 2H, ArH), 7.24 (d, J = 8.6 
Hz, 2H, ArH), 7.05 (d, J = 8.6 Hz, 2H, ArH), 5.37 (d, J = 5.6 Hz, 1H, CH=CMe), 3.16 
(dd, J = 8.1, 18.2 Hz, 1H, CH of CH2), 3.06 (d, J = 18.2 Hz, 1H, CH of CH2), 2.89 (dd, 
J = 6.7, 17.0 Hz, 1H, CH of CH2), 2.76 (d, J = 17.0 Hz, 1H, CH of CH2), 2.63 – 2.57 
(m, 1H, CH of CH2 (Et)), 2.56 – 2.50 (m, 1H, CH of CH2 (Et)), 1.73 (s, 3H, Me), 1.25 
(t, J = 7.4 Hz, 3H, Me of CH2Me). 13C NMR (100 MHz), CDCl3, δ: 213.8 (q), 172.2 (q), 
137.4 (q), 134.8 (q), 134.2 (q), 132.6 (q), 130.0 (CH), 129.6 (CH), 129.4 (CH), 128.8 
(CH), 128.3 (CH), 118.0 (q), 82.8 (q), 63.5 (q), 42.9 (CH2) 35.0 (CH2), 27.7 (CH2), 23.7 
(CH3), 14.2 (CH3).  FTIR  νmax /cm-1: 2965 (m), 2925 (m), 1765 (m), 1589 (m), 1471 
(s), 1260 (m), 1091 (s), 1012 (s), 821 (s), 787 (s). HRMS, m/z calcd. for C23H21Cl2NOS 





Brown solid, from method 1: 1 mg (0.3%), mp 67 – 70 °C. 1H NMR (400 MHz), CDCl3, 
δ: 7.46 (d, J = 8.5 Hz, 2H, ArH), 7.34-7.28 (m, 6H, ArH), 6.31 (dd, J = 10.6, 17.0 Hz, 
1H, CH=CH2), 5.50 (d, J = 17.0 Hz, 1H, =CHH), 5.28 (d, J = 10.6 Hz, 1H, =CHH), 2.58 
– 2.49 (m, 2H, SCH2CH3), 2.48 (s, 1H, CH of ring CH2), 2.46 (s, 1H, CH of ring CH2), 
1.17 (t, J = 7.5 Hz, 3H, SCH2CH3), 0.88 (s, 3H, CH3). Insufficient compound for 13C 
acquisition. FTIR νmax /cm-1: 1667, 1593, 1488, 1399, 1259, 1088, 1012, 794, 481. 
HRMS, m/z calcd. for C23H21Cl2NOS [M+H] reqd. 430.0721, found 430.0790. 
3.8.1.9 1,8-Bis(4-chlorophenyl)-6-(ethylthio)-3,4-dimethyl-7-
azabicyclo[4.2.1]nona-3,7-dien-9-one 461 
Pale brown solid from method 2: 2.5 mg (2%), mp: 66 – 69 °C, Rf: 0.49 (DCM). 1H 
NMR (400 MHz), CDCl3, δ: 7.58 (d, J  = 8.5 Hz, 2H, ArH), 7.33 (d, J  = 8.5 Hz, 2H, 
ArH), 7.26 (d, J  = 8.5 Hz, 2H, ArH), 7.05 (d, J  = 8.5 Hz, 2H, ArH), 3.16 (d, J  = 16.5 
Hz, 1H CH of CH2), 2.90 – 2.79 (m, 2H, CH2), 2.75 (d, J  = 17.1 Hz, 1H CH of CH2), 
2.67 – 2.46 (m, 2H, CH2), 1.70 (s, 3H, Me), 1.68 (s, 3H, Me), 1.26 (t, J  = 7.3 Hz, 3H 
CH2CH3). 13C NMR (100 MHz), CDCl3, δ: 214.4 (q), 172.1 (q) 137.3 (q), 134.9 (q), 
134.1 (q), 130.3 (q), 129.4 (CH), 129.3 (CH), 128.8 (CH), 128.4 (CH), 125.6 (q), 123.7 
(q), 83.0 (q), 62.9 (q), 45.9 (CH2), 42.5 (CH2), 23.8 (CH2), 23.6 (Me), 23.3 (Me), 14.3 
(Me).  FTIR  νmax /cm-1: 2924 (m), 1766 (m), 1590 (m), 1491 (m), 1399 (m), 1092 (s), 






Brown solid from method 2: 18.2 mg (7%), mp: 74 – 76 °C, Rf: 0.58 (DCM). 1H NMR 
(400 MHz), CDCl3, δ: 7.60 (d, J  = 8.6 Hz, 2H, ArH), 7.35 (d, J  = 8.6 Hz, 2H, ArH), 
7.26 (d, J  = 8.6 Hz, 2H, ArH), 7.07 (d, J  = 8.6 Hz, 2H, ArH), 5.40 (s, 1H, C=CH), 3.09 
(d, J  = 16.2 Hz, 1H, CH of CH2), 2.92 (dd, J  = 6.7, 16.2 Hz, 1H, CH of CH2), 2.79 (d, 
J  = 16.8 Hz, 1H, CH of CH2), 2.66 (d, J  = 16.8 Hz, 1H, CH of CH2), 2.11 (s, 3H, Me), 
1.76 (s, 3H, Me). 13C NMR (100 MHz), CDCl3, δ: 213.5 (q), 172.8 (q), 137.5 (q), 134.7 
(q), 134.3 (q), 132.7 (q), 130.0 (q), 129.6 (CH), 129.4 (CH), 128.8 (CH), 128.3 (CH), 
118.1 (CH), 82.4 (q), 63.5 (q), 42.6 (CH2), 34.9 (CH2), 27.6 (CH3), 14.4 (CH3).  FTIR  
νmax /cm-1: 1765 (m), 1589 (m), 1491 (s), 1399 (m), 1091 (s), 1012 (m), 830 (m), 783 




Orange/brown solid from method 1: 6.7 mg (4.6%), mp: 146 – 149 °C, Rf: 0.43 (DCM). 
1H NMR (400 MHz), CDCl3, δ: 7.57 (d, J  = 8.6 Hz, 2H, ArH), 7.35 (d, J  = 8.6 Hz, 2H, 
ArH), 7.26 – 7.24 (m, 2H, ArH), 7.03 (d, J  = 8.6 Hz, 2H, ArH), 3.14 (d, J  = 16.2 Hz, 
1H, CH of CH2), 2.84 (dd J  = 16.2 Hz, 2H, CH2), 2.74 (d, J  = 16.2 Hz, 1H, CH of CH2), 
2.06 (s, 3H, Me), 1.69 (s, 3H, Me), 1.67 (s, 3H, Me).  FTIR  νmax /cm-1: 2921 (m), 2851 
(m), 1766 (m), 1590 (m), 1490 (s), 1399 (m), 1087 (s), 1010 (s), 830 (s), 772 (m), 734 
(m). HRMS, m/z calcd. for C23H21Cl2NOS [m+H] reqd. 430.0802, found 430.0799. 





Off-white solid from method 1: 69 mg, (25%), mp: 152 – 154 °C, Rf: 0.46 (DCM). 1H 
NMR (400 MHz), CDCl3, δ: 7.64 (dd, J  = 5.4, 9.4 Hz, 2H, ArH), 7.13 – 7.01 (m, 4H, 
ArH), 6.94 (t, J  = 8.4 Hz, 2H, ArH), 5.37 (bs, 1H, C=CH), 3.06 (d, J  = 16.4 Hz, 1H, 
CH of CH2), 2.90 (dd, J  = 6.6, 16.4 Hz, 1H, CH of CH2), 2.75 (d, J  = 17.0 Hz, 1H, CH 
of CH2), 2.69 – 2.59 (m, 2H, overlap of CH of ring CH2, and CH of CH2Me), 2.54 (q, J  
= 7.4 Hz, 1H, CH of CH2Me), 1.73 (s, 3H, Me), 1.25 (t, J  = 7.4 Hz, 3H, CH2Me). 13C 
NMR (100 MHz), CDCl3, δ: 214.2 (q), 172.3 (q), 164.3 (d, J = 253.2 Hz, CF), 162.4 (d, 
J = 248.6 Hz, CF), 132.5 (CH), 132.2 (d, J = 3.3 Hz, Cqp-CF), 130.5 (d, J = 8.6 Hz, 
CHm-CF), 128.7 (d, J = 8.3 Hz, CHm-CF), 127.9 (d, J = 3.3 Hz, Cqp-CF), 118.1 (CH), 
116.2 (d, J = 21.6 Hz, CHo-CF), 115.6 (d, J = 21.6 Hz, CHo-CF), 82.6 (q), 63.4 (q), 
43.0 (CH2), 35.1 (CH2), 27.6 (CH2), 26.3 (CH3), 14.2 (CH3).  FTIR  νmax /cm-1: 1767 
(m), 1601 (m), 1509 (s), 1323 (m), 1222 (s), 1177 (m), 1098 (m), 849 (m), 780 (m). 
HRMS, m/z calcd. for C23H21F2NOS [m+H] reqd. 398.1397, found 398.1389. 
3.8.1.13 5-(Ethylthio)-2,3-bis(4-fluorophenyl)-7-methyl-7-vinyl-1-
azabicyclo[3.2.0]hept-2-en-4-one 464a 
Dark brown solid, from method 1: 7 mg (3%), mp 87-89 °C. 1H NMR (400 MHz), CDCl3, 
δ: 7.53 (dd, J = 5.4, 8.8 Hz, 2H, ArH), 7.31 (dd, J = 5.4, 8.8 Hz, 2H, ArH), 7.01 
(apparent t, J = 8.7 Hz, 4H, ArH), 6.32 (dd, J = 10.5, 16.9 Hz, 1H, CH=CH2), 5.50 (dd, 
J = 0.8, 17.0 Hz, 1H, =CHH), 5.28 (dd, J = 0.8, 10.5 Hz, 1H, =CHH), 2.59 – 2.48 (m, 
2H, SCH2CH3), 2.47 (s, 1H, CH of ring CH2), 2.46 (s, 1H, CH of ring CH2), 1.18 (t, J = 
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7.5 Hz, 3H, SCH2CH3), 0.87 (s, 3H, CH3). 13C NMR (100 MHz), CDCl3, δ: 202.9 (q), 
173.1 (q), 164.5 (d, J = 254.0 Hz, CF), 161.9 (d, J = 247.4 Hz, CF), 142.6 (q), 131.7 
(d, J = 8.8 Hz, CHm-CF), 130.3 (d, J = 8.3 Hz, CHm-CF), 128.8 (d, J = 3.3 Hz, Cqp-
CF), 126.9 (d, J = 3.3 Hz, Cqp-CF), 123.9 (CH2), 116.0 (d, J = 21.9 Hz, CHo-CF), 
115.5 (d, J = 21.3 Hz, CHo-CF), 114.2 (CH), 74.3 (q), 69.1 (q), 37.8 (CH2), 23.6 (CH2), 
23.0 (CH3), 14.5 (CH3). FTIR νmax /cm-1: 1651, 1601, 1519, 1494, 1373, 1220, 1155, 




Off white solid from method 1: 46.3 mg (31.7%), mp: 157 – 159 °C, Rf: 0.42 (DCM). 
1H NMR (400 MHz), CDCl3, δ: 7.62 (dd, J  = 5.3, 8.9 Hz, 2H, ArH), 7.10 – 7.00 (m, 4H, 
ArH), 6.94 (t, J  = 8.7 Hz, 2H, ArH), 3.14 (d, J  = 16.4 Hz, 1H, CH of CH2), 2.86 (d, J  
= 16.4 Hz, 1H, CH of CH2), 2.80 (d, J  = 16.8 Hz, 1H, CH of CH2), 2.72 (d, J  = 16.8 
Hz, 1H, CH of CH2), 2.55 (m, 2H, CH2Me), 1.68 (s, 3H, CH3), 1.66 (s, 3H, CH3), 1.24 
(t, J  = 7.5 Hz, 3H, CH2CH3). 13C NMR (100 MHz), CDCl3, δ: 214.7 (q), 172.2 (q), 164.2 
(d, J = 252.5 Hz, CF), 162.2 (d, J = 248.3, CF), 132.2 (d, J = 3.3 Hz, Cqp-CF), 130.4 
(d, J = 8.7 Hz, CHm-CF), 128.7 (d, J = 8.1 Hz, CHm-CF), 128.2 (d, J = 3.3 Hz, Cqp-
CF), 125.5 (q), 123.8 (q), 116.1 (d, J = 21.6 Hz, CHo-CF), 115.2 (d, J = 21.6 Hz, CHo-
CF), 82.9 (q), 62.8 (q), 45.9 (CH2), 42.7 (CH2), 23.7 (CH2), 23.6 (CH3), 23.3 (CH3), 
14.2 (CH3).  FTIR  νmax /cm-1: 1765 (m), 1599 (m), 1570 (m), 1508 (s), 1241 (m), 1227 
(s), 1162 (m), 846 (s), 807 (m). HRMS, m/z calcd. for C24H23F2NOS [M+H] reqd. 





Dark brown solid, from method 1: 10 mg (7%), mp 110 – 113 °C. 1H NMR (400 MHz), 
CDCl3, δ: 7.52 (dd, J = 5.4, 8.5 Hz, 2H, ArH), 7.29 (dd, J = 5.4, 8.6 Hz, 2H, ArH), 7.00 
(td, J = 2.5, 8.7 Hz, 4H, ArH), 5.64 (s, 1H, =CHH), 5.12 (s, 1H, =CHH), 2.52 (m, 2H, 
SCH2CH3), 2.44 (s, 1H, CH of ring CH2), 2.41 (s, 1H, CH of ring CH2), 1.81 (s, 3H, 
CH3), 1.17 (t, J = 7.5 Hz, 3H, SCH2CH3), 0.90 (s, 3H, CH3). 13C NMR (100 MHz), 
CDCl3, δ: 203.1 (q), 173.7 (q), 164.3 (d, J = 253.2 Hz, CF), 161.9 (d, J = 247.1 Hz, 
CF), 147.3 (CH2), 131.7 (d, J = 8.7 Hz, CHm-CF), 130.3 (d, J = 8.3 Hz, CHm-CF), 
128.9 (d, J = 3.4 Hz, Cqp-CF), 127.0 (d, J = 3.3 Hz, Cqp-CF), 124.3 (q), 116.0 (d, J = 
21.7 Hz, CHo-CF), 115.5 (d, J = 21.5 Hz, CHo-CF), 112.7 (q), 74.56 (q), 72.4 (q), 37.4 
(CH2), 23.6 (CH2), 23.4 (CH3), 19.0 (CH3), 14.6 (CH3). FTIR νmax /cm-1: 1678, 1600, 
1493, 1379, 1218, 1154, 1014, 933, 570. HRMS, m/z calcd. for C24H23F2NOS [M+H] 
reqd. 412.1468, found 412.1543. 
3.8.1.16 1,8-Bis(4-fluorophenyl)-4-methyl-6-(methylthio)-7-
azabicyclo[4.2.1]nona-3,7-dien-9-one 466 
Brown solid from method 2: 41.3 mg, (15%), mp: 109 – 113 °C, Rf: 0.37 (DCM). 1H 
NMR (400 MHz), CDCl3, δ: 7.66 (dd, J  = 5.4, 9.0 Hz, 2H, ArH), 7.14 – 7.04 (m, 4H, 
ArH), 6.96 (apparent t, J  = 8.7 Hz, 2H, ArH), 5.40 (d, J  = 5.8 Hz, 1H, C=CH), 3.09 (d, 
J  = 16.3 Hz, 1H, CH of CH2), 2.94 (dd, J  = 6.7, 16.5 Hz, 1H, CH of CH2), 2.79 (d, J  
= 16.5 Hz, 1H, CH of CH2), 2.66 (d, J  = 16.7 Hz, 1H, CH of CH2), 2.12 (s, 3H, Me), 
1.76 (s, 3H, Me). 13C NMR (100 MHz), CDCl3, δ: 213.9 (q), 172.8 (q), 164.3 (d, J = 
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253.0 Hz, CF), 162.3 (d, J = 248.5 Hz, CF), 132.6 (q), 132.1 (d, J = 3.4 Hz, Cqp-CF), 
130.5 (d, J = 8.7 Hz, CHm-CF), 128.7 (d, J = 8.2 Hz, CHm-CF), 127.9 (d, J = 3.3 Hz, 
Cqp-CF), 118.21 (CH), 116.25 (d, J = 21.6 Hz, CHp-CF), 115.6 (d, J = 21.7 Hz, CHp-
CF), 82.2 (q), 63.4 (q), 42.7 (CH2), 35.1 (CH2), 27.6 (CH3), 21.45 (CH3).  FTIR  νmax 
/cm-1: 2921 (m), 1766 (m), 1601 (m), 1508 (s), 1226 (m), 1179 (m), 833 (m), 817 (m), 
781 (m). HRMS, m/z calcd. for C22H19F2NOS [M+H] reqd. 384.1236, found 381.1231. 
3.8.1.17 1,8-Bis(4-fluorophenyl)-3,4-dimethyl-6-(methylthio)-7-
azabicyclo[4.2.1]nona-3,7-dien-9-one 467 
Orange-brown solid from method 2: 57.2 mg (17%), mp: 207-209 °C, Rf: 0.37 (DCM). 
1H NMR (400 MHz), CDCl3, δ: 7.69-7.62 (m, 2H, ArH), 7.14-7.02 (m, 4H, ArH), 7.01-
6.93 (m, 2H, ArH), 3.16 (bd, J = 16.2 Hz, 1H, CH of CH2), 2.89 (d, J = 16.2 Hz, 1H, 
CH of CH2), 2.83-2.73 (m, 2H, CH2), 2.09 (s, 3H, SCH3), 1.72 (s, 3H, CH3), 1.69 (s, 
3H, CH3). 13C NMR (100 MHz), CDCl3, δ: 214.3 (q), 172.8 (q), 164.2 (d, J = 252.6 Hz, 
CF), 162.3 (d, J = 248.8 Hz, CF), 132.3 (d, J = 3.3 Hz, Cqp-CF), 130.4 (d, J = 8.8 Hz, 
CHm-CF), 128.7 (d, J = 8.2 Hz, CHm-CF), 128.2 (d, J = 3.3 Hz, Cqp-CF), 125.6 (q), 
123.7 (q), 116.1 (d, J = 21.8 Hz, CHo-CF), 115.6 (d, J = 21.6 Hz, CHo-CF), 82.5 (q), 
62.8 (q), 45.6 (CH2), 42.6 (CH2), 23.6 (CH3), 23.3 (CH3), 12.5 (CH3).  FTIR  νmax /cm-
1: 2924 (m), 1767 (m), 1601 (m), 1508 (m), 1221 (m), 1162 (m), 846 (m), 819 (m). 
HRMS, m/z calcd. for C23H21F2NOS [M+H] reqd. 398.1393, found 398.1387. 
3.8.1.18 6-(Ethylthio)-3-methyl-1,8-di-p-tolyl-7-azabicyclo[4.2.1]nona-3,7-dien-
9-one 468 
Pale brown solid from method 2: 18 mg (6%), mp: 52 – 54 °C, Rf: 0.43 (DCM). 1H NMR 
(400 MHz), CDCl3, δ: 7.56 (d, J  = 8.2 Hz, 2H, ArH), 7.14 (d, J  = 8.0 Hz, 2H, ArH), 
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7.05 (d, J  = 8.2 Hz, 2H, ArH), 7.01 (d, J  = 8.0 Hz, 2H, ArH), 5.36 (d, J  = 5.3 Hz, 1H, 
C=CH), 3.08 (d, J  = 16.6 Hz, 1H, CH of CH2), 2.93 (dd, J  = 6.6, 16.6 Hz, 1H, CH of 
CH2), 2.77 (d, J = 16.6 Hz, 1H, CH of CH2) 2.68 – 2.48 (m, 3H, overlap between 1 CH 
of CH2, and CH2 of CH2CH3), 2.32 (s, 3H, ArMe), 2.29 (s, 3H, ArMe), 1.71 (s, 3H, 
CH=CMe), 1.25 (t, J  = 7.5 Hz, 3H, CH2CH3). 13C NMR (100 MHz), CDCl3, δ: 215.0 
(q), 173.6 (q), 141.4 (q), 137.6 (q), 133.7 (q), 132.1 (q), 129.8 (CH), 129.0 (CH), 128.4 
(CH), 126.9 (CH), 124.5 (q), 118.6 (CH), 82.7 (q), 63.7 (q), 43.0 (CH2), 35.0 (CH2), 
27.7 (CH3), 23.7 (CH2), 21.4 (CH3), 21.1 (CH3), 14.35 (CH3).  FTIR  νmax /cm-1: 2969 
(m), 2921 (m), 1764 (m), 1513 (m), 1445 (m), 1180 (m), 820 (m), 734 (m). HRMS, m/z 
calcd. for C25H27NOS [M+H] reqd. 390.1895, found 390.1888. 
3.8.1.19 6-(Ethylthio)-3,4-dimethyl-1,8-di-p-tolyl-7-azabicyclo[4.2.1]nona-3,7-
dien-9-one 469 
Orange-brown solid from method 2: 27.3 mg (11%), mp: 123 – 126 °C, Rf: 0.40 (DCM). 
1H NMR (400 MHz), CDCl3, δ: 7.55 (d, J  = 8.2 Hz, 2H, ArH), 7.12 (d, J  = 8.2 Hz, 2H, 
ArH), 7.05 (d, J  = 8.2 Hz, 2H, ArH), 7.00 (d, J  = 8.2 Hz, 2H, ArH), 3.16 (d, J  = 16.1 
Hz, 1H, CH of CH2), 2.91 (d, J  = 16.5 Hz, 1H, CH of CH2), 2.81 (d, J  = 16.1 Hz, 1H, 
CH of CH2), 2.71 (d, J  = 16.5 Hz, 1H, CH of CH2), 2.56 (m, 2H, CH2CH3), 2.31 (s, 3H, 
ArMe), 2.29 (s, 3H, ArH), 1.62 (bs, 6H, MeC=CMe). 1.26 – 1.23 (m, 3H, CH2CH3).  13C 
NMR (100 MHz), CDCl3, δ: 215.5 (q), 173.7 (q), 141.2 (q), 137.5 (q), 133.8 (q), 129.7 
(CH), 129.6 (q), 129.1 (CH), 128.2 (CH), 126.9 (CH), 125.1 (q), 124.1 (q) 82.9 (q), 63.1 
(q), 46.1 (CH3), 42.6 (CH2), 29.7 (CH3), 23.7 (CH3), 23.6 (CH3), 21.4 (CH2), 21.1 (CH2), 
14.3 (CH3).  FTIR  νmax /cm-1: 2920 (m), 1766 (m), 1586 (m) 1445 (m), 1202 (m), 824 





Pale brown solid from method 2: 22.0 mg (9%), mp: 65 – 69 °C, Rf: 0.35 (DCM). 1H 
NMR (400 MHz), CDCl3, δ: 7.59 (d, J  = 8.0 Hz, 2H, ArH), 7.16 (d, J  = 8.0 Hz, 2H, 
ArH), 7.08 (d, J  = 8.0 Hz, 2H, ArH), 7.04 (d, J  = 8.0. Hz, 2H, ArH), 5.40 (d, J  = 5.5 
Hz, 1H, C=CH), 3.11 (d, J  = 16.8 Hz, 1H, CH of CH2), 2.97 (dd, J  = 6.7, 16.6 Hz, 1H, 
CH of CH2), 2.78 (d, J  = 16.8 Hz, 1H, CH of CH2), 2.65 (d, J  = 16.6 Hz, 1H, CH of 
CH2), 2.34 (s, 3H, ArMe), 2.32 (s, 3H, ArMe), 2.12 (s, 3H, SMe), 1.75 (bs, 3H, Me). 
13C NMR (100 MHz), CDCl3, δ: 214.7 (q), 174.3 (q), 141.4 (q), 137.7 (q), 133.6 (q), 
132.2 (q), 129.8 (CH), 129.2 (q), 129.1 (CH), 128.4 (CH), 126.8 (CH), 118.6 (CH), 82.3 
(q), 63.7 (q), 42.8 (CH2), 35.0 (CH2), 27.6 (CH3), 21.4 (CH3), 21.0 (CH3), 12.4 (CH3).  
FTIR  νmax /cm-1: 2918 (m), 1764 (m), 1586 (m), 1556 (m), 1513 (m), 1435 (m), 1304 




Orange solid from method 2: 12 mg (6%), mp: 162 – 165 °C, Rf: 0.32 (DCM). 1H NMR 
(400 MHz), CDCl3, δ: 7.57 (d, J = 8.0 Hz, 2H, ArH), 7.15 (d, J = 8.0 Hz, 2H, ArH), 7.07 
(d, J = 8.0 Hz, 2H, ArH), 7.02 (d, J = 8.0 Hz, 2H, ArH), 3.18 (d, J = 16.1 Hz, 1H, CH of 
CH2), 2.94 (d, J = 16.1 Hz, 1H, CH of CH2), 2.79 (q, J = 16.7 Hz, 2H, CH2), 2.33 (s, 
3H, ArMe), 2.32 (s, 3H, ArMe), 2.09 (s, 3H, SMe), 1.70 (s, 3H, C=CMe), 1.68 (s, 3H, 
C=CMe). 13C NMR (100 MHz), CDCl3, δ: 215.17 (q), 174.3 (q), 141.3 (q), 137.6 (q), 
133.8 (q), 129.7 (CH), 129.5 (q), 126.0 (CH), 128.2 (CH), 126.9 (CH). 125.2 (q), 124.0 
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(q), 82.5 (q), 63.7 (q), 45.7 (CH2), 42.5 (CH2), 29.7 (CH3), 23.6 (CH3), 23.2 (CH3), 21.4 
(CH3), 21.0 (CH3).  FTIR  νmax /cm-1: 2919 (m), 2850 (m), 1762 (s), 1586 (m), 1556 
(m), 1313 (m), 1080 (m), 840 (m), 781 (m). HRMS, m/z calcd. for C25H27NOS [M+H] 
reqd. 390.1894, found 390.1889. 
3.8.1.22 1,8-Bis(2,5-dimethylthiophen-3-yl)-6-(ethylthio)-4-methyl-7-
azabicyclo[4.2.1]nona-3,7-dien-9-one 472 
Brown solid from method 2: 25.3 mg (8.3%), mp: 144 – 147 °C. 1H NMR (400 MHz), 
CDCl3, δ: 6.65 (s, 1H, ArH), 6.01 (s, 1H, ArH), 5.30 (bs, 1H, C=CH), 2.98 (apparent t, 
J = 7.4 Hz, 2H, SCH2CH3), 2.86-2.69 (m, 4H, 2 × CH2) 2.64 (s, 3H, CH3), 2.42 (s, 3H, 
CH3), 2.22 (s, 3H, CH3), 2.06 (s, 3H, CH3), 1.74 (s, 3H, CH3), 1.33, (t, J = 7.4 Hz, 3H, 
SCH2CH3). 13C NMR (100 MHz), CDCl3, δ: 216.3 (q), 170.8 (q), 143.4 (q), 135.6 (q), 
134.7 (q), 133.9 (q), 132.2 (q), 131.7 (q), 129.1 (q), 125.1 (CH), 124.6 (CH), 118.6 
(CH), 80.6 (q), 62.1 (q), 44.3 (CH2), 37.0 (CH2), 27.6 (CH2), 23.1 (CH3), 16.4 (CH3), 
15.3 (CH3), 15.1 (CH3), 15.0 (CH3), 14.2 (CH3).  FTIR  νmax /cm-1: 2918 (m), 1728 (s), 
1573 (s), 1551 (m), 1444 (m), 1145 (m), 834 (m), 755 (m). HRMS, m/z calcd. for 
C23H27NOS3 [M+H] reqd. 444.1411, found 444.1488. 
3.8.1.23 1,8-Bis(2,5-dimethylthiophen-3-yl)-6-(ethylthio)-3,4-dimethyl-7-
azabicyclo[4.2.1]nona-3,7-dien-9-one 473 
Pale brown solid from method 2: 13.2 mg (4.2%), mp: 123 – 126 °C. 1H NMR (400 
MHz), CDCl3, δ: 6.70 (s, 1H, ArH), 6.03 (s, 1H, ArH), 2.95 (apparent t, J = 7.0 Hz, 2H, 
SCH2CH3), 2.90-2.77 (m, 4H, 2 × CH2), 2.64 (s, 3H, CH3), 2.44 (s, 3H, CH3), 2.25 (s, 
3H, CH3), 2.04 (s, 3H, CH3), 1.72 (s, 3H, CH3), 1.67 (s, 3H, CH3), 1.34 (t, J = 7.3 Hz, 
3H, SCH2CH3). 13C NMR (100 MHz), CDCl3, δ: 216.7 (q), 170.9 (q), 142.9 (q), 135.6 
(q), 134.7 (q), 133.8 (q), 131.8 (q), 129.4 (q), 125.2 (q), 125.0 (CH), 124.5 (CH) 123.7 
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(q), 80.9 (q), 61.6 (q), 47.3 (CH2), 44.3 (CH2), 35.4 (CH2), 23.4 (CH3), 23.1 (CH3), 16.0 
(CH3), 15.3 (CH3), 15.1 (CH3), 14.9 (CH3), 14.2 (CH3).  FTIR  νmax /cm-1: 2917 (m), 
1755 (s), 1582 (s), 1438 (s), 1182 (m), 832 (s), 771 (m). HRMS, m/z calcd. for 
C24H29NOS3 [M+H] reqd. 415.1098, found 416.1170. 
3.8.1.24 1,8-Bis(2,5-dimethylthiophen-3-yl)-4-methyl-6-(methylthio)-7-
azabicyclo[4.2.1]nona-3,7-dien-9-one 474 
Dark cream solid from method 2: 5.9 mg (2%), mp: 142-145 °C. 1H NMR (400 MHz), 
CDCl3, δ: 6.67 (s, 1H, ArH), 6.04 (s, 1H, ArH), 5.33 (bs, 1H, C=CH), 2.90-2.70 (m, 4H, 
2 × CH2), 2.66 (s, 3H, CH3), 2.44 (s, 3H, CH3), 2.43 (s. 3H, CH3), 2.25 (s, 3H, CH3), 
2.08 (s, 3H, CH3), 1.77 (s, 3H, CH3). 13C NMR (100 MHz), CDCl3, δ: 216.2 (q), 171.0 
(q), 143.4 (q), 135.7 (q), 134.7 (q), 133.9 (q), 132.1 (q), 131.7 (q), 129.1 (q), 125.0 
(CH), 124.6 (CH), 118.6 (CH), 79.7 (q), 62.4 (q), 43.3 (CH2), 37.1 (CH2), 27.5 (CH3), 
16.34 (CH3), 15.3 (CH3), 15.0 (CH3), 14.1 (CH3), 11.9 (CH3). FTIR νmax /cm-1: 1756, 
1582, 1480, 1439, 1373, 1140, 897, 771. HRMS, m/z calcd. for C22H25NOS3 [M+H] 
reqd. 416.1098, found 416.1170. 
3.8.1.25 1,8-Bis(2,5-dimethylthiophen-3-yl)-3,4-dimethyl-6-(methylthio)-7-
azabicyclo[4.2.1]nona-3,7-dien-9-one 475 
Pale brown solid from method B, 4.7 mg (1%), mp: 165 – 170 °C (decomposes >170 
°C). 1H NMR (400 MHz), CDCl3, δ: 6.71 (s, 1H, ArH), 6.03 (s, 1H, ArH), 2.95-2.79 (m, 
4H, 2 × CH2), 2.65 (s, 3H, CH3), 2.45 (s, 3H, CH3), 2.39 (s, 3H, CH3), 2.26 (s, 3H, 
CH3), 2.04 (s, 3H, CH3), 1.73 (s, 3H, CH3), 1.68 (s, 3H, CH3). 13C NMR (100 MHz), 
CDCl3, δ: 216.6 (q), 171.2 (q), 143.0 (q), 135.6 (q), 134.7 (q), 133.8 (q), 131.8 (q), 
129.4 (q), 125.2 (q), 125.0 (CH), 124.5 (CH), 123.7 (q), 80.1 (q), 61.8 (q), 46.4 (CH2), 
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44.3 (CH2), 23.4 (CH3), 23.0 (CH3), 16.0 (CH3), 15.3 (CH3), 15.1 (CH3), 14.1 (CH3), 
12.0 (CH3).  FTIR  νmax /cm-1: 2917 (s), 2849 (m), 1755 (s), 1582 (s), 1439 (s), 1140 
(m), 1083 (m), 821 (s), 772 (m). HRMS, m/z calcd. for C23H27NOS3 [M+H] reqd. 
430.1255, found 430.1325. 
3.9 Experimental for Further Investigations into the Cycloaddition 
Between Cyclopropenones and Cyclic Imines 
 N-(2-(1H-Indol-3-yl)ethyl)formamide 483 
Tryptamine 481 (2.5 g, 15.60 mmol, 1.0 eq) was added to ethyl formate (25 mL) and 
the mixture was stirred and heated to reflux. After 24 hours, the solvent was removed 
under reduced pressure, affording the desired product as a colourless oil. 2.9 g, 
(quant).  
1H NMR (400 MHz), CDCl3, δ: 8.26 (bs, 1H, ArNH), 8.11 (s, 1H, COH), 7.62 (d, J = 7.8 
Hz, 1H, ArH), 7.39 (d, J = 8.2 Hz, 1H, ArH), 7.23 (td, J = 1.0, 8.2 Hz, 1H, ArH), 7.15 
(td, J = 1.0, 7.6 Hz, 1H, ArH), 7.05 (d, J = 2.4 Hz, 1H, ArH), 5.66 (bs, 1H, NH), 3.66 
(q, J = 6.5 Hz, 2H, CH2), 3.01 (t, J = 6.5 Hz, 2H, CH2). Consistent with published 
values146. 
 4,9-Dihydro-3H-pyrido[3,4-b]indole 479 
N-(2-(1H-indol-3-yl)ethyl)formamide 483 (2.90 g, 15.40 mmol, 1.0 eq) was dissolved 
in DCM (50 mL), and phosphoryl chloride (5.00 mL, 15.30 mmol, 1.0 eq) was slowly 
added to the stirred solution, and the reaction was left for 90 minutes at room 
temperature. The volatile material was evaporated under reduced pressure and water 
(200 mL) was added. The resulting mixture was stirred, followed by the addition of 
concentrated ammonia until basified (pH ~12) (~50 mL). The stirring was slowed, and 
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the precipitate was allowed to form over 15 minutes. The solid material was collected 
and dried under vacuum, furnishing the desired product without the need for 
purification. Dry product a dark yellow/orange solid (1.88 g, 72%). 
1H NMR (400 MHz), CDCl3, δ: 8.41 (s, 1H, CH=N), 8.32 (bs, 1H, ArNH), 7.62 (d, J = 
7.9 Hz, 1H, ArH), 7.40 (d, J = 7.9 Hz, 1H, ArH), 7.30 (td, J = 1.0, 7.5 Hz, 1H, ArH), 
7.15 (td, J = 1.0, 7.5 Hz, 1H, ArH), 3.96 (td, J = 2.2, 8.7 Hz, 2H, CH2), 2.94-2.88 (m, 
2H, CH2). Minor deviations from reported data170. 
 N-(2-(1H-Indol-3-yl)ethyl)acetamide 483 
To a stirred solution of tryptamine 481 (2.4 g, 14.98 mol, 1.0 eq) and triethylamine (3.2 
mL, 22.5 mmol, 1.5 eq) in DCM (25 mL) cooled to 0 °C was added acetyl chloride (1.2 
mL, 16.5 mmol, 1.1 eq) over 5 minutes. The reaction was stirred at 0 °C for 30 minutes, 
then 1 hour at room temperature. Water (25 mL) was added, and the organic phase 
was separated and washed with brine (25 mL). The organic layer was dried and 
concentrated under reduced pressure, affording the desired product as a dark yellow 
syrup. 3.06 g (99%).  
1H NMR (400 MHz), CDCl3, δ: 8.15 (bs, 1H, ArNH), 7.62 (d, J = 7.6 Hz, 1H, ArH), 7.40 
(d, J = 8.0 Hz, 1H, ArH), 7.23 (td, J = 7.6 Hz, 1H, ArH), 7.15 (td, J = 1.0, 8.0 Hz, 1H, 
ArH), 7.06 (d, J = 2.1 Hz, 1H, ArH), 5.53 (bs, 1H, NH), 3.62 (q, J = 6.4 Hz, 2H, CH2), 
2.99 (t, J = 6.5 Hz, 2H, CH2), 1.94 (s, 3H, COCH3). Compliant with literature171. 
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 N-(2-(1-Benzyl-1H-indol-3-yl)ethyl)acetamide 480 
To a stirred suspension of sodium hydride (60% suspension in mineral oil, 480 mg, 
12.47 mmol, 1.5 eq) in dry DMF (10 mL) cooled to 0 °C was added N-(2-(1H-indol-3-
yl)ethyl)acetamide 483 (1.68 g, 8.31 mmol, 1.0 eq) over 5 minutes. The resulting 
mixture was stirred for 30 minutes at room temperature. The reaction was cooled to 0 
°C and benzyl bromide was added. The reaction was stirred at ambient temperature 
for 3 hours, water (30 mL) was added, and the organic material was extracted with 
EtOAc (3 × 25 mL). The organic phase was washed with water (3 × 30 mL) and brine 
(2 × 30 mL), before being dried and concentrated under vacuum, affording the desired 
benzyl-protected product as a pale oil,  1.3 g (36%). 
1H NMR (400 MHz), CDCl3, δ: 7.63 (d, J = 7.8 Hz, 1H, ArH), 7.33-7.28 (m, 3H, ArH), 
7.22 (td, J = 1.2, 7.6 Hz, 1H, ArH), 7.14 (t, J = 7.2 Hz, 3H, ArH), 6.97 (s, 1H, ArH), 5.50 
(bs, 1H, NH), 5.30 (s, 1H, CH2Ph), 3.60 (q, J = 6.3 Hz, 2H, CH2), 2.99 (t, J = 6.6 Hz, 
2H, ArH), 1.92 (s, 3H, COCH3). Agreeing with published data172. 
 
 9-Benzyl-1-methyl-4,9-dihydro-3H-pyrido[3,4-b]indole 484 
Protected indole species 480 (1.3 g, 4.10 mmol, 1.0 eq) was dissolved in dry toluene 
(50 mL). POCl3 (1.15 mL, 12.3 mmol, 3.0 eq) was added dropwise, and the mixture 
was gradually heated to reflux. The reaction stirred at reflux for 3 hours, after which, 
the reaction was cooled to room temperature and the solvent removed under reduced 
pressure. The residue was dissolved in ethanol (50 mL), and water (50 mL) and 2 M 
NaOH (50 mL) was added. The organic material was extracted with DCM (4 × 20 mL) 
and the combined organic extracts were washed with water (50 mL) and brine (50 
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mL). The organic phase was dried over magnesium sulfate and concentrated under 
vacuum, affording the desired product as a dark brown oil- 0.75 g (66%). 
1H NMR (400 MHz), CDCl3, δ: 7.67 (d, J = 7.8 Hz, 1H, ArH), 7.32-7.23 (m, 5H, ArH), 
7.19 (ddd, J = 0.8, 2.4, 6.6 Hz, 1H, ArH), 6.97 (d, J = 7.8 Hz, 2H, ArH), 5.56 (s, 2H, 




Diphenylcyclopropenone (65 mg, 0.313 mmol, 1.0 eq) was added to a solution of cyclic 
imine 484 (86 mg, 0.313 mmol, 1.0 eq) in acetonitrile (50 mL) and the reaction was 
stirred at room temperature for 7 days. The solvent was removed under reduced 
pressure and the crude residue was purified over a column of silica, eluted with EtOAc 
(50% in hexanes) affording the desired product as a dark brown residue, 35 mg (24%). 
1H NMR (400 MHz), CDCl3, δ: 7.59-7.49 (m, 4H, ArH), 7.36-7.25 (m, 4H, ArH), 7.23-
7.10 (m, 8H, ArH), 7.09 (d, J = 5.0 Hz, 1H, ArH), 7.02 (d, J = 7.2 Hz, 2H, ArH), 5.77 
(d, J = 18.0 Hz, 1H, CH of PhCH2), 4.12 (dd, J = 5.0, 13.6 Hz, 1H, CH of CH2), 3.55-
3.46 (m, 1H, CH of CH2), 2.81 (dd, J = 3.5, 15.4 Hz, 1H, CH of CH2), 2.77-2.66 (m, 
1H, CH of CH2). 13C NMR (100 MHz), CDCl3, δ: 198.5, 172.8, 139.3, 137.9, 132.9, 
131.4, 130.8, 130.3, 129.2, 128.7, 128.6, 127.8, 126.7, 126.0, 125.6, 125.5, 122.5, 
119.7, 118.3, 110.7, 108.2, 68.9, 48.9, 41.1, 23.7, 23.1. 
 Attempted Synthesis of 1-Methyl-4,9-dihydro-3H-pyrido[3,4-b]indole 481 
To a stirred solution of cyclic imine 484 (340 mg, 1.24 mmol, 1.0 eq) in dry methanol 
(25 mL) was added 10% palladium on carbon (340 mg) and ammonium formate (40 
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mg, 6.2 mmol, 5.0 eq). The mixture was heated at reflux overnight, allowed to cool, 
and filtered through celite, rinsing through with DCM (5 × 30 mL). The filtrate was 
concentrated under vacuum and purified over a column of silica, eluted with 50% 
EtOAc in hexane, affording nothing of interest. 
 Synthesis of 2,2',3,3'-tetraphenyl-6,6',11,11'-tetrahydro-1H,1'H,5H,5'H-
[11b,11'b-biindolizino[8,7-b]indole]-1,1'-dione 490 
To a stirred solution of cyclic imine 478 (164 mg, 0.96 mmol, 1.0 eq) in dry acetonitrile 
(15 mL) was added DPP (100 mg, 0.96 mmol, 1.0 eq). The reaction was left to stir at 
ambient temperature for a total of five days. The resulting precipitate was collected via 
vacuum filtration and dried under vacuum, affording the desired product as a cream 
solid, 9 mg (1.2%), mp, decomposes > 165 °C. 1H NMR (400 MHz), CDCl3, δ: 9.35 
(bs, 2H, NH), 7.65-7.01 (m, 28H, ArH), 4.02 (bs, 2H, 2 × CH of CH2), 3.55 (bs, 2H, 2 
× CH of CH2), 2.87-2.81 (m, 2H, 2 × CH of CH2), 2.70-2.55 (m, 2H, 2 × CH of CH2). 
13C NMR (100 MHz), CDCl3, δ: 195.1 (q), 174.5 (q), 136.8 (q), 130.9 (q), 130.8 (q), 
130.3 (CH), 129.1 (CH), 129.0 (CH), 127.9 (CH), 126.4 (q),126.1 (CH), 125.8 (q), 
122.8 (CH), 119.6 (CH), 118.5 (CH), 116.5 (q), 112.3 (CH), 110.5 (q), 43.5 (CH2), 22.0 
(CH2). FTIR νmax /cm-1: 1682, 1654, 1604, 1555, 1468, 1403, 1298, 1221, 186, 733. 
HRMS, m/z calcd. for C52H38N4O2 [M+Na] reqd. 773.2887, found 773.2884. This 
structure was confirmed by X-ray crystallographic analysis and the data has been 
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